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1. kidney trAnsplAntAtion
The first successful kidney transplantation was performed in 19541, and renal 
transplantation has since been the most studied organ transplant procedure. At present, 
approximately 28,500 kidney transplantations are performed annually in the US (based 
on Organ Procurement and Transplantation Network data as of March 2, 2012). With 
the improvements in surgical techniques, better immunosuppressive drugs and regimen 
refinements, acute rejection rates have dropped from 80% to a mere 10-20% in current 
daily practice2. However, despite the improved one-year graft survival rates2;3, long-term 
outcomes have not improved concomitantly in the last decade, and beyond the first year 
after transplantation, graft attrition rates remain between 3 and 5% annually4.
There are several factors that may hamper the long-term success of kidney 
transplantation, including both immunological (acute and/or chronic rejection) and 
non-immunological (such as drug-related nephrotoxicity, long-term effects of ischemia-
reperfusion injury, hyperlipidemia and hypertension)5 causes. Acute rejection is caused 
by T-cell- and/or antibody-mediated processes. The focus of the studies described in this 
thesis is on antibody-mediated rejection, which was investigated in both the kidney and 
pancreas transplantation setting. Furthermore, the effect of cellular immune modulation 
was investigated in an allogeneic rodent islet transplantation model.
This chapter provides the reader with an introduction to these topics, starting with 
a general description of transplant rejection and a more detailed overview of antibody-
mediated rejection. Type 1 diabetes, an increasingly prevalent cause of end-stage renal 
failure, will be introduced as well as the currently available potentially curative therapies, 
including whole pancreas and islets of Langerhans transplantation.
1.1 rejection in transplantation
Acute antibody-mediated rejection is the main focus of this thesis, concentrating on 
kidney, pancreas and islets of Langerhans transplantation. Regardless of the transplanted 
tissue, every allograft may be faced with the consequences of the activation of the host’s 
defense immune system. The immune system specializes in distinguishing self from 
non-self, and as such, it can eliminate infectious agents and reduce tissue damage. First, 
the innate immune system tries to fend off the non-self donor tissue, after which the 
acquired immunity starts its course of action. Both these first and second lines of defense 
may result in the rejection of the allograft. Therefore, immunosuppressive therapy should 
preferably be introduced well before the transplant procedure. However, acute rejection 
episodes occur even in the setting of pre-dosed live donor transplants, underscoring the 
fact that immunosuppressive drugs have their inherent limitations.
In transplantation, there are two immunological pathways through which rejection can 
occur: T-cell-mediated cellular rejection (TCR) and antibody-mediated rejection (AMR)6. 
Both types of rejection can occur individually or simultaneously, and as such, they can be 
difficult to discriminate. Distinguishing between these two processes is essential as treatment 
for each type of rejection differs. The treatment of an acute T-cell-mediated rejection 
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episode includes the use of high-dose corticosteroids and/or (T-cell depleting) antibody 
therapy such as polyclonal anti-thymocyte globulin or monoclonal anti-CD3 antibodies7. 
Treatment for AMR is aimed at removing or depleting donor-specific antibodies (DSA) 
from the recipient’s circulation through intravenous immunoglobulins, plasmapheresis, 
anti-CD20 antibody therapy and off-label use of therapies that are still under investigation, 
such as eculizumab (anti-C5 therapy) and bortezomib (proteasome inhibition)8.
Allograft rejection, both T-cell and antibody-mediated, is currently classified according 
to histological grading schemes defined and updated at regular Banff conferences on 
allograft pathology. The first meeting was held in Banff, Canada, in 1991 and resulted in 
the first published Banff scoring schema in 19939. In subsequent years, the hallmarks of 
TCR have been classified in such schemes for solid organ transplants, including kidney, 
liver, pancreas and skin-containing composite tissue10-13. The extent and type of the lesions 
affects therapy regimens, considering that minor tissue damage can be resolved with a short 
course of high-dose steroids. More severe or extensive damage, however, must be dealt with 
more rigorously, or the graft will be lost. Several studies have increased our understanding 
of T-cells and their role in allograft recognition and rejection14. Thus our understanding 
of the mechanisms behind TCR has improved and has resulted in alternative treatment 
options. We have, however, also learned that none of the current drug therapies or regimens 
successfully eradicates both the effector and memory T-cell clones14.
Thus, TCR has been well defined in solid organ transplantation, and current 
immunosuppressive regimens are primarily aimed at preventing this type of acute 
rejection. The typical histopathological and clinical findings in AMR are less well-defined. 
AMR may occur hyperacutely (within hours or days) or acutely (within weeks, months or 
even years) or may follow a more insidious chronic course. Antibody formation and the 
subsequent chronic damage, especially the chronic phase in which the least improvement 
has been made in graft survival, are currently the subject of several ongoing studies. 
Antibody-mediated rejection
Antibody-mediated rejection occurs through distinct pathways. These pathways have 
in common the antibody-antigen interaction at the onset of endothelial damage. The 
antibodies responsible for these interactions are donor-specific antibodies (DSA), 
which are most often directed at human leukocyte antigen (HLA) but may also include 
minor histocompatibility antigens15, endothelial cell specific antigens such as the major 
histocompatibility complex class I chain-related genes A and B (MICA or MICB)16, 
glutathione-S-transferase T117 and transplanted antigens that have not yet been elucidated. 
This interaction may lead to complement-mediated damage through cellular lysis via the 
formation of the membrane attack complex C5b-9 or recruitment of inflammatory cells 
by specific soluble complement degradation fragments, such as C5a. The antibody-antigen 
interaction may also result in direct damage through the interaction with Fc-receptors on 
natural killer (NK) cells and NK-like T-cells, a process known as antibody-dependent 
cellular cytotoxicity (ADCC)18. 
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Not all antibody-antigen interactions lead to rejection. Approximately 14-23% of 
all transplantation recipients with stable, functioning grafts have detectable anti-HLA 
antibodies19;20. Although graft survival is poorer in the anti-HLA-positive group, many 
transplant recipients retain graft function. These antibody-antigen interactions supposedly 
initiate damage repair by the endothelium, and as these antibodies persist, the continuous 
tissue repair process with accumulating damage results in a chronic antibody-mediated 
allograft rejection21.
The importance of AMR has long been overlooked, and specific markers for this process 
have proven hard to find. A consensus was eventually reached for the kidney transplantation 
setting, stating that the presence of circulating DSA, certain histopathological findings 
in the biopsy and the deposition of C4d in the peritubular capillaries are the hallmarks 
of an ongoing AMR. The diagnostic relevance and therapeutic consequences of positive 
C4d staining has been investigated extensively in relation to kidney transplantation22;23. 
Complement factor 4 (C4) plays a central role in the activation cascade of the classical 
pathway of the complement system. Prior to secretion, the single-chain precursor is 
enzymatically cleaved to yield the non-identical chains α, ß, and γ. During activation, the 
α-chain is cleaved by C1 into C4a and C4b, while C4b stays linked to the ß and γ chains. 
Further degradation of C4b by C1 into the inactive fragments C4c and C4d blocks the 
generation of C3 convertase. The activated cascade leads to C5a production, which is 
a chemoattractant for several immune cells. Eventually, the membrane attack complex 
C5b-9 is formed, which can lead to permeabilization and subsequent lysis of the target 
cell. Thus, C4d is an inactive complement degradation product that is covalently bound 
to the site of action and can be used as a relatively long-lasting ‘footprint’ of the classical 
pathway activation of the complement cascade. However, C4d will also be deposited 
when the lectin pathway of the complement system is activated, given that it uses the 
same C3 convertase as the classical pathway. Recent studies have found that high MBL 
levels before transplantation are associated with inferior graft survival after renal and 
simultaneous pancreas-kidney transplantation24;25. This has not, however, been studied in 
conjunction with C4d deposition.
For kidney, heart, lung and small bowel transplantations, the relation between 
histopathological findings, the formation of antibodies after transplantation and C4d 
staining patterns have been previously addressed26. Initially, only diffuse C4d positivity of 
the peritubular capillaries (PTC) was considered clinically significant27 and incorporated 
into the revision of the Banff ‘97 working classification of renal allograft pathology28;29. 
Since the Banff ‘07 classification of renal allograft pathology, the staining of more than 
50% of PTC remains the standard for a truly positive staining, but the clinical significance 
of focal C4d staining (10-50% of PTC) is still a matter of debate30. The Banff ‘07 
publication warrants a prospective case-control study with long-term follow-up in which 
C4d cutoffs are clearly defined, and simultaneous alloantibody detection is employed30. 
Recently, C4d-negative AMR has been described in the renal transplant setting, which 
can be distinguished through mRNA analyses of endothelial activation transcripts31. On 
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the other hand, in small bowel transplantation, the relationship between positive C4d 
staining and AMR is less pronounced than in kidney transplantation32.
The role of AMR in pancreas transplantation has not been extensively studied. A 
search of the literature up to April 2008 (the date of the first publication of the Banff 
classification scheme for pancreas allograft rejection) reveals 2 case reports of patients 
with biopsy-proven AMR of the pancreas33;34 and one study of 136 patients with SPKT, 
in which 2 pancreas transplant biopsies were available that were both positive for C4d35. 
In the first Banff classification of pancreas allograft rejection36, C4d was included as a 
marker for AMR. At that time, however, only a few case reports had documented C4d 
in pancreas transplant biopsies. After April 2008, larger studies were performed to assess 
the role of AMR in pancreas transplantation. Torrealba et al were the first to describe 
C4d staining patterns in pancreas transplants and reported that only the positive staining 
of interacinar capillaries (IAC) was of significance. Furthermore, the authors found 
that the C4d staining of IAC correlated with circulating donor-specific antibodies37. To 
date, four other relatively large studies on the relevance of DSA and AMR in pancreas 
transplantation have been performed38-41. In the latest Banff classification of pancreas 
allograft rejection42, the same characteristics have been defined for AMR as in the kidney 
transplant setting. This definition has resulted in the exclusion of graft dysfunction36 
as a parameter and the incorporation of histological evidence of graft injury. Evidently, 
additional research is necessary for the pancreas transplant setting and is addressed in the 
work described in this thesis.
2. type 1 diAbetes And trAnsplAntAtion
The incidence of diabetes mellitus is growing rapidly, with an estimated 171 million 
affected individuals in 2000, which is projected to rise to 366 million by 203043. Globally, 
50% of all diabetes patients die of cardiovascular diseases and 10%-20% die due to causes 
related to end-stage renal failure. Diabetes is also a leading cause of renal failure, both 
in developed and developing countries44. Approximately 10% of all diabetes mellitus 
patients suffer from type 1 diabetes, which is an autoimmune disease characterized by the 
selective destruction of insulin producing ß-cells in the islets of Langerhans. The onset 
typically occurs before adulthood, and several factors (both genetic and environmental) 
initiate or trigger the poorly understood process of autoimmunization that leads to the 
progressive destruction of ß-cells. 
The incidence of childhood-onset type 1 diabetes is rising worldwide, with an overall 
annual increase of 3.4% for the period between 1995 and 199945. Current estimates for 
Europe indicate that, from 2005 to 2020, the prevalence of type 1 diabetes in children 
below the age of 15 will increase by 70%46. The demand and need to find a more effective 
therapy and, if possible, a curative treatment is rising.
The most frequently used therapy for controlling blood glucose involves the exogenous 
administration of insulin, either by subcutaneous injection or glucose level sensing pumps. 
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Unfortunately, in a substantial proportion of patients, the inadequate control of blood 
glucose levels results in secondary microvascular complications, such as retinopathy47, 
neuropathy, and nephropathy, as well as macro-vascular disease48. When diabetic 
nephropathy with overt proteinuria has developed, it cannot be reversed, and eventually 
renal replacement therapy is necessary. However, kidney transplantation alone has no effect 
on the progression of extra-renal complications. Restoring endogenous insulin production 
by replacing the insulin-producing ß-cell population would provide a more effective means 
to halt or even reverse the debilitating complications of diabetes mellitus. Therefore, 
simultaneous pancreas-kidney transplantation is currently the preferred treatment option 
for diabetic patients with or approaching end-stage renal failure. Preferably, intervention 
would take place prior to the development of secondary complications; restoring the 
ß-cell population by transplanting isolated islets of Langerhans provides an attractive 
option for the future. In the current field of ß-cell replacement therapy, whole pancreas 
transplantation is a well-established cure for type 1 diabetes, while islet transplantation is 
still experimental and only available in a few centers.
1) Whole pancreas transplantation is currently the only approved strategy and has high 
success rates. Pancreas transplantation constitutes a major surgical intervention, 
most often performed simultaneously with a kidney transplantation, which limits its 
acceptability and use to patients with (or approaching) end-stage renal failure.
2) Islets of Langerhans transplantation holds promise but is currently only employed in 
research settings. Islet transplantation offers the attractive option of minimal invasiveness 
and, with further improvement in immunosuppressive therapies, early intervention. 
However, islet transplantation still suffers from poorer results in terms of freedom from 
exogenous insulin and graft survival rates compared with a whole pancreatic transplant.
This thesis focuses on acute (antibody-mediated) rejection in kidney, simultaneous 
pancreas-kidney and islets of Langerhans transplantation. One important difference in 
kidney transplantation alone compared with both whole pancreas and islets of Langerhans 
transplantation is the fact that kidneys are allocated based on algorithms that include 
matching criteria for HLA antigens. Simultaneous pancreas-kidney and islets of Langerhans 
recipients are transplanted if ABO-compatible but without prospective HLA-matching.
2.1 pancreas transplantation
The discovery by Joseph von Mering and Oscar Minkowski in 1889 that the pancreas 
is involved in the development of diabetes established a profound research interest in 
pancreas transplantation. The first successful human simultaneous pancreas-kidney 
transplantation (SPKT) was performed in 1966 at the University of Minnesota. Although 
the results of SPKT were initially poor, it was established that insulin independence 
could be achieved through this procedure. Until 1990, pancreas transplantation was 
considered an experimental procedure. Since 2000, the American Diabetes Association 
has adopted pancreas transplantation as an acceptable therapeutic option for patients 
with end-stage renal failure (ESRF) due to diabetes mellitus on the condition that these 
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patients also previously received or will receive a kidney transplant. In Europe, pancreas 
transplantation is an accepted therapeutic modality for patients with type 1 diabetes. In 
recent decades, further refinement of surgical techniques, better immunosuppressive drugs 
and regimens, and advancements in patient management have decreased the technical 
and immunological failure rates of pancreas transplantation and have established the 
current success rates49. As of 2010, over 35,000 pancreas transplants have been reported 
worldwide to the International Pancreas Transplant Registry (IPTR)50.
Types of pancreas transplantation
A pancreas allograft is most often transplanted simultaneously with a kidney allograft 
(SPKT) to restore renal function and cure the underlying disease, type 1 diabetes. SPKT 
is documented to have a positive effect on the quality of life of recipients51;52 and may even 
halt or reverse secondary diabetic complications53-55. In SPKT, the pancreas and kidney 
are procured from one deceased donor. In the period 2004-2008, 73% of all pancreas 
transplantations in the United States were in the form of an SPKT56.
In addition to an SPKT, the pancreas can be transplanted alone (PTA) or after a 
previous kidney transplantation (PAK). Pancreas transplantation alone, or a solitary 
pancreas, is only performed in patients who suffer from labile diabetes with recurrent 
severe hypoglycemic episodes with loss of consciousness and/or requiring necessary 
assistance from a third party48. Pancreas after kidney transplantation (PAK) is performed 
in patients who have previously undergone kidney transplantation (for example, from a 
live donor) and already receive maintenance immunosuppressive therapy. Another reason 
for PAK is when the pancreas is lost due to thrombosis or acute rejection after an SPKT, 
and a repeat pancreas transplantation is performed to ensure glycemic control. 
Patient and graft survival after pancreas transplantation
Clinically, pancreas graft success is defined as the freedom from exogenous insulin therapy. 
In the first year after transplantation, small differences in pancreas graft survival have been 
found for the three types of transplantation (SPKT, PAK and PTA)57. In the long run, 
however, the results after an SPKT are superior to those after a PAK or a PTA. Pancreas 
graft survival rates for SPKT recipients were 86% at 1 year and 53% after a 10-year 
follow-up, while PAK graft survival rates were lower, with a 1-year survival rate of 77% 
and a 10-year survival rate of 35%. PTA recipients had even poorer graft survival rates 
with 81% at 1 year and only 26% after 10 years57. Patient survival rates after pancreas 
transplantation have markedly improved over the years, with over 90% of patients still 
alive 3 years after transplantation for the period between 2004-200858.
In two studies that assessed mortality risk following transplantation, SPKT patients were 
shown to have a lower mortality risk than diabetic patients who were on the waiting list59;60. 
However, the results for the PAK and PTA procedures in these analyses were inconclusive. 
One study showed an increased mortality risk for transplanted patients compared with 
conventional therapy for patients on the waiting list60, while another study reported no 
difference in survival59. These differences may be explained, at least in part, by the different 
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follow-up periods in these studies. In the first year after pancreas transplantation, there is a 
relative high perioperative mortality rate, but after this initial period, mortality is low. For 
the pancreas transplant waiting list, on the other hand, the mortality rate is low in the first 
year, but increases significantly with time spend on the waiting list.
Finally, various studies found that the quality of life after transplantation is 
improved51;52, although the assessment tools are subject to debate. In addition, pancreas 
transplantation may slow down or even reverse the progression of otherwise progressive 
and often debilitating complications, such as (recurrent) nephropathy54, retinopathy55, 
neuropathy53 and macro-vasculopathy61.
Pancreas transplantation and complications
Although proven to be very successful, SPKT remains a major surgical intervention in 
a vulnerable patient population with often considerable co-morbidity. Compared to a 
kidney allograft, the pancreas has relatively low blood flow, which gives rise to specific 
complications more frequently associated with pancreas transplantation. Transplantation 
of the pancreas may lead to thrombosis, pancreatitis due to ischemia/reperfusion injury, 
and/or acute rejection of the graft and is associated with morbidity due to the need for 
exocrine drainage, either enteric or via the bladder. 
Risks, complications, and adverse events related to pancreas transplantation can be 
divided into short-term procedure-related risks and long-term risks, which are mostly 
associated with the life-long need for immunosuppressive therapy. Technical failure 
within the first 3 months is still the most frequent cause of graft loss, followed by patient 
death with a functioning graft58. The causes for early pancreas graft loss due to technical 
failure are various, with graft thrombosis the most frequent and infection, pancreatitis, 
anastomotic leakage and bleeding the less frequent causes56;62. Drainage of the pancreatic 
enzymes can be established via the bladder or by enteric anastomosis. Primary enteric 
drainage has been associated with higher early technical failure rates58.
After the direct perioperative period, which has a relatively high rate of technical 
failure, the pancreas graft is potentially exposed to the same threats as the simultaneously 
transplanted kidney, including threats such as acute rejection, toxicity of immunosuppressive 
drugs63, and recurrence of the underlying disease64. In the early days of pancreas 
transplantation, the potential toxicity of steroids to ß-cells became apparent, and today 
most immunosuppressive regimens are steroid-sparing or avoiding. However, most of the 
other immunosuppressive drugs that are still widely used are either nephrotoxic or known 
to hamper ß-cell function65. Furthermore, the long-term use of immunosuppressive drugs 
is associated with an increased risk of developing malignancies, in particular, skin cancers 
and certain lymphoproliferative disorders66. In renal transplantation, malignancies caused 
by immunosuppressive therapy are the third most common cause of death67;68. Use of 
immunosuppressive agents is also associated with an unfavorable cardiovascular risk profile 
and an increased risk of cardiovascular events. The increasing number of patients with type 
1 diabetes and the current shortage of donor organs available for transplantation pose the 
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biggest threats to patients with diabetes and end-stage renal failure who are currently on 
the waiting list for kidney and/or pancreas transplantations.
2.2  islets of langerhans transplantation
Islets of Langerhans are the endocrine constituents of the otherwise exocrine pancreas. 
The islets vary in size69;70 (ranging mostly between 50-300 µm in diameter) and 
composition69;71 and are unequally distributed from head to tail72. A mere 1-2% of the 
pancreas is composed of these endocrine islets, while the bulk of the pancreas is composed 
of exocrine tissue producing digestive enzymes. 
Islets of Langerhans are ‘mini-organs’ composed of several hormone producing cells, 
and, to a lesser extent, stromal cells, endothelial cells from the microvasculature, nerves, 
and immune cells such as dendritic cells (DC). The most abundant cell type of the islet 
is the ß-cell, which produces insulin and amylin. Islets consist of α-cells producing 
glucagon, δ-cells secreting somatostatin, PP-cells secreting pancreatic polypeptide, and 
γ-cells producing ghrelin. The ß- and α-cells maintain blood glucose homeostasis. In 
type 1 diabetes, the capacity of the ß-cell to produce insulin is destroyed as autoimmune 
antibodies evoke the selective destruction of these cells. To cure type 1 diabetes, grafting 
of only the insulin-producing ß-cell mass would, in theory, suffice. 
In 1893, 29 years before the discovery of insulin, the use of freshly slaughtered sheep 
pancreas pieces was explored to cure a human diabetes patient. The 15-year-old recipient 
died in coma after 3 days73. In 1972, the effectiveness of islet transplantation as a therapy 
to temporarily resolve diabetes was established in a rodent model74. The first actual 
successful human pancreatic allogeneic islet transplantation was performed in 197875. 
Unfortunately, the extraction of sufficient numbers of functional islets from a human 
donor pancreas proved to be an obstacle, thereby slowing down these first initiatives.
In the United States, the Food and Drug Administration (FDA) has put allogeneic 
pancreatic islets under legislation as a drug product and as a biological product. Legislation 
mandates that, for the isolation of islets as a biologic product, facilities procuring and 
handling pancreatic islets must adhere to Good Manufacturing Practices. Currently, the use 
of pancreatic islets for the treatment of type 1 diabetes is considered experimental. To date, 
approximately 1000 islet transplantations worldwide have been performed, primarily due to 
the lack of donor pancreata and the still disappointing success rates. Several causes have been 
proposed for the poor success rates, such as allograft rejection, the instant blood-mediated 
inflammatory reaction (IBMIR)76, the recurrence of auto-immune type 1 diabetes77-79, ß-cell 
senescence and ß-cell cytotoxicity caused by the immunosuppressive agents65.
In 2000, a breakthrough publication by a research group from Edmonton reported on 
the islet transplantation results of 7 islet recipients one year post-transplantation80. The 
7 recipients remained insulin independent for a median time of 11 months. Although 
this was a small study, its results stirred much enthusiasm in the diabetes community80. 
In Edmonton the islet isolation and transplantation protocol was changed by improving 
the islet isolation procedures, by setting an adequate target islet mass for transplantation 
18
including repeated islet implantations and by altering the immunosuppressive regimen. 
The success of the islet isolation and transplantation protocol developed in Edmonton 
was confirmed by an international study group in 200681. After the initial improvements 
by the Edmonton research group, several modifications to the protocol were tested and 
implemented to further advance the success rate of islet transplantation82;83. 
Given that islet transplantation has not proven as successful as initially anticipated, 
research is currently aimed at various improvement possibilities. Given that the interactions 
between the human immune system and human islets of Langerhans after transplantation 
are difficult if not impossible to monitor and study84-86, most research is conducted on 
animal models. Both rat and mouse models are studied to improve isolation conditions 
and the transplantation process and study the interactions between recipient and host 
tissue. There is one major discrepancy between animal models and the human transplant 
setting. In animal models, the islets are most often transplanted underneath the kidney 
capsule, for numerous practical reasons82;87;88, as opposed to intra-portal infusion and 
subsequent liver engraftment of islets in humans.
Patient and graft survival after islet transplantation
Initially, success of islet transplantation was defined as having prolonged insulin 
independent glucose homeostasis for all treated patients. However, after the first few 
islet transplantations, it became apparent that insulin independence is difficult to 
establish. Most patients had to resume exogenous insulin therapy eventually, although 
insulin requirements to achieve euglycemia were reduced compared with the need before 
islet transplantation. In these patients, residual C-peptide levels could be detected in 
the serum of the recipient, which were absent before transplantation, indicating that 
some transplanted islets still functioned. C-peptide is secreted from the ß-cell together 
with insulin in a 1:1 molar ratio and, as such, can be used as a surrogate marker for 
ß-cell function. These residual C-peptide levels are known to reduce the number of 
hypoglycemic episodes in these patients89. Therefore, the reduction of insulin use, the 
frequency of hypoglycemic episodes, and quality of life90 can be measured as secondary 
definitions of islet transplantation success. In 2003, the US FDA Biological Response 
Modifier Advisory Committee met to discuss an alternative definition of success, which 
they defined as follows: the restoration of sustained euglycemia (i.e., the absence of hyper-, 
and hypoglycemia) with no or reduced exogenous insulin requirement91. 
From the patient’s perspective, an improvement in quality of life can still represent a 
successful transplantation, even if insulin dependency recurs. Autocrine insulin production, 
indicated by blood C-peptide levels, was still detectable even though additional exogenous 
insulin therapy was required. These residual C-peptide levels were related to improved glycemic 
control and resulted in reduced patient fear of hypoglycemia92. In addition, the health-related 
quality of life of the diabetes patient was found to be improved after the islet transplantation93.
Islet transplantation alone (ITA) (i.e., in the absence of renal transplantation) was 
systematically reviewed by Guo et al for the Canadian Institute of Health Economics94. As 
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reported in the 11 key studies included in this systematic review, 30%-69% of the patients 
were insulin independent 1 year after islet transplantation. Two years after islet transplantation, 
only 14%-33% of the patients remained insulin independent94. The procedure itself has a steep 
learning curve, and therefore higher success rates are observed in more experienced centers. In 
a 5-year follow-up study conducted by the experienced Edmonton group between 1999-2004 
that included 65 patients, insulin independence rates were reported at ~69% after 1 year, ~37% 
after 2 years, and 7.5% 5 years after the transplantation. After 5-years of follow-up, C-peptide 
levels could still be detected in ~80% of the patients89.
Few data exist on patient survival after islets of Langerhans transplantation because only 
a limited number of patients have received a transplant to date. Of the 325 adult recipients 
reported to the Collaborative Islet Transplant Registry, 7 died of causes that had an unknown 
relationship with the procedure95. No randomized, controlled trials have addressed the 
mortality risk by comparing islet transplantation with the best medical practice. We can 
speculate, based on the results from pancreas transplantation studies, that the mortality 
risk will ultimately be reduced for patients who receive a successful islet transplantation59;60.
Types of islet transplantation, risks, and complications
Similar to the pancreas transplant setting, islets of Langerhans can be transplanted in 
three different combinations. ITA is the most commonly used procedure. The benefits of 
this procedure include the possibility of early intervention without major surgical risks, 
a direct improvement in quality of life, while secondary complications of diabetes can 
be prevented90. However, whether the discontinuation or reduction in exogenous insulin 
therapy and the improved quality of life outweigh the daily and life-long burden of 
requiring immunosuppressive drugs and dealing with their side-effects must be carefully 
determined for each eligible recipient individually96.
Islet after kidney transplantation (IAK) is another combination in which islets of 
Langerhans can be transplanted. In this case, the secondary diabetic complications have 
already evolved and the patient has received a kidney transplant. These patients already 
receive maintenance immunosuppressive agents, and the clinical decision to proceed with 
islet transplantation has a different risk-benefit ratio97. 
Every operation or procedure has its potential and specific complications. For 
islet transplantation there is little chance that a detrimental complication will develop 
because, unlike whole pancreas transplantation, islet transplantation is a minimally 
invasive procedure98. The main reported infusion-related complications are hepatic 
bleeding, portal vein thrombosis, and transient elevation of liver enzymes99. During the 
peritransplantation period, the direct contact of islets with blood components in the 
hepatic portal system is thought to cause an immediate blood-mediated inflammatory 
reaction (IBMIR)76, which results in a marginal and inadequate islet mass that actually 
reaches the liver tissue100;101. Post-transplantation, revascularisation84, rejection, glucose 
toxicity102, and immunosuppressive drug toxicity65;81;94;103 are additional factors that are 
considered responsible for the further decline of islet allograft survival.
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3.  scope of this thesis
The aim of the work described in this thesis was to obtain greater insight into the 
mechanisms of acute rejection in renal, simultaneous pancreas-kidney, and islets of 
Langerhans transplantation. Within the scope of acute rejection, the main focus of this 
thesis was on antibody-mediated rejection (AMR), which was first described in the renal 
transplant setting, but the pathological process is not completely understood. With the 
recognition of previously unknown manifestations, such as C4d-negative AMR and focal 
C4d-positive staining with DSA, the field has become even more complex. Furthermore, 
in other organ transplant settings, such as the pancreas, even basic evidence of the existence 
or relevance of AMR is lacking. In this thesis, the role of C4d was examined in the renal 
transplant setting, in which prospective HLA-matching is the standard of care, before 
venturing into AMR in the non-HLA matched transplants, which include simultaneous 
pancreas and kidney and islets of Langerhans transplantation. 
Positive C4d staining in the capillaries of transplanted tissue is associated with the 
presence of donor-specific antibodies in the circulation. In Chapter 2, the long-term 
outcome of C4d staining in renal allograft biopsies with an acute rejection was studied. The 
study described in Chapter 2 shows that positive staining for C4d was rare in this cohort 
of kidney transplant recipients and that the mere presence of a positive C4d staining had 
no effect on patient and/or graft survival nor could it predict steroid resistance as defined 
by the need for anti-thymocyte globulin therapy.
To elucidate the role of AMR in pancreas graft failure, a retrospective study of 
pancreas biopsies was conducted in collaboration with the University of Maryland. The 
study presented in Chapter 3 shows that AMR does occur after pancreas transplantation, 
requires the presence of both diffuse interacinar C4d staining and DSA for its diagnosis, 
and is associated with poorer graft survival.
In the study described in Chapter 4, pancreas graft transplantectomies performed 
within one year after the SPKT were compared with pancreas grafts that functioned 
at least 4 years after the SPKT. This study shows that early pancreas graft failure was 
associated with older donor age (>45 years of age) and female gender of the recipient. 
Furthermore, AMR (defined by the C4d-positive interacinar capillary staining in the 
presence of DSA and morphological evidence of graft injury) was present in 7 out of 33 
cases of early pancreas graft loss.
In Chapters 5 and 6, we reviewed islets of Langerhans transplantation. Chapter 5 is a 
clinical review of the status of human islet transplantation. Structural and morphological 
changes of islets transplanted in rodents were assessed in Chapter 6, focusing on blood 
vessel revascularization, neurogenesis and lymphatic revascularization.
Cellular immune modulation in islet transplantation is the topic of Chapter 7. 
Using donor-derived tolerogenic DC, we aimed to prevent rejection in a fully MHC-
mismatched rodent model. The study described in Chapter 7 showed that the use of these 
tolerogenic DC provoked an antibody-dependent accelerated destruction of the allograft. 
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AbstrAct
background and objectives
Diffuse C4d staining in peritubular capillaries (PTCs) during an acute rejection episode 
(ARE) is the footprint of antibody-mediated rejection. In current clinical practice, diffuse 
C4d+ staining during acute rejection is regarded as an inferior prognostic sign. This case-
control study investigated the prognostic role of mere C4d staining for graft outcome 
during an ARE in a well defined cohort of similarly ARE-treated patients.
design, setting, participants, & measurements
All kidney transplant recipients in the authors’ center from January 1, 1995 to December 
31, 2005 were reviewed. From these patients, 151 had a clinical ARE. Paraffin and/or 
frozen material was available for 128 patients showing a histologically proven ARE within 
the first 6 months after transplantation. All ARE patients were treated similarly with 
high-dose pulse steroids and in the case of steroid unresponsiveness with anti-thymocyte 
globulin. Biopsies were scored according to Banff criteria. Frozen and paraffin sections 
were stained by immunofluorescence (IF) and immunohistochemistry (IHC) for C4d, 
respectively, and scored for PTC positivity.
results
Diffuse C4d+ staining in PTCs was found in 12.5% and 4.2% sections stained by IF or 
by IHC, respectively. Four patients showed diffuse positive staining with both methods 
but showed no different risk profile from other patients. No relation between C4d 
staining and clinical parameters at baseline was found. C4d staining was not associated 
with steroid responsiveness, graft, or patient survival.
conclusions
This study shows that C4d staining is not related to clinical outcome in this cohort of 
histologically proven early AREs.
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introduction
In renal transplantation, long-term graft survival strongly depends on events occurring 
early (i.e., within 1 year) after transplantation. A major event is the occurrence of an 
acute rejection episode (ARE), which is a main risk factor for the development of graft 
loss over time1-3. An ARE can be mediated by cellular- and antibody-mediated reactions. 
In antibody-mediated rejection (AMR), donor-specific antibodies (DSAs) can bind 
complement factors and initiate the classical pathway of complement activation. During 
the activation cascade, C4d, a complement split product, is formed. C4d has the capacity 
to covalently bind to target molecules on the endothelium of peritubular capillaries (PTCs) 
and is therefore regarded as a footprint of AMR4. Sensitivity (95%) and specificity (96%) 
of diffuse C4d staining in PTCs for the presence of DSAs is high5. Other studies have 
found a strong relation between diffuse C4d staining of PTCs and the presence of DSAs6-8. 
Acute AMR is associated with nonresponsiveness to standard rejection therapy of steroids 
(i.e., steroid resistance) and has a detrimental effect on graft outcome8-12. The outcome of 
AMR significantly improves when promptly treated with aggressive immunosuppressive 
regimens13 17. The combination of circulating DSAs, histomorphological features of AMR, 
and diffuse C4d deposition is currently the gold standard in the diagnosis of AMR16. 
Previous studies found unfavorable graft outcome for C4d+ stained biopsies7;18-20. This 
might suggest that sole C4d deposition could be used as prognostic marker and also guide 
more aggressive therapy.
In 1993, Feucht et al. were the first to describe C4d staining in renal transplant 
biopsies21. In 93 renal allografts showing dysfunction after transplantation, an incidence 
of 46.2% diffuse C4d and 8.6% focal C4d staining was found. C4d staining significantly 
correlated to 1-year graft survivals of 57%, 63%, and 90% in diffuse, focal, and negative 
staining, respectively. Subsequent studies showed an unfavorable graft out-come in diffuse 
C4d+ stained biopsies taken on clinical indication6-8;18-22. However, these studies have five 
major drawbacks. First, most studies included biopsies with a broad range of histologic 
diagnoses, causing heterogeneity. Second, follow-up time (average 5 years) was relatively 
short in most studies. Third, in some studies rejection therapy differed between C4d+ and 
C4d- patients. Fourth, some studies used other criteria to determine C4d positivity than 
the Banff criteria. Fifth, some studies included more than one biopsy per patient and used 
the biopsy that stained most positive for C4d as the index biopsy. 
The prognostic value for graft survival of untreated C4d+ AREs has not been 
investigated in a cohort of patients with AREs who were not differently treated for 
this. We questioned whether C4d+ AREs show a difference in long-term renal function 
compared with C4d- AREs when treated according to the same therapy regimen.
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mAteriAls And methods
patients
We reviewed all 723 patients who received a renal transplant in our center from 1995 until 
2006, of which 498 (68.9%) never had a rejection episode. One hundred and twenty-eight 
patients who had a clinically suspect and histologically proven first ARE within 6 months 
after transplantation (17.7% of all single renal transplant patients) were included in this 
study. A total of 104 frozen and 118 paraffin-embedded renal biopsies were available, with 
an overlap of 94 patients. Maintenance and rejection therapy were analyzed. 
All patients received calcineurin inhibitor (CNI)-based maintenance immunosuppression 
(Neoral: cyclosporine [CsA] microemulsion [86%]; or Prograft: tacrolimus [Tac] [14%]) and 
corticosteroids (P) with or without mycophenolate mofetil (MMF; 62.5%). Since 2000, all 
patients received prophylactic therapy with an IL-2 receptor antagonist (basiliximab), and one 
patient received induction with anti-thymocyte globulin (ATG). Of the 128 patients with 
biopsy-proven acute rejection, 30% received prophylactic antibody therapy. 
AREs were treated with high-dose methylprednisolone (1 g intravenously for 3 
consecutive days). If serum creatinine (SCr) did not return to baseline within a 20% 
range, a 10-day course of ATG at a dose 5 mg/kg was given. Steroid resistance was defined 
as the use of ATG therapy. Biopsies were taken before steroid therapy was started. Patients 
who had undergone a pancreas-kidney or other combined organ transplantation were 
excluded from this study. All patients had a negative complement-dependent cytotoxicity 
crossmatch before transplantation.
clinical data
Donor and recipient age and sex, donor source, number of rejection episodes and 
re-transplantation, percentage panel reactive antibodies (PRAs) present before 
transplantation, time between transplantation and the occurrence of the ARE, HLA 
mismatches, delayed graft function, patient and graft survival, quantitative proteinuria, 
and steroid resistance were analyzed. Graft failure was defined as return to dialysis. Graft 
failure was censored for patient death. 
SCr was used as a surrogate marker for renal function over time. During patient 
follow-up, SCr was measured at regular check-up times and on additional clinical 
indications. SCr at 1 year after transplantation was taken as baseline. We used time until 
patients reached a SCr value of 150% and 200% of their SCr at 1 year as an indicator of 
renal function follow-up. In a Kaplan–Meier survival analysis, time to these events was 
compared between the C4d+ and C4d- group. 
histology
For routine diagnostic evaluation, paraffin-embedded sections were cut and stained with 
silver methamine, hematoxylin and eosin, and periodic acid–Schiff. Two independent 
pathologists (I.B. and N.G.) blindly scored biopsies for morphologic features by light 
microscopy using the Banff classification16.
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c4d staining
Staining protocols have been described previously23-25. Immunofluorescent staining was 
performed on 4-µm frozen sections with monoclonal mouse anti-human C4d antibody 
(Quidel, San Diego, CA). Immunohistochemical staining was performed on 4-µm 
paraffin sections with polyclonal rabbit anti-human C4d antibody (Biomedica Gruppe, 
Wien, Austria). Two independent and blinded observers (IF: M.E. and K.K.; IHC: I.B. 
and M.vG) semiquantitatively scored all sections. C4d staining in PTCs was evaluated 
according to the area percentage of positive staining in the renal cortex as described in 
the Banff ’07 criteria16. Three C4d staining groups were made: negative (<10% of PTCs), 
focal (10% to 50% of PTCs), and diffuse positive (>50% of PTCs) staining. Necrotic and 
fibrotic areas (if present) were excluded from evaluation.
statistical analyses
SPSS version 16.0 was used to perform statistical analyses. For continuous variables, 
means with standard errors were calculated and differences were assessed by independent 
sample t tests. For categorical data, crosstabs were made and differences were calculated 
by Fisher exact test. Univariate analyses using a logistic regression model were performed, 
and a multivariate analysis was performed using a logistic regression model. Survival 
analyses were performed using Kaplan–Meier survival curves and logrank tests to test for 
differences between C4d groups. The significance threshold was set at p < 0.05.
results
patient characteristics
Of the 128 patients included in this study, 77% received a donor kidney from a deceased donor 
and 23% received a kidney from a living donor. Mean follow-up time was 7.3 years (±3.9).
Immunosuppressive maintenance therapy was comparable for all patients in the 
cohort, consisting mostly of a CNI (CyA or Tac) in combination with low-dose P alone 
or P with IL-2 receptor or MMF. 
prevalence of c4d positivity
We investigated C4d staining patterns by IF (frozen sections) and IHC (paraffin-
embedded sections) staining techniques in the same cohort and related these with clinical 
outcome. Thirteen of the 104 (12.5%) sections stained by IF and 5 of the 118 (4.2%) 
sections stained by IHC showed diffuse C4d+ staining (Table 1). Focal C4d+ staining was 
seen in six (5.8%) and two (1.7%) of the patients, respectively. 
Four patients showed diffuse C4d+ staining with both techniques (Table 2). Overall, 
these patients were not remarkably different compared with the whole cohort in age, 
maintenance therapy, donor age and sex, PRAs, delayed graft function, HLA mismatches, 
rejection episodes, timing of rejection, steroid resistance, or vascular rejection. One of 
these patients lost graft function 10 days after transplantation and transplantectomy was 
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performed. The explanted organ showed severe diffuse vascular rejection with necrosis 
and graft ischemia. The other three patients maintained stable graft function and their 
grafts survived during the follow-up period (range 1.86 to 6.43 years). 
As depicted in Table 2, one biopsy was diffusely C4d+ stained by IHC, but no IF 
staining was performed because of a lack of frozen material. Seven diffusely C4d+ biopsies 
with IF staining were negative using IHC. No paraffin material was available for IHC 
staining of two diffusely C4d+ biopsies using IF. Of the six focal C4d+ cases using IF, only 
one was focal C4d+ using IHC; all others were negative. All biopsies negative for C4d 
staining by IF were also negative in the IHC staining. 
Statistical analyses were performed on IF- and IHC-stained cases. No differences were 
found in the IHC-stained cases. The results hereafter are only those analyzed using the IF 
staining. Diffuse C4d staining was called “C4d+” and focal and negative C4d staining were 
combined as one group, called “C4d”. Others categorized C4d staining in the same way5.
table 2 | Overlap between C4d staining categories using IF and IHC. 
C4d IF→
C4d IHC↓ negative focal positive diffuse positive total
Negative 77 5 7 89
Focal Positive 0 1 0 1
Diffuse Positive 0 0 4 4
Total 77 6 11 94
IF immunofluorescence on frozen tissue; IHC immunohistochemistry on paraffin-embedded tissue.
table 1 | Prevalence of C4d staining categories of PTC stained by IF or IHC. 
c4d staining category prevalence if prevalence ihc
Negative 85 (81.7%) 111 (94.1%)
Focal positive  6 (5.8%) 2 (1.7%)
Diffuse positive 13 (12.5%) 5 (4.2%)
Total 104 (100%) 118 (100%)
PTC peritubular capillaries; IF immunofluorescence on frozen tissue; IHC immuno-histochemistry on 
paraffin-embedded tissue. Data presented as n (%).
c4d and banff histology
C4d staining (IF) only related to the absence of tubular atrophy (8.3% versus 50.6%; p 
= 0.006) and not to any of the other individual components of the Banff score (Table 3). 
After IF and IHC C4d staining and blind scoring of biopsies, the biopsies of 14 patients 
showing diffuse C4d+ were subsequently reassessed (I.B.) to investigate histomorphological 
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characteristics (e.g., granulocytic infiltrate, microthrombi, peritubular capillaritis 
[Table 3], or necrotizing vascular rejection) indicative of a possible AMR4. None of those 
biopsies showed characteristics indicative of an antibody-mediated component. 
table 3 | Banff characteristics in relation to IF C4d staining patterns.
banff characteristic
C4d+ (n=12)
number (%)
C4d– (n=85)
number (%) p
Glomerulitis 6 (50) 29 (34.1) 0.34
Chronic glomerular changes 1 (8.3) 5 (5.9) 0.56
Tubulitis 7 (58.3) 49 (57.6) 1.00
Tubular atrophy 1 (8.3) 43 (50.6) 0.006
Interstitial infiltrate 5 (41.7) 48 (56.5) 0.37
Interstitial fibrosis 2 (16.7) 38 (44.7) 0.12
Intima arteritis (vascular rejection) 4 (33.3) 33 (43.4) 0.75
Chronic vascular changes 5 (41.7) 41 (52.6) 0.55
C4d+ diffuse positive stained slides versus C4d- focal positive or negative stained slides. All characteristics 
were split in presence (score 1-3) and absence (0), except for glomerulitis, tubulitis, interstitial infiltrate, and 
peritubular capillaritis where we dichotomized for mild (0,1) and severe (2,3). Fisher exact test was used to 
calculate significances of differences between groups. Values expressed as mean and number (%).
c4d and baseline clinical characteristics
Baseline clinical characteristics are shown in Table 4. Only donor age was significantly lower 
in the C4d+ group (38 ± 15 years versus 48 ± 14 years; p = 0.02). No significant difference 
in number of living related donors was observed between the C4d+ and C4d- group (1 of 13 
[7.7%] versus 13 of 91 [14.3%], respectively, p = 1.00; data not shown). The interquartile 
range for follow-up was 6.46 years (3.47 to 10.45) and 6.80 years (3.80 to 10.57) for the 
C4d+ and C4d- group, respectively. 
In a multivariate analysis, C4d was only related to donor age and not to any other 
clinical parameter (Table 4). Univariate analyses for clinical characteristics were also 
performed separately for living and deceased donors (data not shown). Results concerning 
differences in graft outcome between C4d+ and C4d- groups were similar in living and 
deceased donor recipients (younger donor age in the C4d+ group in the living kidney 
donors [38 ± 8 years versus 51 ± 12 years; p = 0.049]). 
Twelve of the 13 C4d+ patients were primarily treated with high-dose P; one patient 
primarily received ATG. Eight patients subsequently received ATG because of non-
responsiveness to steroids. These numbers were similar in the C4d- group.
c4d and clinical outcome
Incidence of steroid resistance was comparable between the C4d+ and the C4d- group 
(54%, and 47%, respectively; p = 0.770). Patient survival was similar between the two 
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C4d staining categories (data not shown). One-year graft survival was 92% for the C4d+ 
group and 97% for the C4d- group, whereas 5- and 10-year graft survivals were 92% and 
74% for the C4d+ group and 92% and 82% for the C4d- group, respectively (p > 0.05; 
Figure 1A). Results concerning differences between the C4d+ and C4d- group were 
similar between living and deceased donors. 
No difference was found between the C4d+ and C4d- group for renal function over 
time, as measured by the time when SCr reached 150% or 200% of its value at 1 year after 
transplantation. Both showed a similar curve in the Kaplan–Meier analysis for time and 
the percentage of events of reaching 150% and 200% SCr values (p = 0.981 [Figure 1B] 
and p = 0.482, respectively). No differences were found in development of proteinuria 
(g/24 h) between the C4d+ and C4d- group.
fig 1 | (A) graft survival and (b) renal function follow-up for patients with diffuse c4d+ stained 
ptcs using if (dotted line) and focal c4d stained/negative c4d stained ptcs using if (continuous 
line). (A) No significant difference in graft survival was observed between groups (P= 0.969). (B) Renal 
function follow-up was indicated by a SCr value of 150% of SCr at 1 year posttransplantation. No 
significant difference in renal function over time was observed between groups (P=0.981). Both were 
tested using Kaplan–Meier analysis.
discussion
The occurrence of an early ARE is a risk factor for loss of renal allograft function over time. 
In this study, C4d staining patterns in a group of similarly treated patients during their first 
ARE were investigated. We compared C4d staining patterns in biopsies of patients with 
a histologically proven first ARE within 6 months after transplantation. Patients in this 
retrospective cohort were all treated for their ARE according to the same protocol, firstly 
with high-dose steroids and in the case of steroid resistance with ATG. Biopsy sections were 
stained by two techniques: IF on frozen and IHC on paraffin-embedded tissue sections. 
Diffuse C4d+ staining was seen in 12.5% of IF- and in 4.2% of IHC-stained sections. 
We found no clinical or histologic risk profile related to C4d+ staining. In addition, we 
1
3
4
5
6
7
+
8
2
37
found no difference in occurrence of steroid resistance or graft survival for patients who 
in retrospect showed a C4d+ or a C4d- ARE. We conclude that the C4d staining pattern 
during an early ARE does not predict renal allograft function or survival over time. 
Since the introduction of diffuse C4d staining as a marker for antibody-mediated activity in 
the renal transplant biopsy, several studies concluded that C4d staining of biopsies with allograft 
dysfunction could be used as an adequate predictive marker for graft outcome6-8;18;20-22;26. 
However, previous studies had several drawbacks, as described in the Introduction section, 
which could explain the discrepancies between those studies and our study. 
The consistent histologic findings of an ARE and the consistent treatment of that 
episode makes our patient group unique. Graft survival in our cohort of patients was 
excellent (overall 10-year graft survival: 77.9% ± 4.7%). Our C4d+ ARE biopsies are 
most likely not indicative for AMR, but perhaps of a more subclinical type. The presence 
of C4d in biopsies might reflect some antibody being present in a T cell predominant 
acute rejection, rather than it being an AMR. Aside from tubular atrophy, no concurring 
histopathological parameters could be found. It is not known why there are significantly 
more biopsies showing tubular atrophy in the C4d- group. It is possible that the 
association of C4d- staining with tubular atrophy may reflect the younger age of donors 
in the C4d+ group. More research in a new patient cohort is required to elucidate this 
finding. Furthermore, none of the clinical characteristics related to AMR (e.g., recipient 
being female and/or young, high PRAs, number of successive transplantations, and 
number of HLA mismatches) were significantly more abundant in the C4d+ group. It is 
possible that our C4d+ ARE biopsies are of a more subclinical type, which might be due 
to better HLA matching and adequate DSA screening techniques before transplantation 
and our donor allocation protocol. We therefore strongly recommend adequate screening 
of patients pretransplantation and exclusion of any unacceptable mismatches. 
Nickeleit et al. found no difference in outcome between C4d+ and C4d- AREs27. 
However, in this study, C4d+ patients were treated more aggressively and the paper 
concluded that additionally treated C4d+ AREs may hold the same prognosis as C4d- AREs. 
In the study presented here, we show that patients with a C4d+ ARE who did not receive 
additional acute rejection treatment have the same graft outcome as a C4d- ARE. This could 
be because C4d deposition may indicate a state of graft accommodation that does not lead 
to graft failure28. The question remains how C4d as a marker for graft accommodation can 
be discriminated from C4d deposition due to ongoing AMR. Furthermore, we explicitly 
studied whether the presence of diffuse C4d+ staining during an ARE was associated with 
graft survival if not additionally treated. It is not known whether C4d+ patients (or a 
subgroup of C4d+ patients) would have improved graft function if they would have been 
more aggressively treated. We therefore do not state that additional therapy in C4d+ ARE 
patients is not indicated, but we encourage further investigation on this subject.
The incidence of C4d staining in our cohort seems to be rather low compared with 
earlier studies. In various studies a range of 10% to 55% diffuse C4d+ staining is seen 
using either staining technique5-8;18-21;26;27;29. Different explanations for this can be given. 
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Inclusion criteria in this study were tightly controlled because we required all patients to 
have a histologically proven ARE, whereas other studies show heterogeneity with regards 
to biopsy inclusion criteria, resulting in a broad histomorphological spectrum. Also, the 
time point at which the biopsies were taken differed between studies. There could be 
differences in C4d+ incidence between centers, as has also been suggested by Mengel 
et al.30. In a study with protocol biopsies stained for C4d, they reported that C4d incidence 
was related to the center the biopsy was obtained from. This could be due to differences in 
laboratory techniques, transplantation procedures, or therapy regimens between centers. 
Until now, few studies compared C4d staining techniques with IF and IHC. 
The C4d staining protocol used to be applied on frozen sections by IF using a monoclonal 
antibody21. Recently, an IHC method for paraffin-embedded sections has been developed 
using a polyclonal antibody against C4d. Seemayer et al. investigated both staining 
techniques on inter- and intra-observer variation and found a favorable result for IF-stained 
frozen sections (κ = 0.9 [IF] versus κ = 0.3 [IHC])31. However, in that study, C4d staining 
by both staining techniques was not investigated in relation to graft outcome over time. 
Also, in the most recent Banff criteria it was noted that C4d staining by IF showed more 
positivity and is possibly more sensitive, but both C4d staining techniques show strong 
relations with DSAs and it is still unclear which staining technique is to be preferred14. We 
are the first to investigate C4d staining patterns by both staining techniques in the same 
cohort and relate it with clinical outcome. We found less C4d positivity in IHC-stained 
sections compared with IF sections and found no relation to outcome. 
There are several drawbacks to our study. First, this was a single-center study; therefore, 
the results might be difficult to extrapolate to other studies. Furthermore, although this is a 
relatively large patient cohort, few C4d+ ARE patients were found. In addition, because of the 
retrospective nature of the study, presence of DSAs at the time of biopsy was not measured. 
However, earlier studies repeatedly showed that C4d staining was strongly related to DSAs5;8.
In conclusion, clinicians might feel the urge to more aggressively treat patients with C4d 
positivity during a histologically proven ARE. However, this retrospective study shows that 
C4d staining is not related to clinical outcome in this large cohort of first histologically 
proven early (<6 months) rejection episodes of patients who were not additionally treated.
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AbstrAct
C4d+ antibody-mediated rejection following pancreas transplantation has not been 
well characterized. Therefore, we assessed the outcomes of 27 pancreas transplantation 
patients (28 biopsies), with both C4d staining and donor-specific antibodies (DSA) 
determined, from a cohort of 257 patients. The median follow-up was 50 (interquartile 
range [IQR] 8–118) months. Patients were categorized into 3 groups: group 1, patients 
with minimal or no C4d staining and no DSA (n=13); group 2, patients with either DSA 
present but no C4d, diffuse C4d+ and no DSA or focal C4d+ and DSA (n=6); group 3, 
patients with diffuse C4d+ staining and DSA (n = 9). Active septal inflammation, acinar 
inflammation and acinar cell injury/necrosis were significantly more abundant in group 
3 than in group 2 (respective p-values: 0.009; 0.033; 0.025) and in group 1 (respective 
p-values: 0.034; 0.009; 0.002). The overall uncensored pancreas graft survival rate for 
groups 1, 2 and 3 were 53.3%, 66.7% and 34.6%, respectively (p=0.044). In conclusion, 
recipients of pancreas transplants with no C4d or DSA had excellent long-term graft 
survival in comparison with patients with both C4d+ and DSA present. Hence, C4d 
should be used as an additional marker in combination with DSA in the evaluation of 
pancreas transplant biopsies.
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introduction
Pancreas transplantation is a widely accepted treatment choice for diabetic patients. By 
December 31, 2003, more than 21000 pancreas transplants had been performed worldwide1. 
The 1-year survival of simultaneous pancreas kidney transplantation (SPKT) has greatly 
improved over the last decade, with rates of immunological graft failure of only 2% during 
1996–2002 in technically successful SPKT. Rejection can occur through the immunological 
pathways of acute cell-mediated rejection (ACR) or antibody-mediated rejection (AMR). 
C4d is a complement degradation product of complement factor C4, which is a 
footprint of the classical pathway of the complement cascade. C4d can be identified 
in tissue, and is a reliable marker of AMR in transplanted kidneys, intestines, heart 
and lungs2-6. The typical histopathological and clinical findings in AMR are less well 
defined in pancreas than in other transplanted organs, and the role of C4d in relation 
to AMR is only beginning to be described. In a recent study, C4d+ immunolabeling of 
interacinar capillaries was significantly associated with donor-specific antibodies (DSA) 
and dysfunction of the pancreas allograft7. 
The diagnostic relevance and therapeutic consequences of positive C4d staining have 
been investigated extensively in relation to kidney transplantation. For other solid organ 
transplantations, knowledge of AMR and the role of C4d varies. In small bowel transplants, 
for instance, the relationship between C4d+ staining and AMR is less pronounced than in 
the kidney3. For pancreas transplantation, which is often performed simultaneously with 
kidney transplantation, very little is known about the significance of C4d positivity. In 
the current study, we illustrate the C4d staining patterns in transplanted pancreases, the 
role of C4d in establishing a diagnosis of AMR, and their relationship with the long-term 
outcome of graft recipients from the combined experiences of two transplantation centers.
pAtients And methods
patient selection
The electronic records of the Department of Pathology at the Leiden University Medical 
Center (LUMC) and the Department of Pathology at the University of Maryland 
Medical Center (UMMC) were searched resulting in the identification of 257 patients 
with pancreas allograft transplantation; 109 from LUMC (between 1991 and 2001) and 
148 from UMMC (between 2000 and 2007). Of the 257 patients, 56 biopsies were 
available for this study (37 from UMMC and 19 from LUMC), and 27 patients had DSA 
information. From the LUMC, 26 preoperative pancreas transplant biopsies were available 
which were used to establish pre-transplantation reference values for C4d staining of 
pancreas tissue. Clinical information on donor variables (gender and age at time point 
of death); recipient variables (age at time of transplantation, gender, re-transplantation, 
pregnancy and transfusion history and need for pre-emptive dialysis); transplantation-
related factors (panel-reactive antibodies, human leukocyte antigen (HLA)-A, -B and 
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-DR mismatches, cold ischemia time and induction therapy); and post-transplantation 
features (immunosuppressive regimen, acute rejection history, rejection treatment, time 
and indication for biopsy, cause of allograft loss, cause of death and follow-up in months 
of the pancreas allografts) were obtained from UMMC and LUMC medical records after 
approval for the study by the respective Institutional Review Boards.
biopsies
All pancreas transplant biopsies were performed because of clinically suspected graft 
rejection, except for 1 protocol biopsy (Table 1). From all biopsies, 4-µm sections were 
cut and stained with hematoxylin and eosin (H&E). 
immunohistochemical c4d staining
At LUMC, C4d immunohistochemical staining was performed on freshly cut formalin-
fixed 4-µm paraffin sections of pancreas. Sections were deparaffinized, antigen was retrieved 
with TRIS/EDTA, pH 9.0, and the sections were incubated with a 1:25 dilution of rabbit 
anti-C4d polyclonal antibody (MP products, Biomedica, Austria) for 30 min. Subsequently, 
endogenous peroxidase was blocked and the EnVisionTM Detection Systems Peroxidase/
DAB, Rabbit/Mouse (DAKO cytomation, Glostrup, Denmark) was used for development. 
At UMMC, C4d immunostaining was performed on 5-µm formalin-fixed paraffin sections 
using an automated immunohistochemical stainer (Ventana Medical Systems, Tucson, AZ) 
and labeled with a 1:50 dilution of anti-C4d rabbit polyclonal antibody (American Research 
Products, Inc., Belmont, MA). Target detection was performed using an indirect biotin-
avidin system incorporating diaminobenzidine. Endogenous peroxidase quenching and biotin 
blocking were performed on-instrument with kit reagents (Ventana Medical Systems, Tucson, 
AZ). All stained sections were counterstained with hematoxylin for orientation.
grading
The H&E-stained sections from the pancreas biopsies were scored according to the 
Banff working proposal of 20088. Positive C4d staining patterns in interacinar capillaries 
were scored (Figure 1C). Diffuse C4d positivity was defined as >50% positively staining 
interacinar capillaries, focal C4d positivity was 5% to 50% positively staining interacinar 
capillaries, and minimal positive staining was <5% positively staining interacinar capillaries 
or a negative staining pattern. Table 2 lists the scorings of all individual parameters in 
relation to graft outcome.
immunosuppressive therapy
At LUMC, standard maintenance therapy consisted of prednisone (P), cyclosporine (CsA) 
and azathioprine until May 1995. Transplant recipients after May 1995 received P, CsA and 
mycophenolate mofetil (MMF). Three patients received a 10-day course with 5 mg/day 
OKT3 as induction therapy. Acute rejection episodes were treated according to a standard 
protocol consisting of methylprednisolone (MP) 1 g intravenously for 3 consecutive days 
for the first rejection episode; a 10-day course of antithymocyte globulin (ATG) at a dosage 
46
of 5 mg/kg guided by absolute lymphocyte counts at the second rejection episode and 
again MP for the third rejection episode. None of the patients were treated for AMR. 
Immunosuppressive protocol at UMMC included induction therapy with ATG 
(rabbit) (years 2000–2006) dose of 7–10 mg/kg or alemtuzumab (Alm) (2006–current) 
30 mg. Steroid bolus of P 500 mg was administered intraoperatively and tapered to either 
low dose (before 2004) or off over 21 days (after 2004). Maintenance therapy included 
tacrolimus and MMF. Rejection therapy was tailored based on clinical suspicion, C4d 
staining and presence of detected antibody; and could include additional steroid therapy, 
ATG, plasmapheresis (PP) and intravenous immunoglobulin (IVIg).
dsA assessment
At LUMC, patient serum samples from 14 of 19 biopsies from 18 patients (1 patient had 
2 biopsies) 1 month post-transplantation were procured from −80°C storage. A LATTM 
mixed class I & II ELISA (One Lambda, Canoga Park, CA) was carried out to detect the 
presence of HLA class I and class II antibodies. The ELISA was conducted according to 
protocol with OD readouts at 630 nm. Afterward, seven positive patients were assessed for 
the specificity of the antibodies with a complement-dependent cytotoxicity (CDC) test.
At UMMC, DSA were identified in the patient serum samples at the time of biopsy 
using the Luminex 100 IS System (Luminex, Austin, TX). High definition single beads 
were used with a mean intensity of fluorescence (MFI) cutoff value for one single antibody 
at MFI 1000. When three antibodies were present, for example, the MFI cutoff was 3000.
statistical analyses
Raw data were processed using descriptive statistics and graphical representations. For 
uncensored graft survival, graft failure was defined as resuming insulin therapy or patient 
death with functioning graft. For censored graft survival, graft failure was defined as 
resuming insulin therapy; patient death with functioning graft was considered as lost 
to follow-up. Kaplan–Meier survival curves were compared with the log-rank test for 
uncensored and censored graft loss. Significance for all tests was set at 0.05. In Table 2 
and Figure 2 the differences between groups, C4d−/C4d+ and DSA negative or positive 
were assessed by means of the chi-squared test, with * p<0.05 and ** p<0.001. Statistical 
calculations were performed using SPSS 16.0 for Windows (SPSS, Chicago, IL).
results
patient demographics
The mean age of the recipients was 46 ± 9 years, 45% were female and 91% were 
Caucasian. All the recipients had diabetes and 48% had hypertension as co-morbidity. 
The mean HLA mismatch was 4.4 ± 1.4. The median follow-up was 50 (IQR 8–118) 
months. Table 1 gives an overview of patient and donor demographics, clinical parameters, 
biopsy indication and treatment in relation to pancreas allograft function. No significant 
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table 1 | on the previous page | patient and donor demographics, clinical parameters, biopsy 
indication and treatment in relation to pancreas allograft function.
ACS = abdominal compartment syndrome; Alm = alemtuzumab; ATG = anti-thymocyte globulin; 
Bas = basilixumab; biopsy (days), number of days after transplantation that biopsy was taken; CIT = cold 
ischemia time; creat = creatinin; Dac = daclizumab; G = group; GL = graft loss; HbA1c = hemoglobin 
A1c; HLA mm, human leukocyte antigen mismatches; MI =myocardial ischemia/infarction; MP = methyl 
prednisolone; OKT3 = muromonab-CD3; PAK = pancreas after kidney transplantation; PDFG = patient 
death with functioning graft; peripancreatic fluid = peripancreatic fluid collection; PP/IVIG = plasmapheresis/ 
intravenous immunoglobulins; PRA = panel reactive antibodies; pre-emptive = pre-emptive therapy (to be 
on dialysis prior to Tx); PTA = pancreas transplantation alone; PTLD = posttransplant lymphoproliferative 
disease; SPKT = simultaneous pancreas kidney transplantation; Tx = transplantation.
differences were found between the three groups except for a tendency to have higher 
PRA in group 3 and no pre-emptive therapy in group 1.
hematoxylin and eosin staining
Fifty-six pancreas biopsies had H&E slides of which 24 of indeterminate rejection, 9 
showed grade I (mild) acute cell-mediated rejection (ACR), 12 showed grade 2 (moderate) 
ACR and 7 showed grade 3 (severe) ACR. No chronic rejection was present in 37 pancreas 
biopsies, grade I chronic rejection was present in 10, grade II chronic rejection in 7, grade 
III chronic rejection in 1 and chronic ACR was present in 1. 
Table 2 shows data on specific histomorphological lesions in 28 biopsies of patients 
whose DSA were determined, divided into three groups: patients with minimal or no 
C4d staining and no DSA were placed in group 1 (n=13), six patients (2 patients with 
diffuse C4d+ and absent DSA, 2 patients with focal C4d+ staining and DSA present 
and 2 patients with minimal or absent C4d and DSA present) were placed in group 2 
and nine patients with diffuse C4d+ staining with DSA present were placed in group 
3. Frequency of ACR did not differ between the groups. Between group 1 and 2, there 
was no significant difference in the distribution of lesions. Active septal inflammation, 
acinar inflammation and acinar cell injury/necrosis were present significantly more often 
in C4d+/DSA+ patients (group 3) than in either group 1 or 2. Group 3 differed from 
group 1 on additional lesions, namely ductitis (p=0.02), necrotizing arteritis (p=0.042), 
capillaritis (p=0.004) and edema (p=0.013). Positive C4d staining correlated significantly 
with the presence of ductitis, venulitis, capillaritis, acinar inflammation, acinar cell 
injury/necrosis and edema. In the presence of DSA, capillaritis and acinar cell injury/
necrosis were significantly found more often. Figure 2 shows the incidence of all scored 
histomorphological parameters. 
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c4d staining
There were 56 pancreas biopsies stained for C4d. Sixteen 
biopsies showed a diffuse staining pattern, 3 showed 
focal staining (Figure 1B) and 36 showed minimal or no 
staining. Of the 26 pre-transplant pancreas graft biopsies, 
only one showed diffuse positivity for C4d. All others 
showed minimal or negative C4d staining (Figure 1A).
donor-specific antibodies
Twenty-seven patients were tested for DSA, of which 9 
had anti-HLA class I, 7 had anti-HLA class II and 15 had 
no antibodies. Two different methods were used to assess 
DSA: at UMMC, Luminex was used, at the LUMC, CDC 
was used.
groups and outcome
Twenty-seven patients (1 patient had 2 biopsies for a total of 
28 biopsies) with C4d and DSA information were categorized 
into three groups (Table 2). Patients with minimal or no 
C4d staining and no DSA were placed in group 1 (n=13), 
six patients (2 patients with diffuse C4d+ and absent DSA, 
2 patients with focal C4d+ staining and DSA present and 
2 patients with minimal or absent C4d and DSA present) 
were placed in group 2 and nine patients with diffuse C4d+ 
staining with DSA present were placed in group 3. Figure 
3A shows uncensored overall pancreas graft survival in groups 1, 2 and 3, which were 
53.3%, 66.7% and 34.6%, respectively. The overall group p-value was significant for the 
three groups at the end of follow-up (p=0.044). Figure 3B shows censored overall pancreas 
graft survival in groups 1, 2 which were 100% and group 3, which was 51.9%. The overall 
group p-value was significant for the three groups at the end of follow-up (p=0.006). All 
graft failures due to rejection were found in group 3. Graft failures associated with AMR 
occurred during early follow-up (up to 2 years after transplantation).
discussion
In this study, we found heterogeneous C4d staining patterns in pancreas transplant biopsies 
taken at various time points after transplantation. In the recent Banff classification of pancreas 
transplant biopsies, C4d staining patterns have a role in combination with histologically 
proven acute rejection of the pancreas and confirmed DSA8. In our study, the outcomes of 
patients who had C4d and DSA information available were assessed. Patients with diffuse C4d 
positivity and concurrent DSA had poor graft survival, which was most likely related to AMR. 
Patients who had either DSA or C4d alone did well, similar to patients with no DSA or C4d 
fig 1 | c4d staining patterns. 
A. Negative/minimal staining; 
B. Focal positive staining; C. 
Diffuse positive staining in 
interacinar capillaries. Bar 
represents 5 µm.
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fig 2 | bar graph of specific histological scores as displayed in table 2. This figure gives an indication of 
the abundance of various lesions, regardless of extent of the lesion. Percentages are based on adequate biopsy 
samples (see Table 2). The differences between groups was assessed, with * indicating a p-value of <0.05.
staining detected in the biopsies. Although the number of patients is relatively small, these 
results suggest that the occurrence of either focal C4d positivity or DSA alone are of uncertain 
clinical significance and may not pose additional risk of poor outcome to the pancreas graft. 
The possible reason for C4d positivity in the absence of HLA DSA may be due to the presence 
of major histocompatibility complex class I chain-related gene A (MICA) or glutathione-S-
transferase T1 (GSTT1)9, or due to the timing of DSA assessment.
C4d+ AMR following pancreatic transplantation has not been well characterized. In 
2006, Melcher et al. was the first to report a patient with a SPKT who developed AMR 
with donor-specific HLA-DR allo-antibodies and who had positive C4d staining in the 
pancreas 1 month after a SPKT. The renal transplant biopsy from this patient, taken at 
day 10, was also positive for C4d10. A year later, Carbajal et al. reported a patient with 
pancreas after kidney transplantation (PAK) who developed AMR of the pancreas with a 
C4d positive biopsy. The kidney, which was from a different donor, remained unaffected, 
but the pancreas graft was lost11. In the present study, a small number of simultaneously 
taken kidney biopsies were available with rather heterogeneous findings in the kidney and 
pancreas biopsies in relation to C4d staining patterns and Banff classification. Unfortunately, 
DSA information was scarce in this group, and therefore, no firm conclusions could be 
drawn from these data. Gaber reported one case of a C4d positive surveillance biopsy 
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table 2 | on the previous page | c4d, dsA, specific histological and banff scores for pancreas graft 
biopsies.
Acinar cell injury/ necrosis 0 absent, 1 single cell/spotty, 2 multicellular/confluent; Acinar inflammation 
0 absent, 1 focal, 2 multifocal, 3 diffuse; ACR = acute cell-mediated rejection; CR = chronic rejection; 
d = diffuse; DSA = donor-specific antibodies; f = focal; G = group; HLA = human leukocyte antigen; Intimal 
arteritis 0 absent, 1 minimal, 2 moderate to severe; n = negative; Transplant arteriopathy 0 absent, 1 present 
narrowing <25% lumen, 2 present narrowing 25–50% lumen, 3 present >50% lumen; – = unable to score; 
0 = absent; 1 = present.
fig 3 | uncensored (A) and censored (b) pancreas graft survival with c4d and dsA. Kaplan-meier curve and 
descriptive table of uncensored (A) and censored (B) pancreas graft survival in G1 patients with minimal or no 
C4d staining and no DSA, G2 either negative/minimal C4d or focal C4d+ staining in the presence of DSA or 
focal C4d+ staining in the absence of DSA, and G3 diffuse C4d+ in the presence of DSA.
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taken 2 weeks after transplantation from a patient who was sensitized by two previous islet 
transplants and who had detectable anti-HLA antibodies12. Pascual et al. reported on 13 
patients with an acute rejection of the pancreas, of which 2 were biopsy-proven and stained 
positive for C4d. In one patient, two pancreas biopsies were taken. DSA were negative at 
the time of the first biopsy, which was C4d positive. Three months later, a second biopsy 
was not only C4d positive but DSA positive as well6. In a recent study by Torrealba et 
al., the potential role of C4d in pancreas transplant biopsies in the diagnosis of AMR 
was described in a group of 18 patients7. In our study, an assessment was performed to 
identify specific histological lesions correlating with AMR in the pancreas, next to C4d and 
DSA assessment in relation to graft outcome. Although we have a relatively small number 
of biopsies, results from our study give an indication that septal inflammation, acinar 
inflammation, acinar cell injury/necrosis, capillaritis and edema are associated with AMR.
In the recent Banff classification of pancreas transplant biopsies8, C4d staining patterns 
have a role in diagnosing AMR in combination with histologically proven acute rejection 
of the pancreas and confirmed DSA. As a clinical guideline, the results of our study 
emphasize the importance of taking into account a combination of C4d staining pattern, 
histological diagnosis and the presence of DSA before a diagnosis of AMR of the pancreas 
is made. The limitations of this study include the use of retrospective data and biopsies, 
and heterogeneity in the clinical indications for performing the transplant biopsies. The 
number of patients was too small to describe the clinical phenotype associated with 
AMR. Nevertheless, nearly all biopsies were taken within 1 year after transplantation, and 
the heterogeneity of the histopathological findings was helpful in establishing whether 
C4d could have an additional role in the work-up of pancreas transplant biopsies. The 
methods used to determine DSA levels in this study differed per institution, which may 
raise concern for the analysis and conclusions reached. Nevertheless, both methods are 
clinically used and accepted for diagnosis and subsequent treatment. DSA assessments 
were not always performed at the time of biopsy. However, AMR is a fluid state, and DSA 
levels are known to fluctuate over time. Therefore, it is uncertain what time point would 
be optimal to identify those patients developing an AMR.
In conclusion, C4d is a reliable tissue marker in combination with concurrent DSA 
in the evaluation of pancreas transplant biopsies. The finding that C4d positivity in 
pancreas transplant biopsies can occur in pancreas allografts with a good clinical outcome 
places doubt on the absolute value of C4d. Therefore, C4d staining patterns in pancreas 
transplant biopsies must be interpreted in combination with information about DSA 
and the histopathological lesions classified according to the Banff criteria. This clinical 
approach is similar to the standard procedures used to evaluate renal transplant biopsies. 
In this study, patients with diffuse C4d+ staining in the pancreas biopsy with concurrent 
DSA had poor graft survival, most likely related to AMR. The occurrence of either focally 
C4d+ staining or DSA poses no additional risk of a poor outcome of the pancreas graft in 
this study, although the sample number was relatively small. Further studies are needed to 
determine the value of the presence of a single marker.
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AbstrAct
This case-control study investigated the role of antibody-mediated rejection (AMR) in 
pancreas graft loss after simultaneous pancreas-kidney transplantation (SPK). Patients with 
pancreas graft loss in the first year post-transplantation (n=33) were compared with patients 
with pancreas graft function for ≥4 years (n=66). Two controls per case, one transplanted 
before and one after the case, were selected from all historical SPKs (n=256) performed 
at LUMC from 1985-2010. We investigated which pancreas grafts were lost owing to 
AMR, either in the absence or presence of thrombotic lesions. Early pancreas graft loss was 
associated with older donor age and female sex of the recipient. AMR was found in 7/33 
pancreas graft losses, and characterized by the presence of de novo donor-specific antibodies 
(DSA), C4d+ staining patterns, and interacinar capillaritis as a prominent histological 
parameter. Eight out of 33 cases showed 2 out of 3 diagnostic components consistent with 
AMR. Six of these 15 cases showed pancreas graft thrombosis. DSA was tested in 27/33 
cases; 8 were positive. Eight of the 33 cases showed diffuse C4d+ interacinar staining. Our 
findings provide evidence that AMR can cause pancreas graft loss. Early recognition of 
AMR might provide a means of therapeutic intervention to prevent graft loss. 
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introduction
Pancreas transplantation, predominantly performed in the setting of a simultaneous 
pancreas-kidney transplantation (SPK), is a well-established treatment for type 1 diabetes 
patients with or approaching end-stage renal failure (ESRF). Patients with a SPK have 
a long-term survival advantage over patients with diabetes and ESRF due to diabetic 
nephropathy who are not transplanted and remain on dialysis1. Pancreas graft survival 
(72.6%) appears to lag behind kidney graft survival (78.5%) despite both organs being 
derived from the same donor2. Within one month post-transplantation, a marked drop in 
pancreas versus kidney graft survival can already be noted. After one year, the discrepancy 
between pancreas and kidney loss in SPK is 6.8%, and remains constant as follow-up 
progresses2. Clinically, early loss of the pancreas graft is mostly attributed to technical 
failure, most often implying loss through vascular thrombosis, or removal because of 
anastomotic leaks, bleeding, pancreatitis, or infection3. The first study to systematically 
address pancreas allograft loss described histopathological parameters, such as endothelitis 
and necrotizing arteritis, which seemed to point to a role for antibody-mediated rejection 
(AMR), although diagnostic criteria for AMR had not been defined yet at that time4. 
Currently, there is increasing interest in the role of AMR in pancreas graft loss because a 
consensus on diagnosis might guide therapeutic strategies5. 
The recently updated Banff schema for grading pancreas allograft rejection focuses 
on specific histological parameters in combination with C4d positivity of interacinar 
capillaries (IAC), and circulating donor-specific antibodies (DSA)6. In the present study, we 
investigated whether pancreas graft loss in SPK can be caused by AMR. Pancreas graft loss 
within one year of transplantation was studied in comparison with pancreas graft function 
in successful SPKs from all historical SPKs performed at Leiden University Medical Center 
(LUMC) from 1985-2010. In particular, we focused on how many pancreas grafts were 
lost due to AMR, either in the absence or presence of thrombotic lesions.
mAteriAls And methods
study design and data collection 
This is a case-control study of pancreas allograft transplantectomies conducted at LUMC 
between 1985 and February 2010. A total of 256 pancreas transplantations, including SPK, 
pancreas after kidney (PAK), and pancreas transplant alone (PTA), were performed. Fifty-
nine resulted in pancreas graft failure and transplantectomy. Forty-two patients lost their 
allografts <1 year. All but one specimen was retrieved from the archives of LUMC. Nine cases 
were excluded from the present study because the tissue only showed necrosis or extensive 
scarring, which was unsuitable for Banff scoring (n=4); because patients received a PAK 
or PTA (n=3); or because graft failure was caused by post-transplant lymphoproliferative 
disorder (PTLD) (n=2). This resulted in 33 SPK pancreas allograft transplantectomies <1 
year after transplantation being included in this study. Two SPK recipient controls with 
insulin independence for ≥4 years were selected per case, one transplanted before and one 
1
5
6
7
+
8
2
3
4
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after the case. Clinical characteristics are summarized in Table 1 and shown per case in 
Table 2. Clinical information used for analyses was obtained from LUMC medical records 
after approval of the study by the Institutional Review Board.
immunosuppressive therapy
The maintenance immunosuppressive therapy depended on the time period of 
transplantation: 1986-1996, prednisolone, cyclosporine A gelcaps (Sandimmune, 
Novartis/Basel), and azathioprine were used; 1996-2002, prednisolone, cyclosporine A 
microemulsion formulation (Neoral, Novartis/Basel), and mycophenolate mofetil (MMF, 
Roche/Basel) were used; and since 2002, prednisolone, tacrolimus, and MMF were used. 
In 1994, routine administration of OKT-3 was stopped after 2 cases of PTLD7. No 
induction therapy was given before 1991, or between 1994 and 1999. From 1999 onward, 
induction therapy consisted of either polyclonal rabbit anti-thymocyte globulin (ATG, 
Fresenius, Germany), an IL2 receptor blocker (daclizumab, Roche/Basel or basiliximab, 
Novartis/Basel), or alemtuzumab (Genzyme, Netherlands). 
Acute rejection episodes (ARE) were treated according to a standard protocol consisting 
of methylprednisolone 1 g intravenously for 3 consecutive days for the first ARE, and a 
10-day course of rabbit anti-thymocyte globulin (ATG, Merieux, initial dosage of 5 mg/
kg further guided by absolute lymphocyte counts) in case of a steroid-resistant or second 
ARE. AMR was not recognized in any of the pancreas transplantectomies, and none 
of the patients received specific treatment for AMR. Matching of donor and recipient 
was done according to the Eurotransplant allocation rules, applying ABO blood group 
compatibility without prospective matching for HLA antigens. Anticoagulant therapy for 
all patients consisted of a prophylactic dose of heparin or, more recently, low molecular 
weight heparin for at least 10–14 days8.
prA and dsA assessment 
Anti-HLA antibodies in patient sera were initially analyzed by Lambda Antigen Tray 
(One Lambda, USA) for ELISA HLA class I and II. The ELISA was conducted according 
to protocol with OD readouts at 630 nm. The sera were further tested for HLA antibody 
specificities by complement-dependent cytotoxicity against a panel of peripheral blood 
cells from 54 different donors in the absence and presence of dithiothreitol (DTT), a 
reducing agent that breaks down disulfide bonds in pentameric IgM but has minimal 
effect on IgG when used at low concentrations. The reactions were read in a semi-
automatic system (Leitz, Germany) using single color readout as previously described9. 
Using DynaChip Antibody Analysis (Invitrogen’s DynaChip® Systems, Life Technologies, 
UK; discontinued), the sera showing panel-reactive antibodies (PRA) >5% were analyzed 
for the specificity of these reactions.
(immuno-)histochemical staining and grading
CD3, CD20, CD68 (DakoCytomation, Denmark), insulin (SantaCruz Biotechnology, 
Germany), and C4d (Biomedica Gruppe, Austria) immunohistochemical staining 
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table 2 | on the previous page | patient and donor demographics, clinical parameters, transplantectomy 
indication, and treatment split into 3 groups based on c4d, dsA and histology assessments.
Abbreviations: ATG = anti-thymocyte globulin; biopsy (days) = number of days after transplantation that 
biopsy was taken; CI = cyclosporine ; CIT = cold ischemia time; F = female; G = group; HLA Ab = pre-
transplantation non-donor-specific human leukocyte antigen antibodies; HLA mm = human leukocyte antigen 
mismatches; M = male; MMF = mycophenolate mofetil; .N/A = not applicable; NC = no category; OKT3 = 
muromonab-CD3; pre-emptive = pre-emptive therapy (to be on dialysis prior to Tx); rej. Times = number of 
rejections; T = tacrolimus; Tx = transplantation
G1 = AMR negative/requires exclusion; G2 =consistent with AMR; G3 = acute AMR
was performed on formalin-fixed, paraffin sections of pancreas transplantectomies. 
Additionally, C4d staining was performed on a select number of renal and duodenal 
tissue slides from specimens obtained at the time of pancreas transplantectomy (detailed 
staining protocols in supplemental data, Figure S1).
Hematoxylin and eosin (H&E), Congo red, and C4d stained pancreas transplantectomies 
were scored according to the Banff 2011 grading scheme6 (Table 3). CD3, CD20, and 
CD68 staining patterns were graded by I.B. and H.d.K together on a 0 to 3+ scale.
statistical analyses
Raw data were processed using descriptive statistics and graphical representations. All 
clinical characteristics comparing cases and controls were analyzed with binary logistic 
regression, either univariate or forced-entry multivariate. For normally-distributed data, 
the mean with standard deviation (SD) is expressed; for data not normally distributed, 
the median and interquartile range (IQR) is expressed. Histological parameters within the 
cases were analyzed with two-tailed Fisher exact test if binary, or Kendall’s Tau-b statistic 
using exact significance testing if ordinal. The Kaplan-Meier product limit method was 
used to estimate the pancreas allograft survival times for SPK patients who lost their 
pancreas graft within 1 year after transplantation, and a one-minus survival curve was 
plotted. Significance was set at p≤0.05 and calculated with SPSS 16.0 (SPSS, USA).
results
clinical characteristics
The mean follow-up time after SPK of the 99 recipients was 9.2 (SD ±5.8) years. At the 
time of transplantation, recipients were 39.9 (SD ±7.7) years old, with a documented 
1
5
6
7
+
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history of type 1 diabetes for 26.4 (SD ±7.0) years (Table 1). In multivariable analysis, 
donor age and female gender were significantly associated with early pancreas graft loss. 
The cumulative incidence of pancreas graft loss <1 year post-transplantation is plotted in 
Figure 1. Early pancreas graft loss occurred in 21 (64%) patients within a month after 
transplantation; 18 (86%) of those lost their pancreas grafts within the first week.
fig 1 | time to pancreas allograft failure 
in spk patients who lost their pancreas 
within one-year after transplantation. 
Kaplan–Meier one minus survival plot 
for time (months) to pancreas allograft 
failure in the 33 SPK patients which lost 
their pancreas allograft within 1 year after 
transplantation in the period 1985 to 
February 2010.
dsA, c4d, and Amr
Before transplantation, none of the 99 recipients had DSA. After pancreas transplantectomy, 
DSA were found in 8/27 (30%) tested cases, of which 5 were female recipients. Of the 
DSA-positive cases, 5 showed only anti-HLA class II DSA and 3 showed both anti-HLA 
class I and class II DSA positivity (Table 3).
Before transplantation, non-donor-specific anti-HLA class I antibodies were found in 
the case group in 3/32 (9%) recipients, all of whom were females. After transplantation, 
non-donor-specific anti-HLA class I antibodies were found in 2/27 (7%) subjects, both 
female recipients. One of the two had the same non-donor-specific anti-HLA antibodies 
before and after transplantation, and in the other only post-transplantation non-donor-
specific anti-HLA class I antibodies were identified.
C4d staining of the IAC in the resected pancreas allograft was negative in 19/33 (58%), 
focally positive in 6/33 (18%), and diffusely positive in 8/33 (24%) cases. To investigate 
C4d staining patterns of the duodenum 23 specimens from 33 rejected grafts were retrieved. 
C4d staining of capillaries and small vessels, both in the mucosa, submucosa and muscle of 
the resected duodenum was negative in 16/23 (69%), focally positive in 5/23 (22%), and 
diffusely positive in 2/23 (9%) duodenums of pancreas transplantectomy cases. These cases 
seemed to show a positive staining pattern in clusters of capillaries, but the percentage of 
positive vessels never exceeded 10% of all capillaries. In 16/23 (69%) cases C4d staining 
patterns in the duodenum were similar to those in the pancreas (Table 3).
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Following the Banff 2011 grading schema6, cases were classified into 3 groups: 
18/33 (55%) cases had either 0 or 1 out of the 3 diagnostic components of acute AMR 
(circulating DSA, ≥5% of IAC C4d+, and morphological evidence of tissue injury), 
requiring exclusion of AMR (Group 1). In 8/33 (24%) cases, 2 out of the 3 diagnostic 
components were present, classifying the cases as consistent with acute AMR (Group 2). 
In the remaining 7/33 (21%) cases, acute AMR of the pancreas was present at the time of 
transplantectomy showing 3 out of 3 diagnostic components (Group 3). 
In the control group, 8 patients lost their graft 8.7 [IQR 4.4-10.5] years after 
transplantation. Three pancreas transplantectomy specimens could be retrieved from 
our archives showing chronic AMR (n=1), TCMR grade 2 (n=1), and chronic allograft 
rejection/graft fibrosis stage 3 (n=1). Duodenal C4d staining patterns in these control 
cases were inconsistent with pancreas C4d staining patterns.
histology and pancreas allograft failure
Tissue slide examinations according to the Banff 2011 grading schema6 of the lost 
pancreas grafts in the 33 cases showed the following: in group 1, 8/18 (44%) patients 
had pure TCMR and 10/18 (56%) had no rejection. In group 2, 3/8 (37%) patients 
had only hallmarks consistent with AMR, 5/8 (63%) showed mixed TCMR and features 
consistent with AMR. In 2 of the latter group chronic changes were found. In group 3, 
3/7(43%) showed pure acute AMR, in 1 case chronic active AMR was also found. Mixed 
rejection was found in 4/7 (57%), showing both acute AMR and TCMR hallmarks, in 1 
case together with chronic stages of mild graft fibrosis (Table 3). 
Histologically proven thrombotic lesions were present in 28/33 (85%) pancreas grafts. Loss 
of these grafts was clinically attributed to thrombosis in 21/33 (64%). Of AMR group 3 (Table 
2&3), 6 had been clinically diagnosed as loss due to rejection and 1 loss was clinically attributed 
to thrombosis. Histological analyses identified signs of thrombosis in 5/7 (71%). 
Specific immunohistochemical markers were compared to AMR, C4d, DSA and 
increasing stages of TCMR, to investigate whether these could add to the diagnostic and 
pathophysiologic data (not shown). The presence of DSA was associated with increased 
CD3 staining (p=0.005). All three markers were found to be significantly increased with 
increased TCMR grading (CD3 p=0.005, CD20 p=0.003, and CD68 p=0.018). 
Of the clinical characteristics within the case group, only PRA >5% pre-transplantation 
was associated with C4d staining (p=0.001) and DSA (p=0.027). Patients with increasing 
stages of AMR or with de novo DSA detected after transplantectomy had experienced 
more rejection episodes (p=0.036; p=0.001 respectively). 
Islet pathology6 was analyzed in this cohort, albeit correlation with recurrence of 
autoimmune diabetes or loss of glycemic control could not be assessed. Amylin deposition 
in islets, thought to be associated with loss of glycemic control, was never found. ß-cell 
loss assessed by insulin staining was observed, but in no apparent correlation with other 
markers (Table 3). Specific C4d staining within the microvasculature of the islet was 
observed in 10 cases, in which 5/7 (71%) were found in group 3, acute AMR.
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table 3 | on the previous page | c4d, dsA, and specific histological and banff scores for pancreas 
grafts transplantectomies. 
Acinar cell injury/necrosis; 0 = absent, 1 = single cell/spotty, 2 = multicellular/confluent. Acinar inflammation; 
0 =absent, 1 = focal, 2 = multifocal, 3 = diffuse. TCMR = T-cell mediated rejection; AMR = antibody-mediated 
rejection; d = diffuse; DSA = donor-specific antibodies; f = focal; G = group; HLA = human leukocyte antigen. 
Intimal arteritis; 0 = absent, 1 = minimal, 2 = moderate to severe. n = negative; NC = no category. Transplant 
arteriopathy; 0 = absent, 1 = present narrowing <25% lumen, 2 = present narrowing 25–50% lumen, 
3 = present >50% lumen; – = unable to score; 0 = absent; 1 = present. 
G1 = AMR negative/requires exclusion; G2 =consistent with AMR; G3 = acute AMR.
We also analyzed concurrent renal transplant pathology in our cases where available. 
In 13/33 pancreas transplantectomy cases, a renal transplantectomy was retrieved from 
our archives. Seven had histomorphological lesions consistent with (suspected) AMR and 
were found in all 3 pancreas AMR categories, but predominantly (4 cases) in group 3 
(acute AMR of the pancreas). From 6 patients in pancreas AMR group 3 (Table 2&3), 
concurrent renal transplant biopsies were taken at the time of pancreas transplantectomy 
showing a concurrent diagnosis of AMR (n=5), a concurrent diagnosis of TCMR (n=2). 
In 3/6 renal biopsies, thrombotic lesions were found. These 6 kidney allografts were lost 
<1 year post-transplantation. The anti-HLA class II DSA 7th pancreas AMR loss had no 
concurrent renal tissue specimen and this graft functioned for over 8 years.
discussion
This study is the first to show that early loss of pancreas grafts can be caused by AMR, defined 
as diffuse C4d-positive staining in the presence of DSA, and specific histological parameters. In 
this study, 7 cases had pancreas graft loss due to AMR of which 5 showed thrombosis of the graft 
and of which 4 had previously been diagnosed with acute cellular rejection. The importance of 
identifying pancreas graft loss caused by AMR is illustrated by the 7 patients with AMR in their 
pancreas grafts of whom 6 also lost their kidney grafts <1 year after transplantation. 
In this study, we used pancreas graft loss within 1 year as a starting point to search for AMR 
as a possible cause for early graft loss. All but one of the actual AMR cases, defined according 
to Banff criteria, were transplanted between 1988 and 1992. During this period, induction 
therapy was not a standard part of the initial immunosuppression at our center. Additionally, 
over time maintenance immunosuppression evolved from steroids with cyclosporine gelcaps 
and azathioprine to the more potent combination of tacrolimus and MMF. One case was 
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transplanted in 2002 receiving ATG induction therapy and maintenance immunosuppresion of 
prednisolone, tacrolimus, and MMF. It is possible that the change in therapy regimen reduced 
pancreas graft loss due to AMR. In a recent study, we showed that AMR in the pancreas may 
occur, but need not lead to immediate graft loss10. 
This study also underlines differences in pancreas and kidney allograft behavior from the 
same donor in SPK recipients with respect to both the occurrence of AMR and graft survival. 
Pancreas loss in the majority of patients was due to thrombosis within the first week after 
transplantation in the absence of AMR, with subsequent good survival of the kidney allograft. 
The cause of thrombosis in these cases was most likely non-immunological, and correctly 
designated as ‘lost due to technical failure’ on clinical grounds. It is relevant to note that 6/7 
acute AMR cases identified retrospectively in this study, lost their pancreas beyond the first 
month after transplantation. Although thrombosis was present in most of these grafts, it 
was not as extensive as in grafts lost shortly after transplantation, pointing towards another 
pathophysiological mechanism. In the context of inflammation and stress, the upregulation of 
HLA class II antigens on endothelial cells11 and the relative low vascular flow state may make a 
pancreatic graft more prone to thrombosis. Notably, the DSA-positive cases in our study all had 
antibodies against HLA class II, either with or without antibodies against HLA class I.
DSA were associated with an increased number of CD3 positive-stained cells. In the 
current study, CD3, CD20, and CD68 positively-stained cells were significantly more 
abundant in increasing stages of TCMR. Although worth mentioning, this most likely 
does not reflect a useful additional marker for diagnosing TCMR in pancreas allografts 
as this can easily be distinguished by morphological features. Furthermore, DSA and 
C4d were associated with a PRA of >5%. AMR and DSA were associated with an 
increased number of rejection episodes as well, most likely reflecting the time it takes after 
transplantation for de novo antibodies to form. This time-span allows for the occurrence 
of more rejection episodes prior to graft failure and transplantectomy. 
Duodenal patch biopsies have been proposed for diagnosing rejection of the pancreas 
allograft12. In only 69% of cases did C4d staining patterns of duodenum and pancreas 
from the same donor correspond. In descriptions of renal and pancreas C4d capillary 
staining in SPK, this discordance is well-established10;13;14. Thus, in this study on pancreas 
transplantectomies we did not find grounds to use duodenal allograft nor kidney allograft 
tissue as a surrogate for pancreas allograft tissue. 
This study shows that AMR can cause early pancreas graft loss, and grafts lost through 
AMR are likely to show thrombotic lesions. In this cohort of SPK recipients, AMR of 
the pancreas allograft most often occurred more than 1 month post-transplantation. 
In 3 cases the simultaneously transplanted kidney graft was lost before the pancreas, 1 
kidney was lost at the same time, and in 3 cases the kidney was lost after the pancreas 
graft. DSA development appears the most characteristic feature of AMR diagnosis and 
is associated with rejection episodes. Therefore, DSA monitoring after transplantation in 
combination with histological assessment of the pancreas allograft may help to further 
improve outcomes after SPK transplantation.
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supplementAl dAtA
staining protocol
Sections were deparaffinized; antigen retrieved with TRIS/EDTA, pH 9.0 (except insulin); 
and sections blocked for endogenous peroxidase. Primary antibodies were applied for 1 
hour at room temperature with a 1:300 dilution of monoclonal mouse anti-human CD3 
antibody clone F7.2.38, a 1:800 dilution of monoclonal mouse anti-human CD20cy 
antibody clone L26, a 1:1000 monoclonal mouse anti-human CD68 antibody clone 
KP1, 1:100 dilution of rabbit anti-insulin polyclonal antibody (H-86) overnight, and 
a 1:25 dilution of rabbit anti-C4d polyclonal antibody10, respectively. Primary antibody 
binding was visualized with the REAL™ Detection System, Peroxidase/DAB+, Rabbit/
Mouse (DakoCytomation, Denmark) according to the protocol. All stained sections were 
counterstained with hematoxylin.
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fig s1 | (immuno-) staining of patient 32 (table 2&3). (A) H&E staining, (B) T-cell (CD3) staining, (C) 
B-cell (CD20) staining, (D) monocyte and macrophage (CD68) staining, (E) diffuse interacinar capillary 
C4d staining pattern on pancreas, (F) C4d staining in inter-islet capillaries (blue circle around islet of 
Langerhans), (G) diffuse C4d staining of capillaries and small vessels, both in the mucosa, submucosa and 
muscle of the resected duodenal patch, (H) insulin staining of ß-cells in islet of Langerhans.
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summAry points
•	 Islet of Langerhans transplantation is used in a select group of patients with type 1 
diabetes with severe glycaemic lability, recurrent hypoglycaemia, and hypoglycaemia 
unawareness
•	 The procedure is minimally invasive, with few procedure related complications
•	 Two to three islet infusions are usually needed to achieve insulin independence
•	 Most patients need insulin by five years post-transplantation owing to declining 
graft function; beneficial effects on the frequency of hypoglycaemic episodes and 
hypoglycaemia awareness remain
•	 Most long term complications are related to systemic immunosuppression
•	 The risk-benefit ratio of islet transplantation should be carefully weighed by the treating 
physician and the potential recipient, who should be given adequate information
sources And selection criteriA
We searched PubMed, Embase, Web of Science, Cochrane, CINAHL, Academic Search 
Premier, and ScienceDirect using the keyword “islet transplantation”. We limited our search 
to the English language and to human studies. We found no randomised controlled trials, 
and most publications lacked an appropriate control group that was intensively managed by 
insulin using modern treatment regimens. Data were mainly derived from case series, follow-up 
studies, crossover studies, and small trials. We also consulted published reviews and expert 
knowledge if considered necessary.
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A clinical review in the BMJ in 2001 anticipated that by 2010 transplantation of islets 
of Langerhans would be the treatment of choice for most patients with type 1 diabetes1. 
Currently, islet transplantation is an option for a specific group of patients with 
type 1 diabetes only—those with severe glycaemic lability, recurrent hypoglycaemia, and 
hypoglycaemia unawareness. Patients with type 1 diabetes—who must deal with daily 
subcutaneous insulin injections, regular finger pricks for glucose measurements, and worries 
about hypoglycaemic episodes and long term complications of diabetes, hope for a cure for 
their disease and may ask their doctors about islet transplantation. Therefore, doctors who 
treat such patients should understand the potential benefits of islet transplantation as well 
as the hurdles that need to be overcome before it is widely used (box 1).
box 1 | what general practitioners need to know.
•	 Most patients with type 1 diabetes do not fit the criteria for islet 
transplantation
•	 It is not a treatment option for patients with type 2 diabetes, who 
usually have insulin resistance and considerable remaining islet function
•	 Patients who have undergone successful islet transplantation usually 
have greatly improved hypoglycaemia awareness and experience fewer 
hypoglycaemic episodes
•	 Although insulin independence can be achieved, most patients will 
ultimately have to resume insulin treatment, but the frequency of 
hypoglycaemic episodes remains reduced
•	 Islet transplantation can improve glycaemic control and reduce risk of 
progression of vascular complications
•	 The clinical problems related to long term use of immunosuppressive agents 
include drug interactions, infections, and an increased risk of certain cancers
why islet trAnsplAntAtion?
Type 1 diabetes is caused by the autoimmune destruction of insulin producing ß cells in 
the pancreatic islets of Langerhans. A well defined worldwide population based survey 
showed that the incidence of childhood onset type 1 diabetes is rising rapidly, with an 
overall annual increase of 3.4% between 1995 and 19992. A multicentre prospective 
registration study from Europe predicted that the number of prevalent cases of type 1 
diabetes in children below the age of 15 will increase by 81% from 18 500 in 2005 to 
33 500 in 2020 in the United Kingdom3. For patients with type 1 diabetes, exogenous 
insulin administration to control blood glucose is a lifesaving treatment, but it also has a 
negative impact on personal and social functioning, not least because of the daily risk of 
hypoglycaemic episodes. In addition, normoglycaemia cannot be achieved by exogenous 
insulin and secondary complications such as retinopathy, neuropathy, nephropathy, and 
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cardiovascular disease occur despite good glycaemic 
control4;5. Consequently patients with type 1 
diabetes face living with the long term debilitating 
consequences of their disease.
Pancreatic islets constitute only 1-2% of 
the pancreas. They consist of clusters of mainly 
hormone producing cells (fig 1), with insulin 
producing ß cells being the most abundant cell 
type6. Replacement of ß cells is the only treatment 
capable of normalising glycaemia without the risk of 
hypoglycaemia because ß cells respond to changes in 
glucose concentrations by subtly adjusting insulin 
secretion to maintain glucose homoeostasis.
Whole pancreas transplantation, a form of ß cell 
replacement that has been performed since 1966, 
is a major surgical procedure with considerable 
peri-transplant complications and post-transplant 
morbidity related to the transplantation of 
superfluous exocrine pancreatic tissue. Islet 
transplantation, however, is minimally invasive 
and has low morbidity because the islets are infused 
percutaneously via a catheter into the hepatic 
portal vein. Figures 2 and 3 illustrate the complex 
processes of islet isolation and transplantation.
fig 1 | (A) histological section showing 
two islets (yellow arrows) in the pancreas. 
(B) Isolated islets stain red with dithizone; 
non-islet (exocrine) tissue is yellow. Image 
B courtesy of Marten Engelse, Human 
Islet Isolation Facility, Leiden University 
Medical Centre, Netherlands
who is eligible?
Islet transplantation has not become a mainstream treatment for type 1 diabetes largely 
because of a shortage of (high quality) donor organs for islet isolation, the high costs of 
isolation procedures and maintenance of a specialised human islet isolation laboratory, and 
the need for lifelong use of immunosuppressive agents. Islet transplantation is therefore 
usually reserved for a highly selected group of patients with severe glycaemic lability, 
recurrent hypoglycaemia, and a reduced ability to sense symptoms of hypoglycaemia 
(reduced hypoglycaemia awareness). A cross sectional Danish-British multicentre survey 
found that patients with type 1 diabetes have an average of 1.3 severe hypoglycaemic 
episodes per patient year7. However, the distribution was highly distorted, with about 5% of 
patients accounting for 54% of all reported episodes. Because islet transplantation improves 
recipients’ hypoglycaemia awareness and reduces the frequency of hypoglycaemic episodes 
in the long term, this subgroup of patients would probably benefit most from the procedure. 
Islet transplantation is not a treatment option for type 2 diabetes, which is caused mainly 
by insulin resistance, with patients usually having considerable remaining islet function.
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fig 2 | process of clinical islet transplantation for the treatment of type 1 diabetes (adapted from 
naftanel and harlan38)
Most patients who undergo islet transplantation participate in clinical research studies 
with varying inclusion criteria. Inadequate glycaemic control with recurrent hypoglycaemia 
is the entry criterion most often used. However, because microvascular and perhaps 
macrovascular complications have stabilised in some recipients of islet transplantation, 
studies that focus on microvascular complications and inadequate glycaemic control 
rather than hypoglycaemia related problems have begun. A retrospective cohort study 
found that islet transplantation may also prolong the survival of a previous kidney graft8. 
For these patients, who already receive immunosuppressive agents, the clinical decision 
to perform islet transplantation is influenced by a different risk-benefit ratio. In the UK, 
islet transplantation is now funded by the NHS and is particularly indicated for patients 
with reduced hypoglycaemia awareness or those taking immunosuppressive drugs because 
of a previous kidney transplant.
how do we define success of islet 
trAnsplAntAtion?
Observations from long term studies triggered a debate about how to define the “success” 
of islet transplantation. Historically, the primary goal of islet transplantation has been the 
ability of donor islets to maintain normal glucose control and removal of the need for 
exogenous insulin. “Insulin independence” is a comprehensible clinical outcome parameter 
for success, but success can also be measured in terms of frequency of hypoglycaemic 
episodes and positive effects on vascular complications or quality of life9. Researchers 
found that islet transplantation often could not achieve long term insulin independence. 
Patients with this “partial graft function” have persistent insulin secretion from ß cells 
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but require additional oral or subcutaneous antihyperglycaemic agents, such as insulin. 
A retrospective cohort study found that the hypoglycaemia score (measure of severity 
of hypoglycaemia) of 31 islet transplant recipients was significantly reduced from 5.29 
(standard deviation 1.51) before transplantation to 1.35 (1.92) at an average 47 months 
after transplantation, indicating a substantial benefit even with partial graft failure and 
subsequent loss of insulin independence10. Partial graft function has been shown to be 
associated with reduced frequency and severity of hypoglycaemic episodes and increased 
quality of life9. Today, most clinicians regard an absence of severe hypoglycaemic episodes 
and return of hypoglycaemia awareness as indicators of successful islet transplantation.
Fig 3 | The islet isolation and transplantation procedure. Islet isolation from a donor pancreas is laborious, 
time consuming, and costly. A donor pancreas (1) is allocated to a potential recipient on the waiting 
list, procured (2), and transported to an islet isolation facility (3), which adheres to good manufacturing 
practice guidelines (box 2). At the facility, enzyme is infused into the pancreatic duct (4) and the islets 
are separated from the exocrine pancreatic tissue by combined enzymatic and mechanic digestion (5), 
then purified by density gradient centrifugation (6). Reported numbers of isolated islets vary greatly; an 
estimated 300 000 to 600 000 islet equivalents (mathematical conversion of varying islet sizes to equal a 
standardised islet of 150 μm in diameter) can be isolated from one pancreas44. The actual number depends 
on the number of islets in the donor pancreas and the islet yield after isolation. Most centres culture the 
islets in incubators for several hours to several days to perform safety and viability tests and prepare the 
recipients. Shortly before transplantation the islets are collected in an infusion bag (7). Transplantation 
involves the infusion of pancreatic islets into the hepatic portal vein (8). Access to the portal vein is usually 
achieved by ultrasound guided percutaneous catheterisation under local anaesthesia. The islets are infused 
over 10-30 minutes and embolise the small branches of the portal vein. Patients usually stay in hospital for 
several days. The islets will engraft in the recipient liver (9) and begin to function
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whAt results hAve clinicAl islet 
trAnsplAntAtion studies shown?
There are currently about 1000 recipients of islet transplantations worldwide. No randomised 
controlled trials have evaluated the effectiveness of the intervention. Small observational studies 
have been heterogeneous in their design. We review the best evidence from relatively large 
studies performed in established centres. Most studies report on patients with type 1 diabetes 
who had glycaemic lability, recurrent hypoglycaemia, and hypoglycaemia unawareness despite 
optimal self management. We focus on outcome parameters in terms of insulin independence 
and effects on vascular complications, quality of life, and patient survival.
AdditionAl educAtionAl resources 
Additional resources for healthcare professionals
Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. Am J 
Transplant 2008;8:1990-7
Bretzel R, Jahr H, Eckhard M, Martin I, Winter D, Brendel M. Islet cell transplantation 
today. Langenbecks Arch Surg 2007;392:239-53
Low G, Hussein N, Owen RJT, Toso C, Patel VH, Bhargava R, et al. Role of imaging in 
clinical islet transplantation. Radiographics 2010;30:353-66
Collaborative Islet Transplant Registry (www.citregistry.org/) —Map of affiliated transplant 
centres and regular updates on all recipients registered
Lecture by L Fernandez of the University of Wisconsin on islet of Langerhans transplantation. 
http://videos.med.wisc.edu/videoInfo.php?videoid=1112
Animation on islet cell isolation. www.youtube.com/watch?v=aMNKu-ZVUls
European Association for the Study of Diabetes. Stem cells to cure diabetes: where do we 
stand? http://webcast.easd.org/Halban/index.htm
Additional resources for patients
Diabetes UK (www.diabetes.org.uk/Research/Islet_cell_transplantation/) —Comprehensive 
information on the islet transplantation procedure and eligibility criteria
National Institutes of Health (http://diabetes.niddk.nih.gov/dm/pubs/ pancreaticislet/) 
--More detailed information with links to USA based clinical trials
Juvenile Diabetes Research Foundation (www.jdrf.org.au/living-with-type-1-diabetes/what-is-type-
1-diabetes) —Website on what type 1 diabetes is and how you can help further research in this area
insulin independence
In 2000 a landmark case series reported on seven patients one year after islet transplantation. 
The seven recipients had remained insulin independent for an average of 11 months. The 
results of this small study were enthusiastically received1;11. It also became clear, however, 
that most patients needed two to three donor islet infusions to achieve insulin independence 
and that insulin independence was rarely sustained. Follow-up of a larger cohort of 65 
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patients reported in 2005 showed that insulin independence was present in about 69% 
at one year, 37% at two years, and 7.5% at five years. However, C peptide—a measure of 
insulin secretion (for every molecule of insulin one molecule of C peptide is released from 
ß cells)—was detected in 82% of subjects, indicating persistent but insufficient islet graft 
function at the end of this study12. More recently, in a cohort of 14 patients, about 64% 
were insulin independent and 83% had detectable C peptide at two years of follow-up13. 
The multicentre voluntary Collaborative Islet Transplant Registry (CITR) reported on 412 
allograft recipients recruited from 1999 to 2008 with three year follow-up data for 257 islet 
transplant recipients14. At three years, about 27% of recipients were insulin independent, 
C peptide was detected in about 57%, and 16% of the patient data were missing14. Thus, 
long term partial graft function seems to continue and be expressed clinically by more 
stable glucose control and lower insulin requirements. Indicators of declining islet graft 
function in patients who have resumed insulin administration are worsening of glycaemic 
control, higher insulin demand, and a reduction in C peptide concentrations. Recent trials 
using a single islet infusion and new immunosuppressive protocols showed promising 
results at one year15;16. After one islet infusion all five patients treated with a belatacept 
based immunosuppressive regimen were insulin independent at one year15.
vascular complications
Islet transplantation is associated with improvement or stabilisation in microvascular 
complications (neuropathy, retinopathy, and nephropathy) and cardiovascular outcome 
box 2 | good manufacturing practice. 
Good manufacturing practice is part of a quality system for the 
manufacturing and testing of foods, diagnostics, active drug ingredients, 
drug products, and medical devices. Islets of Langerhans, as a drug and 
biological product, are included in this quality system. In Europe, fewer 
than 15 islet isolation facilities currently generate islets for transplantation. 
Good manufacturing practice guidelines and enforcement are subject to 
country or continent specific legislation (see websites below). 
World Health Organization (www.who.int/medicines/areas/quality_safety/
quality_
assurance/production/en/)
European Union (http://ec.europa.eu/enterprise/sectors/pharmaceuticals/
documents/
eudralex/index_en.htm)
United States (www.fda.gov/Food/
GuidanceComplianceRegulatoryInformation/
CurrentGoodManufacturingPracticesCGMPs/default.htm)
Canada (www.hc-sc.gc.ca/dhp-mps/compli-conform/gmp-bpf/index-eng.php)
Australia (www.tga.gov.au/docs/html/gmpcodau.htm)
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parameters8;17;18. An important clinical question, however, is whether it reduces 
microvascular complications more effectively than optimal glycaemic control achieved by 
subcutaneous insulin administration. Because no randomised controlled trials have been 
performed, we report the findings of one study of 42 patients that compared the effect of 
islet transplantation versus intensive medical treatment on microvascular complications 
using a one way crossover design18. This study found that islet transplantation improved 
glycated haemoglobin (6.6 (0.7) v 7.5 (0.9)), halted progression of retinopathy 
(0/51 v 10/82 eyes), and stabilised glomerular filtration rate compared with intensive 
medical treatment. In a prospective study of 44 patients with type 1 diabetes and previous 
kidney transplantation, islet transplantation performed in 24 patients improved kidney 
graft survival at six years compared with kidney transplantation alone (86% v 42% kidney 
graft survival, respectively)8. Improved cardiovascular function after islet transplantation 
was shown in the same patient group17.
quality of life
Several groups have studied the effect of islet transplantation on health related quality 
of life19;20. Recipients of islet transplants have indicated that stable glucose control and 
absence of hypoglycaemic episodes are the most beneficial outcomes of the procedure, 
providing a feeling of reliability and improved independence21.
patient survival
Whole pancreas transplantation has been shown to improve patient survival22. Because 
of the small number (about 1000) of patients who have undergone islet transplantation 
worldwide, the short length of follow-up, and the small size of individual studies, it is not 
yet known whether islet transplantation improves survi
ongoing reseArch And unAnswered questions
•	 How can the islet yield be improved to decrease the number of donors needed for one 
successful transplant39?
•	 Identifying the best islet implantation site and technique that will result in an optimally 
functioning graft29
•	 How can biomaterials be used to create alternative transplantation sites?
•	 Which in vitro tests can best predict in vivo functioning of transplanted islets40? 
•	 What alternative cell sources (such as embryonic stem cells or tissue specific progenitor 
cells) can be used to overcome the shortage of donor organs41? 
•	 What immunosuppressive strategies are less toxic to ß cells?
•	 Can tolerance be induced by cellular immunotherapy, thereby making immuno-
suppressants obsolete42? 
•	 What are the key factors in long term islet allograft failure?
•	 How can islet mass be visualised and monitored43? 
•	 How can long term islet function be improved?
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What affects outcomes?
Box 3 and fig 4 list some of the factors that can lead to the loss of islets of Langerhans 
before, during, and after transplantation.
Box 3 | factors that contribute to islet loss before, during, and 
after transplantation.
Factors affecting islet yield and quality
Donor characteristics
Organ procurement
Preservation and transportation
Isolation technique
Culture conditions
Factors contributing to loss of transplanted cell mass during and after 
transplantation
Immediate blood mediated inflammatory reaction
Recurrence of autoimmunity
Toxicity of immunosuppressive drugs
Allorejection
Glucotoxicity
Hepatic steatosis
fig 4 | Islet loss before, during, and after transplantation.
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pretransplantation and peritransplantation factors
Although glucose concentrations immediately normalise after successful whole pancreas 
transplantation, glucose lowering after islet transplantation is delayed. This is probably because 
an insufficient number of functional ß cells are transplanted. A single islet infusion—the islets 
of one donor—is often insufficient to establish normoglycaemia. Donor characteristics, the 
procurement of the donor pancreas, pancreas preservation during transportation, the islet 
isolation procedure used, and culture conditions have important effects on the number and 
quality of transplantable islets23. A substantial loss of islets is also thought to occur during 
transplantation24, mainly because direct contact of islets with blood components in the hepatic 
portal system triggers an immediate blood mediated inflammatory reaction25. Thus, often an 
inadequate or marginally adequate islet mass reaches the liver tissue. Several measures can help 
avoid this loss of functional islet mass, such as administration of heparin during and after 
transplantation26 and perioperative delivery of anti-inflammatory agents27. Still, many experts 
believe that the best way to improve the outcome of islet transplantation would be to prevent 
inflammatory reactions during and immediately after islet transplantation.
post-transplantation factors
After infusion into the portal vein, the islets travel to the liver. Here they need to adjust 
to their new environment and also face adverse conditions. The islets are immediately 
exposed to drugs and nutrients, such as glucose, which are present in higher concentrations 
in the portal system than in the peripheral circulation, and which can negatively affect 
islet function. One of the obvious potential problems is acute rejection, for which 
immunosuppressive drugs are given. Unfortunately, some immunosuppressive drugs, such 
as calcineurin inhibitors and steroids, interfere with ß cell function28. Measures that can 
help to give the islets a favourable start include using immunosuppressive drugs that have 
little effect on glucose metabolism and strict glycaemic control to avoid glucotoxicity26. In 
addition, alternative implantation sites are being sought to avoid triggering the immediate 
blood mediated inflammatory reaction and the toxic drug levels found in the liver, and at 
the same time optimise vascularisation of the transplanted tissue29. Recently, islets have 
also been transplanted in human forearm muscle30. The omental pouch, bone marrow, and 
implants consisting of islets within a biomaterial structure (scaffolds), are other potential 
transplantation sites29. Islet revascularisation occurs within several weeks, but the intra-
islet vascular network is less developed in islets transplanted into the liver than in eutopic 
pancreatic islets31. Thus, if not rejected early, the islet graft may not reach maximal efficacy 
with respect to glucose metabolism until one to three months after transplantation.
After one to three months islet efficacy becomes apparent, but on average only half 
of patients remain insulin independent at 15 months9. Chronic allograft rejection is a 
potential cause of long term graft failure32. Autoimmunity may also recur because islet 
recipients with positive T cell responses to autoantigens are more likely to lose full graft 
function33. Furthermore, the long term toxic effects of immunosuppressive drugs on ß 
cells are probably of considerable importance28.
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In patients who remain insulin independent after islet transplantation, a substantial 
portion of ß cell mass may already have been destroyed before glucose concentrations start 
to rise. The absence of methods to monitor ß cell mass, or alloimmune and autoimmune 
reactivity against ß cells, render the intrahepatic grafted islets a “black box.” Whereas 
in whole organ transplantation, biopsies provide information on potential problems 
such as rejection, ischaemia, and immunosuppressive toxicity, it is difficult to biopsy 
the islets dispersed throughout the liver. Liver biopsies have been performed to evaluate 
transplanted islets by light microscopy31. However, this is an invasive procedure with 
low islet sampling rates and lack of reference values, which has limited value in clinical 
practice. Consequently, when islet function decreases and glucose concentrations rise 
over time there is little basis for intervention strategies other than re-evaluating the 
need for immunosuppressive drugs that negatively affect glucose metabolism and the 
use of glucose lowering agents. Therefore, current research is focused on increasing the 
functional ß cell mass before, during, and after transplantation and on improving the 
functional assessment of grafted islets34.
whAt Are the potentiAl complicAtions  
of islet trAnsplAntAtion?
Complications can occur early (procedure related) or late (usually related to the use 
of immunosuppressives). Reports of early procedure related complications have come 
from different centres with a variety of expertise that have performed varying numbers 
of transplants. We try to give an indication of how often complications arise, how to 
monitor them, and how to try to prevent them.
short term procedure related complications
Islet transplantation is a minimally invasive procedure compared with whole pancreas 
transplantation. Few detrimental procedure related complications exist. Hepatic bleeding 
during transhepatic portal vein catheterisation occurs in about 12% of infusions12, but 
this has become less common with the use of fibrin sealant, Gelfoam pledgets, or coils to 
seal the catheter tract on withdrawal of the catheter35. Hepatic bleeding into the peritoneal 
cavity usually resolves spontaneously. Only rarely is surgery needed and no detrimental 
effect on graft survival has been reported. The infusion of foreign cell material into the 
portal system inevitably poses a risk for portal vein thrombosis. In an experienced centre 
this complication occurred in less than 4% of islet infusions12. Low dose heparin, given 
prophylactically during and after transplantation, limits the risk of portal vein thrombosis 
and carries an acceptable increased risk of bleeding. The liver parenchyma surrounding 
the new islets is temporarily damaged, but this is entirely reversible probably because of 
the excellent regenerative capacity of the liver. Resolution of the damage can be monitored 
by measuring liver enzyme concentrations after transplantation.
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long term complications
Similar to other transplants, long term complications are mostly related to the side 
effects of systemic immunosuppressive agents. Systemic immunosuppression increases 
the risk of infections and cancers, particularly virus related skin cancers and certain 
lymphoproliferative disorders. The most widely used agents in organ transplantation 
are calcineurin inhibitors. Unfortunately, these agents also have a nephrotoxic effect, 
which increases the risk of worsening renal function, especially in patients with diabetic 
nephropathy. The risk of complications can be reduced and their early management 
ensured by monitoring drug concentrations to prevent overdosing, using measures 
to prevent and recognise the development of infections, having a low threshold for 
starting antibiotics and antivirals in transplant recipients, and regularly checking for 
dermatological complications.
Organ transplantation can lead to the formation of anti-HLA antibodies. Recipients 
of islet transplants are usually exposed to a wide range of HLA antigens from multiple 
donors because over time they usually receive several islet infusions matched for ABO 
blood group only36. Although antibodies to donor derived HLA antigens are detected in 
only a minority of islet transplant recipients taking immunosuppressive drugs, patients 
taken off these drugs, either because of transplant failure or immunosuppressive related 
toxicity, show an increase in these antibodies36. This is important in patients who develop 
end stage diabetic nephropathy and require kidney transplantation because the presence of 
anti-HLA antibodies limits the chance of finding an acceptable donor kidney. Currently, 
we have no way to prevent the development of such antibodies.
whAt should i tell my pAtient who Asks About 
this procedure?
Islet transplantation has been shown to be beneficial for a specific group of patients 
with type 1 diabetes who have severe glycaemic lability, recurrent hypoglycaemia, and 
hypoglycaemic unawareness, although lifelong use of immunosuppressive drugs is 
necessary. The lack of randomised control trials prevents a thorough comparison between 
this procedure and best medical practice (intensive insulin treatment) or pancreas 
transplantation. This lack of evidence has led to scepticism about the clinical value of this 
procedure among some diabetologists37. Currently the initial goal of long term insulin 
independence is achieved by only a small proportion of patients—an important message 
to communicate to potential recipients. However, the select group of patients treated 
with islet transplantation has shown improved glycaemic control, reduced frequency 
of hypoglycaemic episodes, and reduced rate of progression of vascular complications. 
Researchers now need to identify factors that will lead to better graft survival and function.
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conclusion
Although progression in the islet transplantation field is not as rapid as was envisaged1, 
the pitfalls and difficulties of this procedure are now clearly identified, and advances in 
islet isolation, transplantation, and patient management are likely to improve the clinical 
outcome of islet transplantation in years to come.
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AbstrAct
Islet of Langerhans transplantation is a relatively new and promising type of ß-cell 
replacement therapy, which could be applied to patients with type 1 diabetes in various 
stages of their disease. Unfortunately, one-year graft functioning of the islet transplant 
has turned out to be rather disappointing worldwide. Islet transplantation in humans 
is still only performed within a research setting, and many studies are performed to 
investigate why short-term outcome is relatively poor. Much research has focused on islet 
isolation, storage, transplantation site, and rejection. In this review our focus is on the 
revascularization of both the blood vasculature and lymphatic system and on renervation 
after islet of Langerhans transplantation. These topics are currently investigated in small 
animal models, i.e. rats and mice, instead of humans. It is expected that our better 
understanding of these three issues in experimental models will greatly contribute to further 
improvement of human islet transplantation. In this review, we describe that targeting the 
induction of blood vessel revascularization and renervation will most likely prolong islet 
allograft survival. Preliminary findings on lymphangiogenesis after islet transplantation 
gives reason to assume that inhibition of this process would be most beneficial to islet 
transplant survival. Recent literature on experimental islet transplantation is used, and we 
elaborate on how developments could improve islet transplantation therapy for patients 
with type 1 diabetes.
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introduction
Diabetes mellitus is a worldwide disease affecting over 171 million people in 2000, with 
a projection to rise up to 366 million people in 2030. The majority of patients suffer 
from type 2 diabetes, but both types of diabetes are increasing. Approximately 10% of 
patients with diabetes suffer from type 1 diabetes (T1D), which is essentially caused 
by auto-immune destruction of the ß-cell population in the islets of Langerhans1. The 
incidence of type 1 diabetes has increased as well (3.4% annual increase; 1995-19992, 
while the reasons for this increase remain elusive. Exogenous insulin administration is 
the most frequently used therapy to control blood glucose levels in T1D. Unfortunately, 
this therapy cannot prevent blood glucose fluctuations associated with secondary 
complications such as retinopathy, neuropathy, nephropathy, and cardiovascular 
disease. Reinstituting endogenous insulin production by replacing the affected ß-cell 
population is the only means to halt or even reverse the disease3. Replacement of the 
ß-cell population can be achieved by either vascularized pancreas transplantation or islet 
of Langerhans transplantation. Vascularized pancreas transplantation is a major surgical 
intervention, most often performed simultaneously with a kidney transplantation, and 
thus in patients with end stage renal disease as a result of diabetic nephropathy and other 
secondary complications, with significant morbidity and peri-operative mortality4;5. Islet 
transplantation is a relatively new and promising treatment which could be applied in 
patients at various stages of their disease.
Islet transplantation is a minimally invasive procedure during which the islets are 
infused percutaneously via the portal vein under local anesthesia. Hospital stay does 
not exceed 2 days. Islet transplantation has the advantage of less donor material being 
discarded since many potentially ‘good’ organs which are unsuitable for whole organ 
transplantation because of donor and technical deficits6, can be used for islet isolation and 
subsequent transplantation. Unfortunately, one-year graft function of transplanted islets 
has turned out to be rather disappointing worldwide. Since its first successful application 
in humans in 19787, it has become clear that after initial adequate graft functioning, 
practically all recipients become insulin dependent again with a 5-year graft survival of 
6.5%8. Hypo-awareness is relatively well obtained. 
Islet transplantation in humans is still only performed within a research setting, and 
many studies are being performed to investigate why short-term outcome is relatively 
poor9. Most of these studies use animal models to investigate various issues involved 
in islet transplantation outcome. In these models, the conditions under which islet 
transplantation takes place can be completely controlled. Most research is performed in 
small animals, i.e. rats and mice. In human islet transplantation, islets are infused into the 
hepatic portal vein where they will embolise small branches of the portal vein, while in 
rodent islet transplantation the preferential site for islet transplantation is underneath the 
kidney capsule. The site under the kidney capsule in rodents has the advantage of being 
easy to reach. The transplanted islets stay compartmentalized, and it is possible to confirm 
graft function by nephrectomizing the islet-bearing kidney. The first successful report on 
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rodent models with islets transplanted under the kidney capsule appeared in 1974, by 
Brown et al10. Ever since, experimental islet transplantation has generated important data 
that are relevant for the clinical care of patients with T1D in want of transplantation. 
In the early years, research emphasis was on islet isolation, storage, transplantation 
site and rejection, the development of which made important contributions to refining 
models of islet transplantation11. More recently, attention was drawn to three important 
issues: 1) the vascularization and revascularization of the transplanted islets being of 
course essential for islet survival and function. 2) Lymphatic vessel formation emerged as 
a subtopic of the endothelial neogenesis theme. 3) Neuronal reconnection, which of the 
3 topics discussed here is the most recently described item, is closely related to endocrine 
function. It is expected that our better understanding of these three issues in experimental 
models will greatly contribute to further improvement of human islet transplantation. In 
this review, we discuss the state-of-the-art literature of experimental islet transplantation, 
and elaborate on how its developments could improve islet transplantation therapy for 
patients with type 1 diabetes. 
vAsculAture: blood vessels
In the whole pancreas, islets of Langerhans are intricately vascularized by small capillaries 
so that each specific islet cell is in direct contact with the vasculature12, resembling a 
glomerulus-like structure13. Islets consist of at least 5 hormone producing cells: ß-cells 
which produce insulin and amylin; α-cells which produce glucagon; δ-cells which 
produce somatostatin; polypeptide cells which produce pancreatic polypeptide and 
ε-cells which produce ghrelin. Size of the islets and distribution of these cell types differ 
throughout the pancreas14. Vascularization is crucial for islet functionality, which is to 
keep metabolic homeostasis through hormone responses on blood glucose fluctuations. 
Islets receive 5-15% of the blood flow of the pancreas, although they compromise <1% 
of that organ. In addition, the islets have a higher oxygen tension and their vessels have 
a greater volume than vessels in the exocrine part of the pancreas15-18. The endothelium is 
essential as a barrier to keep autoreactive lymphocytes, ready to destruct the ß-cell, out of 
direct contact with the ß-cells. 
The blood flow route through the islets under physiological conditions is incompletely 
understood. There are three theories on islet microcirculation, recently reviewed by 
Ballian and Brunicardi16. One suggests that blood flows first through the non ß-cell 
region before it enters the ß-cell region; the second suggests that the blood flows first 
through the ß-cells and than through the non-ß cell region. The third option is that 
the blood flows without a clear distinction between cell types. Most importantly, these 
different theories mainly reflect the lack of knowledge on normal islet physiology and on 
transplanted islet physiology. Recently, the assumption that a prototype islet even exists is 
under debate rendering the dispute on islet vascularization unresolved14;19;20. It is evident 
that we cannot begin to investigate what revascularization of the transplanted islets entails 
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for their function and survival, as long as we do not understand how the vascularization 
of islets in their entopic location is structured. 
During islet isolation, the vasculature of the isolated islets is disconnected from the direct 
environment rendering the isolated islets ischemic. Subsequently, both in humans and in 
animal models, the islets are transplanted to an ectopic location where revascularization is 
not immediately established. Even when the transplanted islets are eventually revascularized, 
it is not inconceivable that the original level of blood flow, volume, and oxygen tension 
will never be reached. In fact, it was shown that the original islet architecture is altered 
upon transplantation, and although the orientation of the microvascular blood flow 
within the graft after revascularization appears the same 21 perfusion and oxygen tension 
are chronically impaired15;22 most likely contributing to graft dysfunction and even failure. 
In a recent publication by Morini et al, it was shown that a microvascular network arises 
in the islet graft underneath the kidney capsule within 3-5 days23. Until that time, islets 
are dependent on diffusion of oxygen and nutrients from surrounding tissue and remain 
relatively hypoxic. Actual blood perfusion is established within 10-14 days. Remodeling of 
the morphology, through angiogenesis, continues up until 2-3 weeks post-transplantation 
when engraftment was considered stable15;23. Figure 1C depicts the endothelial lining of 
the microvasculature established 7 days after transplantation.
Recent publications on transplanted islets have shown that endothelial cells of both 
recipient and donor origin are involved in the revascularization process. The mixed origin 
of the vasculature imposes a situation of which the consequences in terms of rejection are 
not well known. 
Much research has focused on the revascularization of the transplanted islet as 
an essential premise for its function. Optimizing the revascularization after islet 
transplantation is still the centre of attention of much research, concentrating on 
administration of angiogenic factors24 or additional cell therapy25. Less emphasis has been 
put on other essential structure formations, such as lymph vessel formation and neuronal 
innervation. From embryology it is known that both lymph and neuronal patterns follow 
the blood vasculature26;27. The following paragraphs will discuss lymph and neuronal 
patterns in islet transplantation.
The knowledge gathered on the necessity of adequate and rapid revascularization of islets 
after islet transplantation might lead to therapeutic intervention strategies. For instance, 
erythropoietin (EPO) has been shown to reduce hypoxic and ischemic stress in kidneys 
of a non-human primate model28. The expression of the EPO receptor was shown in islets 
from several species, including human, and administration of EPO to an in vitro culture 
of isolated islets prolonged islet cell survival29. Experiments involving implants consisting 
of islets within a biomaterial structure provide means to apply pro-angiogenic growth 
factors (GF). When the matrix of the implant is supplemented with vascular endothelial 
GF and hepatocyte GF, the engrafted islets show enhanced vascularization compared to 
unsupplemented matrix islet recipients30. Concluding, although the exact mechanisms 
responsible for the revascularization of islets after transplantation are still partly unknown, 
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with knowledge gained over the last few years, therapeutic intervention has proven to be 
feasible and helpful, and may give the human islet transplant a better start and outcome.
vAsculAture: lymph vessels
Entopically, islets of Langerhans lack lymphatic microvasculature although the adjacent 
exocrine tissue does have inter- and intra-lobular lymphatic vascularization31. Lymph 
function in the pancreas is comparable to that of other encapsulated organs such as the 
kidney and liver31. The lymph vasculature is of critical importance in the pancreas to 
drain excess proteolytic-enzyme-containing fluid from the interstitial space, which would 
otherwise damage the tissue32.
During the autoimmune destruction of ß-cells leading to T1D, dendritic cell infiltration 
of the islets is facilitated by lymphatic vessels33. The way dendritic cells infiltrate islets 
was demonstrated in the well-defined spontaneously non-obese diabetic mouse model. 
This mechanism is ‘nicely demonstrated’ to exist in the spontaneously non-obese diabetic 
mouse model: When the exit of lymphocytes from tertiary pancreatic lymph nodes is 
blocked, the spontaneous non-obese diabetic mouse does not develop diabetes34. In 
a rodent model of human type 1 diabetes, the manifestation of diabetes could also be 
prevented by retention of activated immune cells in the lymph nodes35. These findings 
demonstrate that although lymphatic vessels are absent in the islets themselves, islets do 
have a close relationship to the lymphatic vasculature surrounding them. In view of the 
role of the lymph vasculature in the development of diabetes, an interesting notion would 
be that whereas it seems essential to stimulate the revascularization of blood vessels in the 
islets after transplantation, lymphatic vessel formation should be avoided around the islets. 
The formation of lymph vessels in islet transplantation occurs as early as one week 
post-transplantation, with a small increase in abundance at 1 month and 9-12 months 
after transplantation36. Reported data differ on the exact location of the newly formed 
lymphatic vessels. At 7 days after transplantation, we have seen new lymph vessels formed 
at the boundaries of transplanted islets in close approximation to the kidney capsule, 
but not in the transplanted islets themselves (fig 1D). Other groups reported new lymph 
and blood vessel formation in close proximity to each other, lymph vessels in connective 
tissue between transplanted islets, and lymph vessels localized on the boundary between 
pancreatic tissue and kidney tissue36. Recently it was found that interfering with lymphatic 
function after islet transplantation in an allogeneic mouse model resulted in inhibition 
of lymphangiogenesis and prolonged islet allograft survival37. One of the three agents 
tested, FTY720, had previously been shown to be able to protect the islet allograft in an 
allogeneic mouse model from allo- and auto-immune destruction38.
That lymphangiogenesis takes place after islet transplantation near the allograft36 and 
that islet allograft survival can be prolonged by lymphangiogenesis inhibition37;38 are the 
most important findings in lymphatic vessel formation in islet transplantation today. More 
is known about this subject in other transplanted organs. In an allogeneic transplantation 
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setting, lymph vessel formation is considered to be of importance to facilitate drainage 
of antigen presenting cells to regional lymph nodes39, which could be a driving force 
behind cellular rejection. However, in sequential protocol kidney biopsies taken at 6, 12, 
and 26 weeks after transplantation it was shown that lymphatic vessel formation within 
inflammatory infiltrates resulted in better graft function at one year, compared to the 
absence of lymphatic vessel formation at inflammatory sites40. Tertiary lymphatic structure 
formation has been described in transplanted kidneys with chronic allograft nephropathy, 
resembling secondary lymph nodes41. Tertiary intra-graft lymphoid organ formation 
appears to be driven by neurons which will be discussed below. The biological function 
of these tertiary lymphatic structures is supposed to be detrimental to the graft as these 
structures might lead to misguided immune responses whereby auto-antibodies are formed. 
fig 1 | islet transplantation beneath kidney capsule of rodent model. (A) H&E, (B) insulin, (C) 
endothelial vessel staining (JG12), and (D) podoplanin.
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Perhaps the formation of tertiary lymph nodes is neither detrimental nor beneficial, but 
relies on the balance of both functions and is merely representative of chronic rejection42-44.
It seems evident that in solid organ transplantation, research on new lymphatic vessel 
formation and tertiary lymphatic structures has only just begun, and the role of lymphatic 
vessels in terms of being beneficial or detrimental is unclear. At this point, it is known 
that new lymphatic vessel formation in islet transplantation takes place. Furthermore, 
with studies targeting lymphangiogenesis in islet transplantation in an allogeneic islet 
transplantation mouse model37;38, clues on possible effective therapeutic interventions 
are gathered. The agents tested in mouse models should be transferred to larger animal 
models, where the islets are infused via the portal vein into the liver, to verify their 
potential in the human islet transplantation setting. 
neuronAl networks
Islets are richly innervated and have both sympathetic and parasympathetic nerves45, but 
are mainly supplied with extrinsic nerves via the splanchnic and vagus nerves46. Several 
neuropeptides (vasoactive intestinal polypeptide, neuropeptide Y, calcitonin gene-related 
peptide, substance P) and classic neurotransmitters (noradrenaline) are known to have 
an influence on ß-cell insulin secretion. In type 1 diabetes onset, the auto-immune 
destruction of sensory afferent neurons promotes islet inflammation through altered 
glucose homeostasis and ß-cell stress47. In addition, from research in non-obese diabetic 
mice it is proposed that neurons and Schwann cells surrounding ß-cells within the 
islet are destroyed before the ß-cells themselves48;49. This emphasizes the essential role 
of neurogenesis after transplantation for a healthy and functional islet allograft. The 
upregulation of tissue factor (TF) in isolated islets known to cause the instant, blood-
mediated, inflammatory rejection is also driven by neurons. It was established that the 
induction of brain death in combination with the warm ischemia time necessary to isolate 
islets, causes the expression of TF in isolated rat pancreatic islets50. 
The neurotrophic factors guiding neuronal in-growth are produced by the endocrine part of 
the pancreas and insulin could well be one of them51. It is feasible that due to islet denervation 
upon isolation and transplantation to an ectopic site, the allograft’s function is impaired. 
Therefore, renervation might be another crucial area of interest, which few researchers seem to 
address even though it seems essential for normal ß-cell functioning. Several publications52-54, 
imply that the innervation pattern in transplanted islets is altered, and that this is related both 
to factors within the transplanted islet, as well as to the environment of the transplantation 
site. This altered innervation pattern may affect the ß-cells’ capacity for metabolic control. As a 
possible means to improve innervation of the islet allograft after transplantation, one study has 
co-transplanted neural crest stem cells with the islet transplant55. The co-transplanted neural 
crest cells interact with the islets and their addition results in improved islet functionality 55. 
Whether it is the renervation or release of growth factors from these neural cells that induces 
the improved islet function is unknown.
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After isolation of islets, nerve fibers are still present although completely separated 
from their environment. Already at two weeks after transplantation the first nerve fibers 
are observed which increase in number considerably between 26 and 51 weeks after 
transplantation. It has been proposed that this fiber in-growth occurs by accompanying 
the blood vessels revascularizing the graft52;56;57. 
It is suggested that adequate islet innervation is essential for normal islet cell 
functioning58. Still, the exact interactions between the endocrine part of the pancreas and 
the autonomic nerve system need to be established. From initial studies there is reason to 
assume that enhancing renervation, in this case via co-infusion of neural crest stem cells, 
can enhance islet function in vivo55. Therefore, targeting of the nervous system to improve 
islet transplantation outcome is likely to be beneficial.
concluding remArks 
Transplantation of islets of Langerhans is a very promising cell therapy for an ever enlarging 
group of type 1 diabetes patients. Many areas of interest are studied as improvement is 
necessary to make it a success. Both the isolation and the transplantation of the islets pose 
many challenges, and the factors essential for advancement are still unclear. In this review 
we have shown that all processes involved in graft adaptation by the host through neuronal 
reconnection, lymph and blood vessel vascularization (figure 2) are intertwined and 
therefore the analyses of merely one cannot predict the outcome of islet transplantation.
fig 2 | schematic depiction of islets of langerhans in situ (A), after isolation (b), and after 
transplantation underneath the kidney capsule (c). Blood vessels (red), lymphatic vessels (yellow), 
and neurons (green) in all stages of islet of Langerhans transplantation.
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AbstrAct
background
Allogeneic islets of Langerhans transplantation is hampered in its success as a curative 
treatment for type 1 diabetes by the absence of potent, specific, and non-toxic 
immunosuppressive drugs. Here, we assessed whether donor bone-marrow-derived, 
dexamethasone-treated dendritic cells (dexDCs), could prolong islet allograft survival in 
a full MHC mismatch rat model. 
methods
Rodent allogeneic islet transplantation was performed from DA rats to Lewis rats and vice 
versa. Permanently immature DCs were generated from the bone marrow of DA and Lewis 
rats by treatment with dexamethasone. Animals were either vehicle or donor dexDCs 
pre-treated. Serum was used to monitor glucose, C-peptide, and allo-reactive antibodies. 
results
The transplantation of DA islets into Lewis recipients showed direct graft failure with 
reduced numbers of ß-cells when rats were pre-treated with donor dexDCs. In the reverse 
model (Lewis islets into DA recipients), dexDC-treated DA recipients even showed a 
significantly accelerated rejection of Lewis islets. Immunohistochemical analysis of 
allograft tissue of dexDC-treated recipients showed a predominant NK cell infiltration 
and a presence of antibody reactivity in the absence of complement deposition. Allo-
reactive antibodies were solely found in dexDC-treated recipients. 
conclusion
Our study shows that pre-treatment with donor-derived dexDCs induces an antibody-
mediated rejection in this islet transplantation rodent model.
106
introduction
Transplantation of islets of Langerhans is a promising cure for patients with type 1 diabetes. 
Thus far it is only being offered as a clinical research procedure1 with a relatively good short term 
survival (1 year 69% insulin independence) but with a rapid decline in graft function overtime 
(5 year 7.5% insulin independence)2. Reasons for this loss of function include allograft rejection 
and complications caused by immunosuppressive therapy. Current immunosuppressive 
regimens are toxic to ß-cells, and influence insulin transcription, translation, synthesis, and 
secretion3. To inhibit rejection in a non-toxic way, alternative methods need to be developed, of 
which cell-based tolerance induction would be an attractive option.
DCs are bone marrow-derived, antigen-presenting cells that play an essential role in 
both innate and adaptive immunity. To prime the immune system and stimulate T-cells, 
DCs must undergo maturation, which can occur through a variety of signaling pathways 
after recognizing microbial and viral pathogens or inflammatory cytokines, or by CD40-
CD40L binding4. However, when they remain immature, as in the steady state, DCs take up 
antigens and process and present peptides to T-cells in a tolerogenic manner5. Tolerogenic 
DCs have been shown to prolong allograft survival in various transplantation models6-10. 
Dexamethasone-pretreated, dendritic cells (dexDCs) have been reported to preserve a 
permanent immature phenotype and influence the immune system to create a tolerized 
environment through the induction of regulatory T-cells, which dampen the allo-immune 
response11;12. On the other hand, dexDCs have been proposed to lead to the processing and 
presentation of alloantigen by endogenous DCs, resulting in increased allo-immunity13.
In islet transplantation, several immuno-modulating therapies have been shown to prolong 
allograft survival, such as hepatic DC progenitors14, vitamin D3 with MMF15, allopeptide-
pulsed host DCs16, intravenous infusion of Sertoli cells17, and induction of donor chimerism 
through post-transplant donor-lymphocyte infusion18. However, the role of dexDCs in islet 
transplantation has not yet been investigated. In this study, donor bone marrow-derived, 
dexamethasone-treated dendritic cells were tested in a full MHC mismatch rodent model for 
their capacity to prolong islet allograft survival as well as their safety and efficacy. 
mAteriAls And methods
Animal models 
Female 11-week-old Lewis (LEW/Crl, Germany) and Dark Agouti (DA) rats (DA/OlaHsd, 
Netherlands) were islet of Langerhans donors, male 8-week-old DA and Lewis rats were 
transplant recipients. Non-diabetic recipients were PBS injected i.v. and experimental 
recipients were rendered diabetic by a single freshly prepared streptozotocin (STZ, Sigma-
Aldrich, Netherlands) i.v. injection (67.5 mg/kg in 0.91% w/v NaCl (pH 4.5)) under 
isoflurane anesthesia 2-3 days prior to transplantation. Diabetes was defined as 2 days of 
blood glucose levels >20 mmol/dl. All rats were housed under standard conditions and 
principles of laboratory animal care were followed in accordance with the animal ethical 
committee of the LUMC.
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generation of rat dendritic cells
BM was derived from both DA and Lewis tibias and femurs. DexDCs were generated from 
BM as previously described12. Briefly, BM was cultured at a density of 1.5*106 cells/well 
in 3 ml of RPMI1640 (Invitrogen, Netherlands) containing 10% heat-inactivated fetal 
calf serum (FCS; BioWhittaker, Belgium), penicillin/streptomycin/fungizone (Gibco), 
ß-mercaptoethanol (50 M, Merck, Germany), L-glutamine (2 mM, Gibco), rat GM-CSF 
(2 ng/ml, Invitrogen), rat IL-4 (5 ng/ml, Invitrogen), and human Flt3L (50 ng/ml, kindly 
provided by Amgen). At days 2 and 4, medium was replaced by fresh medium containing 
the cytokines. For the generation of dexDCs, 10-6 M dexamethasone (Pharmacy LUMC, 
Netherlands) was added to the culture on day 4. On day 7, non-adherent and semi-
adherent cells were harvested. DexDCs harvested and generated via this protocol were 
characterized previously12.
islet isolation 
Under isoflurane anesthesia, the abdomen was opened and the rat was perfused with cold 
PBS via the descending aorta after clamping of the thoracic aorta, relieving pressure by 
opening the posterior vena cava. The common bile and pancreatic duct were clamped off 
at the duodenum, the common bile duct was cannulated, and 8 ml of cold Liberase RI 
or TL (Roche Diagnostics, Germany) in RPMI1640 (Sigma-Aldrich, Netherlands) was 
infused. The extended pancreas was excised and stored on ice in 2 ml Liberase RI or TL 
in RPMI1640, until all donor pancreata were collected. Animals were sacrificed in the 
process; femurs and tibia were used to collect BM. 
All pancreata were simultaneously incubated at 37°C for 17 min, after which 
digestion was stopped with cold RPMI1640 containing 10% FCS, 100 mg/ml penicillin/
streptomycin. Islets were separated by density-gradient centrifugation with 1.077 g/
ml Ficoll-amidotrizoate (Pharmacy LUMC, Netherlands). Isolated allogeneic islets 
(800-1100 per recipient) were transplanted on the day of isolation.
islet transplantation 
Male Lewis or DA recipients were injected i.v. with PBS (vehicle) or 5×106 donor-
derived dexDCs. Five days later, recipients were either rendered diabetic with STZ 
or mock injected with PBS. Two days after diabetes induction, islets of Langerhans 
were transplanted underneath the kidney capsule or a sham operation with vehicle 
was performed. All procedures took place under isoflurane anesthesia and during islet 
transplantation 0.01 mg/kg buprenorphine-hydrochloride (Temgesic, Schering-Plough, 
UK) was injected s.c. Prior to transplantation, the recipient received a s.c. injection of 
1-1.5 U insulin (Insulatard, Novo Nordisk, Denmark). Transplantations were deemed 
successful when blood glucose levels dropped <11 mmol/dl and were deemed failures when 
glucose levels raised >14 mmol/dl. On days 2 or 7 days or more after transplantation, the 
recipients were sacrificed. First serum was collected, then the animal was perfused with 
PBS and subsequently kidney and pancreas were harvested.
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tissue analysis 
For the Lewis to DA transplantation, each islet-bearing kidney was mounted on Tissue-
Tek (Sakura, Netherlands) and snap-frozen in -80°C. All other organs were split in half 
and one half was snap frozen, while the other half was fixed in 4% buffered formalin for 
24 h and paraffin-embedded, for (immuno-) histochemical analyses. Frozen samples were 
cryosectioned at 3-µm and stored at -20°C until use. For the DA to Lewis transplantation, 
all tissues were directly fixed and paraffin-embedded.
immunohistochemistry 
Frozen islets containing consecutive kidney sections were fixed for 10 min in acetone and 
then incubated at RT with the following primary mouse monoclonal antibodies: R73γ1 
(α/ß TCR, 1:500, overnight32), ED1 (CD68, 1:5, overnight33), NK3.2.3 (NKR-P1, 
1:120, overnight34), OX1 (CD45, 1:200, 1 h35), PL1 (platelet marker, 1:1, overnight36) 
OX6 (MHC RT1-B class II, 1:50, 2 h37)) diluted in 1% BSA/PBS. Secondary antibodies 
(either horseradish peroxidase (HRP) conjugated rabbit anti-mouse IgG or IgG1) were 
diluted in 1% normal rat serum/ 1% BSA/PBS at 1:100 and, after an 15 min incubation, 
were applied to the sections for 60 min. HRP was visualized with 3-3’-diaminobenzidine 
(DAB). Then, the sections were dehydrated and prepared for light microscopic analyses.
Insulin staining was performed on formalin-fixed frozen sections. Frozen sections 
were fixed for 2 h in 4% phosphate-buffered paraformaldehyde and incubated at RT with 
rabbit anti-insulin antibody H-86 (1:100; overnight; Santa Cruz, Germany) in 1% BSA/
PBS. Antibody binding was visualized with REAL™ Detection System, Peroxidase/DAB+, 
Rabbit/Mouse (DakoCytomation, Denmark).
indirect immunofluorescence (iif) 
To visualize donor-specific antibody formation upon Lewis-derived dexDC pre-treatment 
of DA recipients, serum of recipients collected at the termination of the experiment was 
incubated on frozen DA and Lewis pancreas control sections38. Serum diluted 1:10 in PBS 
was applied to acetone-fixed pancreas sections for 30 min at 37°C. Antibody binding was 
visualized by 1:200 FITC-conjugated rabbit anti-rat IgG (H+L) (KPL, USA) for 30 min 
at 37°C. Subsequently, the same slide was stained for OX6 as described above with the 
following changes. The secondary antibody used was Alexa Fluor 546-conjugated goat anti-
mouse IgG1(γ1) (Invitrogen, Netherlands), and slides mounted with DAPI containing 
Vectashield (Vector Laboratories, USA) until further analysis by fluorescence microscopy.
flow cytometry 
BM-derived DCs from DA and Lewis rats were cultured as described above12 and used for FACS 
analysis. Serial dilutions of serum from PBS- or dexDC-treated DA recipients were diluted in 
FACS buffer (PBS, 1% BSA, 0.02% Sodium azide) and incubated with the cells for 2 h. After 
washing, cells were incubated with 1:150 diluted goat anti-rat Ig-PE (BD Biosciences) for 1 h, 
washed and analyzed by flow cytometry (FACScalibur; BD Biosciences). 
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statistical analyses
Graphs and analyses were computed with the use of GraphPad Prism for Windows, 
version 5.03 (GraphPad Software Inc., USA). Survival analyses were assessed by a log-rank 
(Mantel-Cox) test. Data are expressed as mean ± SD.
results
DA islets transplanted to diabetic Lewis recipients provoke rapid, immediate rejection 
irrespective of whether recipients were vehicle- or dexDC-treated
DA-derived islets of Langerhans were transplanted into diabetic Lewis recipients. 
These strains have been described as a high-responder allogeneic combination19;20. An 
immediate failure of the allograft was observed by blood glucose monitoring when no 
immunosuppression was administered. With an immunosuppression of 15 mg/kg/day 
cyclosporine A (CsA), rejection could be halted, but rejection occurred when CsA therapy 
was stopped (data not shown (DNS)). 
Subsequently, the effectiveness of dexDC therapy was tested (Fig. 1A). DexDCs 
have been shown to produce IL-10 and completely lack IL-12 production, resulting in a 
reduced capacity to stimulate allogeneic T-cells in vitro and the capacity to induce T-cell 
hyporesponsiveness in vivo21. The blood glucose measurements of both groups showed 
the same results: an immediate failure of the allograft, even when treated with CsA. After 
transplantation, a short, transient drop in blood glucose levels was observed until day 5, 
which is consistent with the duration of CsA therapy, after which the blood glucose levels 
rise again (Fig. 1A). However, while in both PBS- and dexDC-treated recipients, no 
functioning graft was observed, grafted DA islets underneath the kidney capsule of Lewis 
recipients consistently showed residual insulin staining in the PBS-treated recipients 
(Fig. 2AB), but this was not observed in the dexDC-treated recipients (Fig. 2CD).
pre-treatment with donor-derived dexdc abbreviates allograft survival in a model of 
lewis islets transplanted to diabetic dA recipients
To gain a better idea of when immune regulation of the allogeneic islet transplantation 
was reversed, we transplanted Lewis islets into low-responder diabetic DA recipients19;22. 
In this model, an acceptance of the graft was observed for approximately 5 days, without 
CsA therapy (DNS).
Pre-treatment of diabetic DA recipients with donor (Lewis)-derived dexDCs resulted 
in accelerated graft loss (Fig. 1B). The PBS-treated recipients showed stable graft function 
for 5 days, after which rejection-induced graft loss began. After transplantation, the 
dexDC-treated recipients exhibited significantly increased levels of blood glucose above 
baseline (21 mmol/l compared with 11 mmol/l) while the PBS-treated recipients did 
not. Serum analyses at 7 days or more after transplantation showed a marked decrease 
in C-peptide in the dexDC-treated compared with the PBS-treated rats (234±46 pmol/l 
versus 301±83 pmol/l, respectively, p=0.069, normal rat C-peptide levels 450-900 
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fig 1 | effect of donor-derived dexamethasone-treated dendritic cell therapy on islet allograft survival 
in dA to lewis rats and lewis to dA rats transplantation. (A) Blood glucose measurements of PBS-
treated (black line, n=4) or dexDC-treated (dashed line, n=4) Lewis recipient groups that received DA 
islets (mean ±SD). On day -7, PBS or 5-10*106 DA-derived dexDCs were injected; on day -2, diabetes 
was induced by streptozotocin administration; on day 0, the Lewis rat received the transplant; and on 
day 10 the islet-bearing kidney was nephrectomized and paraffin-embedded for immunohistochemical 
analysis. (B) Blood glucose of PBS-treated (black line, n=8) or dexDC-treated (dashed line, n=8) DA 
recipient groups that received Lewis islets (mean ±SD). On day -7, PBS or 5-10*106 Lewis-derived 
dexDCs were injected; on day -2, diabetes was induced by streptozotocin administration; on day 0, the 
DA rat received transplant; and on day 2 or 8 the islet-bearing kidney was excised and snap frozen for 
immunohistochemical analysis. Dashed horizontal line indicates cut off blood glucose value by which the 
transplantation was deemed successful. At the time point indicated with *, the dexDC-treated recipients 
significantly differed (p<0.05) from the cut off blood glucose value. At time points indicated with ∞, the 
PBS-treated recipients significantly differed (p<0.05) from the cut off blood glucose value. On day 2 and 
4, ‡ indicates a significant difference (p<0.05) between PBS-treated and dexDC-treated recipients.(C) 
Diabetes-free survival of DA recipients with or without dexDC pre-treatment. Day count started when 
blood glucose levels dropped below 11 mmol/dl and transplants were deemed failed when levels rose 
over 14 mmol/dl. The black dashed line indicates Lewis islet donor  DA recipient with Lewis-dexDC 
pre-treatment (cases, n=8) and the black solid line indicates Lewis islet donor  DA recipient with PBS 
pre-treatment (controls, n=8).
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pmol/l). Furthermore, immunohistochemical analysis of Lewis islet-bearing DA kidney 
sections of the dexDC-treated animals (Fig. 2GH) consistently showed lower insulin 
content compared with the PBS-treated animals (Fig. 2EF). This finding is in line with 
observations recorded in the reversed high-responder rodent strain model.
The survival curve shows that only the Lewis islet allografts in the PBS-treated DA 
recipients survived (Fig. 1C), which significantly differed from survival of the Lewis islet 
allografts in the dexDC-treated DA recipients (p=0.002). Survival of the dexDC-treated 
versus PBS-treated Lewis recipients of DA islets were not significantly different (DNS). 
Importantly, this accelerated allograft loss and reduction in insulin expression upon 
donor-derived dexDC treatment was already present when experiments were ended 2 
days after transplantation.
immunohistochemical analyses of the dexdc-treated rats showed a distinct nk cell 
graft infiltrate in the islet allograft 
To assess the mechanism of accelerated rejection, frozen tissue sections from kidneys 
of DA rats that had received Lewis islet allografts were investigated 2 and 8 days 
after transplantation. Infiltrates were characterized on sequential slides by several 
immunohistochemical markers (Fig. 3), including ones for T-cells, natural killer (NK) 
cells, platelets, and macrophages. The most distinct difference in the infiltrates was the 
large NK cell (Fig. 2IK) and cytotoxic T-cell population in the dexDC-treated group at 
day 2. At 7 days after transplantation, the remains of the transplanted islets were almost 
indistinguishable in the dexDC-treated recipients, while in the PBS-treated rats, the 
infiltrate at the islet transplantation site was still prominently visible (Fig. 2JL).
No difference could be found when comparing PBS- and dexDC-treated recipients 
with direct immunofluorescence (IF) for C3 deposition (Fig. 2MO). As expected, within 
the kidney, C3 deposition was seen along the tubular basement membrane in half-moon 
shapes and at the capsule, functioning as an internal control. In between the kidney 
capsule and the cortex, at the actual islet transplantation site, there was no C3 deposition. 
Direct IF with IgG showed no prominent IgG deposition, in line with the absence of 
C3. However, when indirect IF was used to examine the binding of serum on normal 
donor and recipient-derived tissue, IgG deposition was seen. When dexDC-treated DA 
recipient serum was incubated on donor Lewis-derived pancreas tissue co-localization of 
MHC class II (red) and serum-derived IgG (green) was observed (Fig. 2P). This staining 
was donor-specific, as the same serum did not show co-localization on recipient-derived 
DA pancreas tissue (DNS). Serum derived from PBS-treated DA recipients did not show 
co-localization, either on Lewis (Fig. 2N) or DA-derived pancreas tissue (DNS). 
serum samples of dexdc-treated rats show markedly higher allo-reactive antibody 
reactivity 
To further confirm and quantify the presence of allo-reactive antibodies, serum samples 
were taken at different time points, incubated with bone marrow (BM)-derived DCs of 
donor origin, and monitored by FACS analysis. Serum of PBS-treated DA rats that had 
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fig 2 | (immuno-)histochemical staining on paraffin-embedded islet-bearing kidney sections. 
(ABCD) Two Lewis recipients were transplanted on the same day, receiving 910 DA islets underneath 
their kidney capsules in combination with 4 days CsA therapy. Islet-bearing kidneys were procured 10 
days after transplantation. (A) and (B) depicts a recipient treated with PBS 7 days prior to transplantation, 
while (C) and (D) shows a recipient treated with DA-derived dexDCs 7 days prior to transplantation. 
(Immuno-)histochemical staining on frozen islet-bearing kidney sections (EFGHIJKL). Two DA recipients 
were transplanted on the same day, receiving 1012 Lewis islets underneath their kidney capsules. Islet-
bearing kidneys were procured 2 days after transplantation. (E), (F), and (I) depicts one DA recipient 
treated with PBS 7 days prior to transplantation. (G), (H), and (K) depicts one DA recipient treated 
with Lewis-derived dexDCs 7 days prior to transplantation. Two other DA recipients were transplanted 
on the same day, receiving 1100 DA islets underneath their kidney capsules. Islet-bearing kidneys were 
procured 7 days after transplantation. (J) was PBS-treated at day -7, (L) was dexDC-treated at day -7 
(H&E (ACEG); insulin (BDFH); NKR-P1A (IK); CD45 (JL)). Direct immunofluorescence staining 
of C3 on frozen islet-bearing kidney sections (MO). Two DA recipients were transplanted on the same 
day, receiving 1055 Lewis islets underneath their kidney capsules. Kidneys were procured 2 days after 
transplantation. (M) was PBS-treated at day -7 and (O) was dexDC-treated at day -7. Indirect immuno-
fluoresence, incubating dexDC-treated DA islet recipient serum procured at day 2, on a normal frozen 
Lewis pancreas section (green) in combination with an OX6 (major histocompatibility complex RT1-B 
class II) staining (red) and DAPI counterstain (blue) (NP). (N) was PBS-treated at day -7 and (P) was 
dexDC-treated at day -7. In the square, an enlargement of two single OX6 stained cells (N) and of OX6 
and serum double stained cells (P) can be seen.
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been transplanted with Lewis islets did not show a significant reactivity with Lewis DCs 
(Fig. 4A). In contrast, serum from DA rats, pre-treated with Lewis dexDCs and transplanted 
with Lewis islets, showed increased reactivity towards Lewis DCs compared with control 
DA serum (Fig. 4B). When analyzing different time-points, antibody reactivity was most 
pronounced 2 and 7 days after transplantation (Fig. 4C). However, already before islet 
transplantation, allo-reactive antibodies could be detected, indicating a priming of the 
humoral immune response by dexDC pre-treatment. Allo-reactive antibodies were not 
detectable in the recipients of Lewis islets without pre-treatment with Lewis dexDCs.
discussion
The preconditioning of islet transplant recipients with donor-derived dexamethasone-
treated dendritic cells induces a hyper-acute, antibody-mediated rejection through the 
sensitization of the recipient for donor antigens. Blood glucose monitoring showed a 
significant difference in duration of graft acceptance between PBS- and dexDC-treated 
recipients. We have shown through several independent methods (FACS analysis using 
serum, and (in)direct immunofluorescence) that allo-specific antibodies were formed.
The use of dexDCs was derived from the safe DC vaccine trials for cancer, which 
proved to be efficacious and to have minimal side effects in some patients23. As testing of 
fig 3 | immunohistochemical analyses on frozen consecutive tissue sections of dA rat kidneys 
transplanted with lewis islets at 2 days after transplantation. Black columns are dexDC pre-treated 
DA recipients (n=6) and white columns are PBS-treated DA recipients (n=6). All markers have been 
scored with a ranking system ranging from 0 (no staining) to 3 (extensive staining). Data are shown as 
mean ± SD, * p<0.05, ** p<0.01, ***p<0.001. PL1, platelet marker; TCR, T-cell receptor, CD8, cytotoxic 
T-cell marker, CD45, leukocyte common antigen, NKR-P1A, natural killer cell receptor, and CD68, 
macrophage/monocyte marker. This style of representation was derived from other studies39-41. 
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cellular therapy via DCs in human autoimmune disease is already underway, also the use 
of cellular therapy via DCs in transplantation and rejection becomes a realistic option24. 
In our model of allogeneic islet transplantation, strain-dependent reactions regarding 
rejection and tolerance induction were observed, as has been described in an allogeneic 
heart transplantation model25. Some have expressed their concerns that instead of 
inducing tolerance, dexDCs could lead to the processing and presentation of alloantigen 
by endogenous DCs, resulting in increased allo-immunity13;26. Recently, it was shown 
that allo-antibodies can facilitate not only antibody-mediated rejection (AbMR), but 
fig 4 | detection of donor-specific antibodies in dA recipients. (A,B) Representative FACS plot of 
Lewis BM-derived DCs incubated with (A) PBS-treated (control) DA serum at end of experiment, or (B) 
dexDC-treated (cases) DA serum at end of experiment (gray curve). Open curve is the control of the same 
cells incubated with normal DA serum. (C) The ratio of the mean fluorescence of Lewis-DC incubated 
with serum of DA recipients, divided by the mean fluorescence when incubated with normal DA serum 
(mean ± SD, * p<0.05). Comparison of PBS-treated (white bars) with dexDC-treated (black bars) at -7, -2, 
0, 2, and >7 days after transplantation. All experiments with Lewis donors and DA recipients are included. 
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also function as opsonins to enhance alloreactive T-cell priming27. The role of AbMR is 
becoming increasingly well-defined, and even low, “smoldering” levels of antibody are 
now thought to be responsible for the chronic deterioration observed in almost every 
allograft28. In vitro islets have been shown to be able to express HLA class II when 
stimulated29 and in the clinical islet transplantation setting pre-formed HLA antibodies 
have been shown to reduce islet graft survival30, allowing for the accelerated rejection 
observed in our sensitized islet transplantation model.
Similar dexDCs as the ones described in this study were used in other transplantation 
settings and have resulted in different outcomes. In an allogeneic full-mismatch kidney 
transplantation model using similar dexDC administration as in the present study, no 
allograft survival prolongation was found21. However, dexDCs did give rise to a donor-
specific T-cell hypo-responsiveness. In both PBS- and dexDC-treated recipients, strong 
IgG antibody responses were found (unpublished data,21), but no indications of accelerated 
rejection were present. Alternatively, with a similar dexDC pre-treatment, prolongation 
of skin graft survival was reported, in which rejection was considered to have occurred 
when the tissue was fully necrotic, or the graft completely lost8. In the present study using 
an allogeneic islet transplantation model, the same dexDCs even accelerated graft loss. 
This occurred possibly because islet transplantation offers a unique situation in which 
the exterior of the cells come in direct contact with the blood of the recipient, while 
in whole organ transplantation, the endothelium forms a barrier. This most likely also 
contributes to the observation that in clinical islet transplantation recipients are prone to 
lose graft function through recurrence of auto-immunity while on immunosuppression, 
more so than recipients of vascularized pancreas transplants31. Therefore, islet recipients 
might be more prone to antibody-mediated effector mechanisms than pancreas transplant 
recipients, or recipients of other solid organs.
An accelerated rejection after dexDC induction therapy was shown in this study, 
which is most likely due to donor-specific AbMR. We have not been able to detect 
complement deposition (C3, C4 and C5b-9 immunohistochemical staining) at the 
site of transplantation, suggesting complement-independent effector mechanisms. 
Importantly, we showed a predominant NK cell infiltrate at the transplantation site in 
dexDC-treated recipients. This is different from the PBS-treated recipients, in which 
rejection was dominated by a T-cell infiltrate and occurred at a later time point. Our 
results strongly suggest that the rejection is complement-independent and that it most 
likely occurs through antibody-dependent cell-mediated cytotoxicity (ADCC). The speed 
of the rejection in particular favors a direct lysis of the allograft via ADCC in combination 
with the NK cell infiltrate observed. Human islet transplantation differs from the rodent 
transplantation model studied here in view of the streptozotocin-induced hyperglycemia 
investigated , and due to the fact that the recipient rats were not under the conditions that 
are required in human islet transplantation (humoral immunity, and immunosuppressive 
treatment). More research is necessary before cell-based therapy as an immunomodulating 
therapy can be considered in the human islet transplantation setting.
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In allograft transplantation, whether vascularized or cellular, the graft is potentially exposed 
to several adverse events, which include ischemia/reperfusion injury, acute rejection and 
immunosuppressive drug-related toxicity. Much scientific research is aimed at preventing 
graft damage caused by alloreactivity (i.e., acute rejection), which may eventually lead 
to an irreversible loss of function and/or premature graft failure. Two types of rejection 
have been defined: T-cell mediated and antibody-mediated rejection. Both types of 
rejection may occur either acutely or follow a more insidious and chronic course. The 
characteristic features and discriminating markers of these types of rejection are currently 
under investigation to identify the risk factors associated with inferior graft outcomes. To 
prevent rejection, immunosuppressive therapy is administered, and if rejection occurs, 
additional treatment is initiated and maintenance therapy can be adjusted accordingly. 
However, current immunosuppressive therapies may not always be adequate or specific 
enough to resolve the rejection process and may cause additional complications, including 
(opportunistic) infections. Therefore, alternative immunosuppressive strategies are being 
explored, with cellular immune modulation representing one potential approach. The 
envisioned outcomes of this research include the improvement of current short- and 
especially long-term graft survival rates through patient-tailored therapy regimens or, 
preferably, tolerance induction. 
For kidney transplantation alone, the 5-year graft survival rates reported in the United 
States are 69.3% for deceased donor kidney transplantation and 81.4% for kidneys 
obtained from living donors1. With respect to simultaneous pancreas-kidney transplants 
(SPKT), the graft survival rates for the kidney and the pancreas are 78.6% and 73.4% 
at 5 years post-transplant, respectively. After islet transplantation, only 6.5% of patients 
remained insulin independent after 5 years1;2. Based on these numbers, it is obvious 
that further improvements are required for pancreas and especially islet transplantation. 
Rejection represents a serious threat to allograft survival. The work described in this thesis 
focuses on acute antibody-mediated rejection (AMR) in relation to allograft survival. 
AMR as a causative factor for the rejection of the kidney allograft was first described 
in 1993 by Feucht3. With increasing appreciation of its clinical relevance in kidney 
transplantation, the role of AMR in other transplant settings is beginning to be explored. 
New insights into AMR have fuelled research directed toward prolonging long-term 
survival of the renal allograft.
In this thesis, acute rejection after kidney, simultaneous pancreas and kidney, and 
islets of Langerhans transplantation was addressed. The focus of the thesis is on acute 
antibody-mediated rejection after pancreas transplantation and on a potential strategy 
using cellular immune modulation to prevent acute rejection. First, we retrospectively 
evaluated the relevance of diffuse C4d-positive peritubular capillary staining in a well-
defined cohort with proven early acute rejections (Chapter 2). Second, the negative 
impact of AMR on pancreas graft survival was investigated, which proved to be significant 
(Chapter 3). We subsequently analyzed all SPKT patients at the Leiden University 
Medical Centre (LUMC) with early pancreas graft loss to examine the role of AMR in 
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early pancreas graft loss due to presumed thrombosis and/or acute rejection (Chapter 4). 
In Chapter 5, a clinical update is presented on islets of Langerhans transplantation, 
focusing on the alternative ß-cell replacement therapy that is currently employed in the 
LUMC (Chapter 5). Furthermore, we reviewed the role of both lymphatic- and blood-
vessel vascularization and the role of neuronal reconnection after islet transplantation 
with data from our own rat islet transplantation models (Chapter 6). Finally, in a rodent 
allogeneic islet transplantation model, we attempted to induce tolerance by using donor-
derived, dexamethasone-pretreated dendritic cells (dexDC) (Chapter 7). In the following 
paragraphs, these studies are placed in a broader perspective and future plans are discussed.
1. Antibody-mediAted rejection
Antibody-mediated rejection is induced when donor-specific antibodies (DSA) are 
produced, which can bind to the endothelium of the allograft and cause classical pathway 
complement activation. This ability of the antibody proves its cytotoxic capacity, as 
complement activation leads to immune activation through the release of growth factors, 
cytokines, and chemokines and changes in adhesion molecule interactions and leads to lytic 
injury via the formation of the membrane attack complex (MAC), resulting in apoptosis. 
After antibody-induced complement activation, C4d is bound to the endothelium as a 
‘footprint’ of the processes that have taken place. Histologically, AMR-induced damage 
can be represented by capillaritis (neutrophil and/or mononuclear cell margination in 
dilated capillaries), fibrinoid necrosis of arteries, and/or the presence of microthrombi, 
although none of these lesions are specific to AMR.
1.1 Antibody-mediated rejection in a historic perspective
AMR is a relatively new entity that was first discovered in the kidney transplantation 
setting. As outlined by Colvin, the occurrence of AMR after pancreas transplantation has 
been scarcely studied4. Figure 1 shows the distribution of publications on C4d per type 
of organ transplant according to the year of publication. The kidney was the first allograft 
in which AMR was described, and as represented in Figure 1, studies aimed at exploring 
the role of AMR in kidney transplantation have significantly increased over the years. 
Interest in AMR has now extended to other solid organ transplants, and it appears that 
the definition of AMR is not clear-cut in every type of allograft. For example, in small 
bowel transplantation, the relationship between C4d positivity and AMR is not evident5. 
In pancreas and heart transplantation, a first consensus agreement on the definition and 
criteria for the diagnosis of AMR has been established6-8. These agreements will be further 
discussed at upcoming Banff conferences on allograft pathology, and improvements are 
regularly made based on scientific advancements. 
To diagnose AMR, most classifications require the presence of C4d-positive staining 
(>10% of specified capillaries), circulating DSA must be detected, and either graft dysfunction 
or certain defined histological lesions must be present in the organ. However, a biopsy is 
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fig 1 | number of publications on c4d per transplantation organ per year4. Copyright (2011) Wiley. 
Used with permission (Colvin RB, Dimensions of antibody-mediated rejection, American Journal of 
Transplantation, John Wiley & Sons Inc.)
only a small sample of the organ at a specific moment in time. DSA have the advantage 
that they can be assessed systemically in allograft recipients; however, their relationship with 
injury at the tissue level may not always be clear. A schematic depiction of the proposed 
kinetics of DSA and C4d is provided in Figure 2. The depiction is speculative because the 
exact kinetics of the in vivo interactions of these two components is unknown9. Thus, a 
sampling error due to the timing of the biopsy or due to the timing of the serum sampling is 
entirely possible. Even so, DSA and C4d are still important tools for the diagnosis of AMR. 
There are two reasons for searching for C4d depositions in the biopsy specimen instead 
of searching for the actual antibody binding to the endothelium. C4d is a general marker 
that is deposited irrespective of the specificity of the antibody, and as such, C4d deposition 
in the capillaries is a uniform marker for antibody-dependent complement activation. Of 
equal importance is the fact that C4d remains bound much longer and more potently than 
the actual antibody, providing a larger window of opportunity to find it as a hallmark of 
AMR. The length of time that C4d stays covalently bound to the place of activation after 
the first antibody priming is not known. Thus, when evaluating the results discussed in this 
thesis and in other studies on AMR, this basic lack of knowledge needs to be considered. 
The studies described in Chapters 3 and 4 of this thesis contributed to our understanding 
of AMR in pancreas transplantation. In a multi-center international setting, we found 
that AMR, which was defined by the diffuse C4d deposition in interacinar capillaries in 
combination with de novo DSA in the recipient’s blood, was associated with pancreas graft 
failure (Chapter 3). This study also provided the organ transplantation field with the first 
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histological correlates for AMR in the pancreas. We showed in an LUMC-based (1985-
2010) case-control study of pancreas transplantation patients that some transplantectomy 
cases, which had been previously diagnosed as lost due to thrombosis, also showed signs 
of an AMR component (Chapter 4). Whether these grafts were in fact lost due to AMR 
or thrombosis remains to be determined. Prospective studies are necessary to establish 
the treatment of choice when de novo DSA and C4d deposition in the pancreas allograft 
are observed. Close monitoring of SPKT recipients for the occurrence of DSA to guide 
biopsies of both the kidney and pancreas allograft may prove to be the best strategy 
to improve early pancreas graft outcome. On the other hand, excluding specific HLA 
antigens in specific recipients may reduce the risk of AMR after pancreas transplantation 
to a level comparable to kidney transplantation.
In the study described in Chapter 4, all but one of the seven acute AMR cases (i.e., 
C4d deposition in combination with de novo DSA and morphological evidence of graft 
injury) with allograft loss were clinically categorized as loss due to rejection. The studies 
described in Chapters 3 and 4 showed that, in accordance with other studies10-13, the 
transplanted pancreas and kidney from one donor may indeed show discordant rejection 
grades in simultaneously obtained graft biopsies. A prospective study may provide more 
insight in the divergence of alloreactivity at the tissue level of multiple organ transplants.
1.2 chronic antibody-mediated rejection
Several types of AMR have been reported in the kidney: hyperacute, acute and chronic 
rejection. The use of the terms acute and chronic is not related to the time of occurrence 
after transplantation but is defined by the type of morphological changes due to the 
damage and/or remodeling present in the allograft14. In particular, chronic AMR is now 
considered relevant in late allograft failure, and AMR is not seen as an episode but as a 
process. Acute rejection may occur long after transplantation and can be induced by a 
decrease in immunosuppressive therapy, due to non-compliance, iatrogenic effects, and/
or intercurrent malabsorption. Acute rejection is different from chronic rejection because 
in chronic rejection there is no clear option for acute intervention, and maintenance 
immunosuppressive therapy is continued mostly without major alterations to the regimen. 
Nonetheless, chronic damage will eventually lead to progressive graft dysfunction and 
premature graft loss. 
Histologically chronic AMR is distinguished from acute AMR by the lack of 
inflammation markers such as neutrophils, edema, necrosis, and/or thrombosis. 
Regardless, DSA are considered to be an important contributing factor to chronic AMR; 
however, the contribution of the presence and levels of DSA to the development of either 
acute or chronic rejection remains unclear. Low levels of antibodies are thought not to 
provoke a direct reaction, while in the long term, these low levels may induce cumulative 
damage that can become fatal to the functional integrity of the transplanted organ. It 
was recently shown that the timing of de novo DSA development may have an impact on 
long-term graft survival15. In addition to DSA titers, the avidity of the specific antibody 
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or antibodies involved, their effector function, and endothelial resistance are all thought 
to play a role in the development of acute or chronic AMR. 
The formation of antibodies has also been proposed as part of the tolerogenic process 
or in the adoption of an accommodative state in the recipient. In vitro studies have 
established that cells can be rendered insensitive to antibody-induced activation when 
exposed to prolonged suboptimal concentrations of this antibody16;17. The use of the words 
“accommodation” and “tolerance induction” for this phenomenon is still the subject of 
debate, but based on two studies (one in Europe and the other in the United States), it 
is clear that some patients will not reject their renal grafts while off immunosuppressive 
therapy, a condition known as operational tolerance18;19. The one remarkable alteration 
in the systemic immune cells found in both the European and the US studies is the 
up-regulation of specific B-cell markers. The significance of this finding needs further 
exploration, but it does seem to suggest a crucial role for antibodies in tolerance as well 
as rejection. Once the facilitating hallmarks of the renal allograft recipients who have 
acquired operational tolerance have been elucidated, it might be possible to wean other 
renal transplant recipients off immunosuppressive therapy in a patient-tailored manner18.
Chronic AMR is currently a “hot topic” in organ transplant settings; however, in our 
pancreas transplantation studies (Chapters 3 and 4), we did not have the opportunity 
to study chronic AMR. The biopsy material was limited and tissue from the pancreas 
transplantectomies were mostly from graft losses within 1 year. Within that first year, one 
pancreas transplantectomy specimen showed chronic active AMR. Of the 66 transplanted 
grafts that were included as controls, with pancreas grafts that functioned well for at least 
4 years, 8 patients later lost their grafts. Tissue specimens from 3 controls were retrieved 
from our archives, and only one showed the histological hallmarks of chronic AMR. Data 
on DSA in these cases were not available.
1.3 relevance of c4d and donor-specific antibodies in antibody-mediated rejection
C4d without donor-specific antibodies
The marker C4d is used as a ‘footprint’ of antibody-mediated classical complement 
pathway activation. However, the sole occurrence of C4d is not specific enough to 
diagnose AMR, as further highlighted in the study described in Chapter 2. Circulating 
DSA are an essential part of a more reliable diagnosis of AMR, which has implications 
for clinical outcomes. A potential confounder, for instance, can be that C4d is deposited 
through AMR involving DSA other than the tested donor-specific anti-HLA antibodies. 
Therefore, one should be cautious in stating that AMR is absent in the case of C4d 
positivity without DSA. Some non-HLA antibodies that can be involved in AMR are 
not regularly tested, such as the major histocompatibility complex class I chain-related 
genes A and B (MICA, MICB), vimentin, agrin, glutathione-S-transferase T1 (GSTT-1), 
angiotensin type 1 receptor, and anti-minor HLA antibodies20-24. These antibodies may 
all play a role in AMR, and in all probability there will be many more antibodies against 
transplanted antigens still to be discovered. 
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Organ-specific reactions to antibody-mediated rejection
As has been shown in other studies10;12;13, the findings described in Chapters 3 and 4 
confirm that discordant, organ-specific rejection patterns can occur in the pancreas and 
kidney allografts of SPKT patients. When the duodenal patch attached to the pancreas 
allograft was studied (Chapter 4), only 69% of the cases showed consistency in the C4d 
staining of the duodenal patch, with C4d staining of the pancreas allograft. This gives rise 
to the speculation about the existence of organ-specific endothelial antibodies that are 
able to induce complement activation in specific organs from the same donor. The fact 
that these antibodies need to be able to bind and subsequently activate the complement 
system is established. However, the proteins that these organ-specific endothelial 
antibodies may bind to still need to be elucidated. Another explanation for the tissue-
specific reaction to the de novo DSA as highlighted in Chapter 4, could be the tissue-
specific endothelial expression of complement activation regulatory proteins such as the 
complement decay accelerating factor (DAF), the membrane cofactor protein (MCP), 
and CD5925. In addition, the finding of C4d deposition in the absence of DSA could 
be explained, for example, by the described ability of the renal allograft to absorb DSA 
from the circulation26. It has been observed clinically that following renal graft failure and 
transplantectomy, the antibody titers can rise immediately as the produced DSA are no 
longer absorbed. In these cases, AMR can be determined as the causative factor only after 
graft failure26. Another explanation for organ-specific AMR may be the presentation of 
tissue-specific peptides on HLA27. As more DSA epitopes are identified, the diagnosis of 
AMR may become even more complicated. 
A new pre-transplantation screening method for antibodies is currently under 
investigation to gain insights into preformed endothelial antibodies and preformed donor-
specific anti-HLA antibodies. The method involves pre-transplantation flow cytometric 
cross-matching of recipient serum on a panel of peripheral blood endothelial progenitor 
cells28;29. Unfortunately, this screening method is not able to discriminate between 
autoantibodies and alloantibodies because the target antigen expressed on the endothelial 
progenitor cells to which the antibodies bind is still undetermined. Another drawback 
might be that the characteristics of these blood-derived endothelial progenitor cells are 
different from fully differentiated endothelial cells. A possible alternative method would 
focus on the incubation of pre- and post-transplantation serum samples on both donor- 
and recipient-derived endothelial cells, with a read-out of either complement-induced 
cytotoxicity or flow-cytometry. Although such an approach would technically be feasible, 
the cost and complexity of the procedure makes it impractical for diagnostic purposes. 
Furthermore, the acquisition of endothelial cells from both donor and recipient would 
be a cumbersome exercise30. This method could provide an answer to the autoantibody 
or alloantibody characteristics of the de novo antibody, but the antigen it recognizes 
remains undetermined. A few commercially available endothelial antibody systems 
are currently on the market, and some validation studies have been undertaken. In a 
commercially available human umbilical vein endothelial cell (HUVEC) preparation and 
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antibody detection system by indirect immunofluorescence (Titerplane, EUROIMMUN, 
Germany), de novo anti-endothelial cell-antibodies were found after transplantation in 
the absence of C4d staining and in the absence of detectable common DSA tested for, 
but with histopathological signs of microvascular injury indicative of graft injury. Graft 
dysfunction was significantly more abundant in patients with detected de novo endothelial 
antibodies compared with recipients that remained negative for endothelial antibodies31. 
All in all, it appears likely that one of the standardized endothelial antibody detection 
systems might be added, in the near future, to the pre- and post-transplantation screening, 
in addition to the lymphocyte cytotoxic and solid-phase assays currently employed.
Donor-specific anti-HLA antibodies in antibody-mediated rejection
Donor-specific anti-HLA class I or II antibodies are found in 88-95% of patients 
with C4d deposition and graft dysfunction, while less than 10% of the C4d-negative 
patients have detectable DSA32. In a large kidney transplantation study at 1 year post-
transplantation, only the sole occurrence of donor-specific anti-HLA class II antibodies 
was found to be detrimental to the graft, independent of C4ddeposition33A. A separate 
study on renal biopsies found that DSA determined at the time of the protocol biopsy 
were not indicative of graft function or survival. If DSA were present when a biopsy was 
taken when indicated, the graft function and survival were impaired compared with cases 
where no DSA were found at the time of indication biopsy34. 
The presence of DSA without C4d deposition was found in many studies, including 
ours as described in Chapters 3 and 4, and there are several explanations for this finding. 
First, all antibodies targeting HLA are picked up when using Luminex technology, 
independent of their ability to activate the complement system. Numerous DSA cannot 
induce a cytotoxic effect and as such are of no immediate threat to the allograft. Therefore, 
a cell-based cytotoxicity assay such as a complement-dependent cytotoxicity (CDC) assay 
is necessary to ensure the cytotoxic capacity of the detected donor-specific anti-HLA 
antibodies. To complicate things further, some antibodies are capable of inducing 
a cytotoxic effect without complement activation, a condition known as antibody-
dependent cell-mediated cytotoxicity (ADCC)35. Recently, biomarkers at the mRNA 
level have been described to distinguish renal allograft rejection through ADCC by 
means of endothelial activation transcript signatures36. In Chapter 7, in all probability we 
unintentionally induced ADCC while attempting to apply cellular immune modulation 
toward a tolerogenic state in the rodent allogeneic islet transplantation model.
Several techniques can be used to detect anti-HLA antibodies, auto-antibodies, and 
other antibodies. There are solid-phase assays that use immobilized proteins and peptides 
as substrates, and there are cell-based assays using lymphocytes and, more recently, 
endothelial cells as substrates. The most important differences between these techniques lie 
in their specificity, sensitivity, and the costs involved per test30. The use of one technique 
over the other is based on the infrastructure per screening laboratory or country, the 
country-based regulations, and the information needed from the assay. Often, several steps 
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are taken to define DSA, starting with a relatively cheap, fast assay with low specificity 
and acceptable sensitivity to screen all samples. Based on the results gathered, the sample 
is further tested to determine the exact DSA and its capabilities. New techniques are still 
under development and the most optimal method has not yet been found37. 
Focal C4d staining and subclinical rejection
Focal C4d staining is defined as 10% to 50% of capillaries positively staining for C4d. 
In renal transplantation, the C4d staining is scored on peritubular capillaries, while in 
pancreas transplantation, C4d staining of the interacinar capillaries is scored. Especially 
in renal transplantation, the significance of focal C4d staining remains a topic for debate 
where some studies claim that it is predictive for AMR while others have not found a 
correlation with AMR and graft failure. For example, Kayler et al found that focal C4d 
staining in renal allograft biopsies was a harbinger of acute AMR38;39. Fior et al found that 
focal C4d staining was correlated with poorer graft survival40. Kedainis et al only found 
a trend towards poorer graft survival when focal C4d staining was present41. In a more 
recent study by Crary et al, immunoperoxidase C4d staining of over 10% of PTC was 
found to be predictive of graft loss42. 
As described in Chapter 2, the renal biopsies stained positive for C4d deposition in a 
small number of acute rejection episodes, but the C4d-positive episodes were of a more 
subclinical rejection type. Due to the small number of cases in our study, the power 
did not allow for the three categories (negative, focal, and diffuse C4d deposition) to 
be compared. We considered these C4d-positive cases subclinical because no difference 
between the C4d-positive and C4d-negative renal allograft recipients was observed, either 
in graft function or survival. Moreover, none of the biopsies showed the histological 
parameters of AMR. This is not a subclinical rejection per definition, described as AMR 
without graft dysfunction43, but it is subclinical nevertheless. Some authors propose 
that the detection of C4d without any of the histological hallmarks of AMR may be an 
indication of graft injury that was easily repaired44.
C4d-negative antibody-mediated rejection
C4d-negative AMR has recently been described by Sis et al on the basis of an mRNA 
expression study of renal biopsies45. Theoretically, the assumption that AMR can be 
present while the marker C4d has already lost its covalent binding with the endothelium 
is plausible (Figure 2), as is the assumption that AMR may occur through ADCC, 
inducing no complement activation while causing injury to the graft. The problem is how 
to distinguish these cases of AMR from the ones that have DSA without any damaging 
capacity. In other words, the question is which markers on the mRNA level show repair 
and which predict permanent damage. Sis et al claim to have found a way to answer this 
question through the use of endothelial activation (ENDAT) transcripts, which show a 
specific profile indicative of C4d-negative AMR. In the same study, other transcripts in 
renal biopsy-derived mRNA were assessed, and analyses revealed other cell cluster markers 
that were differentially expressed, such as the NK cell repertoire and the B-cell repertoire 
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markers46;47. Several groups are exploring the relevance of these and other molecular 
markers. In the United Kingdom, a validation study on specific ENDAT transcripts in 
renal transplantation has been initiated.
fig 2 | proposed kinetics of dsA in serum and c4d deposition in peritubular capillaries in kidney 
transplantation. Adapted from Cornell et al, 20089. Annual review of pathology, Copyright 2008 by 
ANNUAL REVIEWS, INC. Reproduced with permission from ANNUAL REVIEWS, INC. in the 
Dissertation format via the Copyright Clearance Center.
1.4 Antibody-mediated rejection in pancreas transplants
The first reports on AMR in the pancreas were case studies. These case studies showed that 
AMR in pancreas transplantation was likely to represent a mechanism of graft rejection 
and that AMR had to be determined with a combination of C4d staining of the biopsy 
and donor-specific antibody determination. The first large cohort study in 2009 on 27 
pancreas biopsies concluded that C4d deposition specifically in the interacinar capillaries 
is most likely associated with AMR, de novo DSA, and clinical outcome48. These results 
were followed by a study correlating C4d staining with several serum- and urine-derived 
markers in the rejection of the pancreas allograft49. Our study was the third to discuss the 
role of AMR in pancreas transplantation in 2010 (Chapter 3), and up until the publication 
of this thesis, only three other studies have followed10;50;51. One of the studies is a case 
report on a pancreas after kidney transplantation (PAK) recipient with AMR, TCR, and 
pancreatic panniculitis, with well-preserved graft function after a treatment with high-dose 
steroids50. The second study confirmed the differences between pancreas and renal allografts 
in terms of the rejection status after SPKT10, following previous observations12;13. The third 
study addressed the formation of (donor-specific) anti-HLA antibodies in 167 pancreas 
transplantations. Twenty-six patients developed post-transplant DSA, which was found to 
be an independent risk factor for pancreas graft survival51. Histological parameters typical 
of AMR thus far include interacinar capillaritis, (inter-) acinar inflammation, thrombosis, 
and acinar cell and overall tissue injury (Chapter 3)6. In the study described in Chapter 
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4, 7 out of the 33 pancreas transplantectomy cases within 1 year after transplantation 
showed all 3 hallmarks of AMR. Furthermore, we found that AMR is associated with 
a poorer outcome of the pancreas graft (Chapter 3); however, larger cohorts need to be 
studied to confirm this observation. The possible clinical impact of these findings can only 
be determined by prospective studies. Once transplantation patients are treated based on 
the rejection status of their pancreas, we will have the opportunity to determine whether 
improvement of the graft and/or patient survival is feasible.
One reason for the small number of studies on rejection of the pancreas allograft 
is the shortage of pancreas allograft tissue samples, due to the reluctance to biopsy the 
pancreas. Most studies evaluate clinical parameters but fail to include any histological 
assessment, which is the gold standard in other transplant settings to assess rejection. 
Only a few large histological studies have been performed that discuss rejection and the 
role of AMR in thrombosis52;53. However, at the time those studies were conducted, C4d 
had not been recognized as a marker for antibody-dependent complement activation, 
and the role of de novo DSA was also not clear. At present, pancreas graft biopsy material 
is scarce. Pancreas allograft function is most often monitored by serum amylase, serum 
lipase, or (when bladder-drained) amylasuria49. Often the renal transplant biopsy is 
used as a surrogate for pancreas graft rejection status in SPKT. Our data, as outlined in 
Chapters 3 and 4, emphasizes the continuing importance of monitoring pancreas graft 
function by taking pancreas biopsies to distinguish immune and non-immune injury 
to the graft, as has been previously stated54. Especially considering that PAK becomes 
increasingly frequent due to an increase in living donor kidney transplantation, cases 
such as those reported by Carbajal et al may become even more abundant55. Carbajal 
et al reported a patient with PAK who developed AMR of the pancreas with a C4d-
positive biopsy. This patient’s kidney, which originated from a different donor than the 
pancreas, remained unaffected, but the pancreas graft was lost. Obviously, in the case of 
a PAK, a kidney biopsy will not be predictive of the clinical course of the pancreas graft 
because the organs originate from different donors. Our data emphasizes that, due to the 
level of discordance in the morphological findings between kidney and pancreas biopsies 
from the same donor, biopsies of both organs (when indicated) are likely justified, as has 
been previously shown56. However, prospective studies are necessary to ascertain whether 
intervention based on findings in either organ could improve allograft survival. 
The reluctance to perform biopsies on the pancreas is based on a combination of factors. 
In SPKT, many physicians still believe that findings in the kidney biopsy are predictive 
of the processes taking place in the transplanted pancreas, in spite of the evidence against 
this assumption10;12;13. Therefore, there is the opinion that there is no legitimate reason to 
risk a biopsy of the pancreas. A biopsy of the pancreas is not without risk, but whether 
the assumed risk is equal to the actual risk remains to be determined. There is the fear of 
causing injury to the organ or inducing serious complications such as bleeding11. Several 
studies have addressed the mortality, morbidity, and risk of complications following 
percutaneous fine-needle aspiration in pancreatic neoplasms and pancreatitis. Mortality 
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and morbidity range from 0.006-0.08% and from 0.05-0.18%, respectively57, and the 
incidence of major complications has been reported in 0.005-0.18% of fine-needle 
pancreas aspirations58. Although the risks are low, they are present, and death due to 
hemorrhagic pancreatitis induced by a percutaneous fine-needle aspiration is not only 
theoretical but has been described in a case-report59. 
In the pancreas transplant setting, the orientation of the pancreas is altered which 
hinders access, providing another reason for the lower number of biopsies taken after 
pancreas transplantation compared with pancreatitis and pancreatic neoplasms, and for 
the even fewer number of studies addressing the complications. A 1995 study reported 
the prolonged bleeding from the pancreas biopsy site (8%), clot retention (1%), and 
transient hyperamylasuria (20%) after the cytoscopically guided biopsy of the transplanted 
pancreas11. A 2000 study addressed pancreas transplant biopsies and found an adequate 
yield for the histopathological analyses in 83.3% of cases, regardless of the biopsy needle 
gauge and imaging used to guide the procedure. In a study that included 42 biopsies on 
21 patients, 11% of the cases showed minor complications for all gauges and methods 
used. These minor complications comprised mild local bleeding (2%), air within the 
transplanted pancreas, and streaky density appearing adjacent to the biopsy site60. Boggi 
et al performed retroperitoneal pancreas transplantation with portal-enteric drainage and 
direct apposition of the pancreas body/tail to the lateral abdominal wall61. This method 
facilitates the percutaneous pancreas biopsy and results in 90% of biopsies being fit for 
diagnostic purposes (oral communication, Banff 2011 conference).
Studies from our lab and others indicate that rejection of the pancreas and kidney can 
take place discordantly in SPKT (Chapters 3 and 4)10;12;13. It is also generally known that 
the pancreas allograft has a poorer graft survival than the kidney allograft. Considering 
the risks associated with taking biopsies determined by the pancreatic neoplasm studies, 
the benefits may outweigh the risks in the pancreas transplant setting. The additional 
information acquired from histopathological analyses of pancreatic biopsy tissue may prove 
to be essential for the survival of the pancreas. To test this hypothesis, prospective SPKT 
biopsy studies should be initiated that compare current practice with the proposed practice 
of taking pancreatic biopsy tissue findings into account. This approach means that the 
immunosuppressive regimens adapted to just the findings in the kidney biopsy (as is often 
the current practice) should be compared to the immunosuppressive regimens adapted to 
the findings in both pancreas and kidney biopsies in order to assess survival advantage. In 
PAK and PTA, pancreatic biopsies will most likely be of even greater value, given that in this 
setting the pancreas is either the only allograft or has been derived from a different donor.
1.5  ß-cell replacement therapy (vascularized versus cell-based) and antibody-
mediated rejection 
Vascularized organ transplantation differs from cell-based transplantation in several 
aspects. In vascularized organ transplantation, only the donor endothelium is exposed to 
the recipient. In cell-based transplantation, various cell types and structures are directly 
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exposed to the recipient’s blood and immune system. Islets of Langerhans transplantation 
differs from other cellular therapies, such as stem cell transplantation, as the islet itself 
is a miniature organ that needs to be revascularized in order to function properly. When 
the islet is extracted from the pancreas and transplanted, the previously embedded islet 
cell comes into direct contact with blood components. The normally embedded “outside” 
of the islet is known to express tissue factor (TF), a component driving thrombosis, after 
isolation62. Using a rodent islet isolation model, Saito et alreported that the induction 
of brain death, in combination with the warm ischemia time necessary for isolation 
of the islets, triggers the production of TF by islets63. When TF expressed on the cell 
surface comes into contact with blood, a process of immediate cell lysis known as the 
immediate blood-mediated inflammatory reaction (IBMIR) can be induced62. The co-
infusion of heparin together with the islet transplant, which is directly infused into the 
bloodstream via the portal system of the liver, should dampen this effect64. When the islets 
have evaded IBMIR, they will not function properly until vascularized, which requires 
sufficient time65. Furthermore, the memory for autoantibodies directed against ß-cells 
that rendered the patient diabetic in the first place is still there and can provoke a new 
auto-immune reaction66;67. Consequently, many transplanted islets will be prematurely 
lost due to ischemic stress, apoptosis and necrosis.
2. islets of lAngerhAns trAnsplAntAtion
Currently, islet transplantation is not the cure that labile type 1 diabetes patients have 
been hoping for68, and pancreas transplantation as a ß-cell replacement therapy surpasses 
islet transplantation in every aspect. There are several reasons why islet transplantation is 
currently not as successful as we would wish. This result is partly due to the late clinical 
onset of the treatment compared with other organ transplant settings. The first successful 
islet transplantation was reported in 1978, while the first reported successful pancreas 
transplantation was performed in 196669. Vascularized pancreas transplantation is still 
undergoing improvements, as is islet transplantation. Only time will tell which of the two 
ß-cell replacement therapies will ultimately provide the most benefits to patients. 
2.1 obstacles in islet transplantation
Several theories on the causes of islet allograft failure after transplantation have been 
put forward, and some are discussed in Chapters 5 and 6, along with ideas regarding 
all pre-transplantation procedures and their effect on the yield and functionality of the 
isolated islets. The current protocols for islet isolation generate unsatisfactory low yields. 
At present, what is generally considered a highly successful isolation only yields 40% of 
all islets present in one pancreas, and often significantly fewer islets are isolated70. Several 
steps within the islet isolation procedure are currently under investigation. Studies are 
being conducted that are aimed at preserving larger numbers of functional islets in the 
excised pancreas, as many islets are lost during the transportation of the donor organ to 
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the Good Manufacturing Practice facility71. Furthermore, alternative isolation methods 
are being explored, such as magnetic retraction, instead of density gradient centrifugation. 
Magnetic retraction involves the intra-arterial infusion of iron particles into the islet 
capillaries. In rats, this islet extraction method appears successful, and the iron particles 
infused in the islet and subsequently transplanted with the islet do not adversely affect 
the recipient72. Furthermore, the technique was faster than the original density gradient 
purification. This reduction in the ischemic period may result in improved functionality. 
In addition, the isolate was of higher purity, with less exocrine contamination72. This 
islet isolation protocol has also been applied in humans and pigs. The isolation of human 
pancreatic islets using iron particles was not as successful as the rodent islet isolation 
with iron particles, and neither the time nor the yield were improved when compared 
with density gradient purification73. Isolation of islets from pigs was more successful 
and had higher yields, although the yields were not as pure as was aimed for in the 
study74. Furthermore, the homogenous distribution of the iron particles throughout the 
pig’s pancreas proved to be difficult, and the functional potency of the islets was not 
markedly improved74. Currently, once islets are isolated there is no means to predict the 
quality of the isolate in terms of in vivo functioning. The isolate is extensively tested to 
ensure quality standards as prescribed by the FDA and Good Manufacturing Practices, 
but this does not provide any indication of in vivo function. If a method to predict in 
vivo functioning existed, the amount of islets infused could be tailored for each patient, 
preventing the excessive use of islets while still providing adequate therapy. Numerous in 
vitro assays are currently being tested, and new assays are being developed to gain a better 
understanding of islet viability, potency, and function75;76.
Although islets are infused into the liver in current practice (which has been shown to 
be successful in auto-islet transplantation77), the liver is presumably not the most optimal 
transplantation site. Alloislet transplantation faces many adverse complications, such as 
the risk of inducing an instant blood-mediated inflammatory reaction, induction of an 
hypoxic environment due to the lower oxygen tension and lack of vascularization in the 
liver, altered autonomic innervation, the energy status of the ß-cells, the balance of pro- 
and anti-apoptotic mediators, and the occurrence of ß-cell senescence62;78-81. Alternative 
sites have been explored (mostly in animal models), the most promising of which are 
the omentum and implants consisting of islets within a biomaterial structure (e.g., bio-
artificial scaffolds82 and microencapsulation83). Several factors need to be considered in 
the search for an optimal implantation site: 
•	 Surgical and technical, as the operation should be minimally invasive and islets should 
be held within a restricted area for monitoring 
•	 Cellular and metabolic, as oxygen should be readily available and metabolites and 
hormones have to be delivered to the vasculature
•	 Immunological, as most immunosuppressants are toxic for ß-cells and decreased direct 
blood contact potentially minimizes the chances for IBMIR78. 
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Alternative sources of ß-cells are of interest because it is clear that the current lack 
of donor material hampers the success and employability of islet transplantation and 
will continue to do so. An advantage of islet transplantation over vascularized pancreas 
transplantation is the potential for an unlimited ß-cell supply through several possible 
strategies, such as stem cells84, islet progenitor cells85, xeno-islets86, and the transition 
of other cell types such as duct cells87, of which the latter seems promising. These 
research initiatives hold the future for islet transplantation, and the development of 
these alternative ß-cell sources is essential as there will always be a shortage of donor 
organs. To date, however, pancreas transplantation is favored over islets of Langerhans 
transplantation for almost all type 1 diabetes patients.
Another obstacle to implementing islet transplantation more widely (once it is 
successful) is the toxicity of the immunosuppressive regimen for ß-cells88. The kidney (native 
or transplanted) will also be damaged by most currently available immunosuppressive 
drugs, which in turn will negatively affect the islet allograft. To overcome this vicious 
circle of curing the patient through transplantation while inducing damage resulting 
in graft loss by immunosuppressive therapy, we explored methods to prolong allograft 
survival through cellular immune modulation. Cellular immune modulation may one 
day render immunosuppressive drugs obsolete. In this thesis, we show that donor-
derived tolerogenic dexamethasone-treated dendritic cells (dexDC) were not capable of 
prolonging allograft survival and even showed an accelerated rejection most likely caused 
by antibody- and NK cell-mediated rejection (Chapter 7). This result will be expanded 
upon in the following section on cellular immune modulation. 
The current success rates for islet transplantation are not as high as theory would predict. 
Eventually, almost all islet transplant recipients experience a reduction in functionality of 
their graft resulting in the reinstatement of exogenous insulin therapy, although at a 
lower dosage. A prerequisite to improving the success rate is to understand the underlying 
cause for islet allograft failure, both in the short and long term, thereby creating a better 
framework for intervention strategies. There are some clues from other transplant settings 
as to the causes of this graft failure65. For example, chronic allograft rejection may play 
a role65, or the accumulating toxic effects of immunosuppressive drugs on ß-cells may 
induce islet transplantation failure at a later stage88. Recurrence of the underlying disease, 
type 1 diabetes, may also be potentially harmful. Furthermore, it has been reported that 
islet recipients with positive T-cell responses to auto-antigens were more likely to lose full 
graft function67. To assess failure, it is essential to monitor the graft. In other transplant 
settings that involve whole organs, a biopsy is regarded as the gold standard for diagnosis. 
Thus, performing a biopsy of the islet graft for monitoring would be preferred. Initial 
attempts to biopsy the liver in the hopes of attaining some liver engrafted islets revealed 
that almost all needle-biopsy cores do contain islets. However, the number of islets in the 
biopsy was so limited that it had no practical value for diagnosis89. It is, however, essential 
to visualize the graft to ascertain how to intervene and check whether the intervention 
was successful. New approaches using scaffolds consisting of islets within a biomaterial 
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will most likely reduce the side effects of the biopsy procedure and will ensure that all 
biopsy cores contain sufficient numbers of insulin-producing cells for diagnosis. 
Other methods to visualize the transplanted islets have also been attempted. First 
attempts at the implantation of small amounts of syngeneic islet tissue in forearm muscle 
have provided a proof of principle that magnetic resonance imaging (MRI) would allow 
for insights into the processes occurring after transplantation90. Once the mechanisms 
of islet loss after transplantation are known, the possible means for intervention can be 
developed. Based on the preliminary findings in both human90 and rodent models91, the 
use of scaffolds and biomaterials to seed the insulin-producing cells seems promising. 
These approaches ensure that the islets will not be exposed to IBMIR, are easily accessible, 
and that engraftment and vascularization can be enhanced by supplement additions. 
2.2 immune modulation
Tolerance induction, or the creation of an accommodating environment for an allograft, 
is the “Holy Grail” of graft acceptance after allogeneic transplantation. Very few 
individuals are capable of acquiring this type of adaptive state by themselves19;92. The 
requirements for allograft tolerance are unclear, and much research has been conducted 
to understand the changes that have taken place in tolerant individuals. Once these 
adaptive changes have been elucidated, the requirements can be adopted and instated in 
new transplant recipients and would theoretically render them instantly tolerant. Several 
attempts have been made to create such an environment through various interventions 
at an early stage. Although blood transfusions were already known to potentially cause 
hyper-acute rejections, in 1978, Opelz and Terasaki93 found that, in a large cohort of 
kidney transplantation recipients, those patients who received blood transfusions before 
transplantation had better graft survival than patients who did not receive transfusions. 
Later studies found that donor-specific transfusions were successful. However, with the 
discovery of cyclosporine A and the acquired knowledge that transfusions could lead 
to HLA sensitization, the use of transfusions in transplantation has been abandoned. 
Cellular immune modulation therapies have evolved from whole blood to specific 
components94, such as dendritic cells or macrophages. More recently, recipient-derived 
cells have been modulated to become tolerogenic carriers of foreign (donor) antigens95 to 
further fine-tune the system. Eventually, the goal is to make all immunosuppressive drugs 
obsolete, ensuring a non-toxic therapy for transplantation recipients without life-long 
compulsory and harmful drug administration, while achieving optimal graft function. 
Cellular immune modulation has shown its potential in cancer therapy, although with 
limited success rates96;97. The problem in cancer therapy is that the targeted tissue is “self ”, 
and the tumor is effective at evading the immune system on which the cellular immune 
modulation therapy is based. In cancer, cellular therapy is only administered after all currently 
employed methods have failed. However, in the transplant setting, it is preferable to start 
cellular immune modulation therapy immediately after transplantation, given that this is 
the time when the immune response against foreign antigens is most active98. In addition, 
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the transplant setting has its own obstacles. Due to the necessary “non-self ” targeting, it 
is unclear, for example, whether to use donor- or recipient-derived cells. In addition, it 
is unethical to test novel therapeutics without the use of concurrent regular maintenance 
immunosuppressive therapy. These drugs will most likely also alter the functionality of the 
cell-based therapy. The allogeneic transplanted tissue is not free from antigen-presenting 
cells (APCs) and lymphocytes, as these reside in the tissue, and additional effects of these 
co-transplanted cells are difficult to predict. In some animal models, tolerance induction in 
transplantation has been successful, but humans trials are just starting98. 
The hazards of cell-based therapeutic approaches are numerous. The tolerogenic status 
of the cell must remain intact, and in vitro studies cannot account for the full complexity of 
the in vivo situation. Furthermore, upon administration, the tolerogenic cells must be able 
to actually induce native immune cells of the host to become tolerogenic cells, resulting 
in full tolerance induction on location. As individuals differ in their make-up, the effects 
of the infused cell therapy will vary. One example of cellular immune modulation is the 
use of dendritic cells (DC) that have attained permanent immaturity99. In their immature 
state, DC have a tolerizing phenotype, which is capable of inducing regulatory T-cells. 
In theory, when a recipient is treated with permanently immature DC from the organ 
donor, a tolerant, accommodative environment may be created prior to transplantation. 
This would prevent the rejection of the allograft and render the use of immunosuppressive 
drugs obsolete. Dexamethasone-treated DC have been demonstrated to promote donor-
specific T-cell hyporesponsiveness in two fully mismatched kidney transplant models100. 
As described in Chapter 7, we have tried to induce a tolerogenic state in a rodent islet 
transplantation model with the use of cellular immune modulation. The donor-derived 
tolerogenic dexamethasone-treated DC used were tested in vitro and shown to express 
reduced levels of CD86 and MHC class II molecules compared to non-tolerogenic DC 
after lipopolysaccharide stimulation. This result showed the preserved immature status of 
the dexDC even after a strong maturation signal was provided. Furthermore, the donor-
derived dexDC have been shown to be capable of excreting IL-10, an anti-inflammatory 
cytokine, while lacking the ability to produce IL-12, a known pro-inflammatory cytokine. 
Therefore, the dexDC have a reduced capacity to stimulate allogeneic T-cells in vitro and have 
the capacity to induce T-cell hypo-responsiveness in vivo100;101. However, in our allogeneic 
rodent islet transplant setting, donor-derived dexDC actually accelerated rejection. As 
stated before, in theory these tolerogenic DC may induce a ‘negative vaccination’ resulting 
in increased alloimmunity102, which we describe in Chapter 7. This does not imply that 
cellular immune modulation has no chance of becoming successful. Extensive research in 
all fields of organ transplantation and cancer therapy is still underway, and the knowledge 
gained will eventually lead to a workable treatment. In the end, DC may prove not to be 
the cell type of choice, as highlighted by the current heightened interest in macrophages103.
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3. concluding remArks
Acute rejection in organ and islet transplantation has many facets, and only a few have 
been touched upon in this thesis. In these concluding remarks, the main topics discussed 
are summarized. 
In SPKT, immunosuppressive rejection therapy is currently administered based on the 
findings in the kidney allograft biopsy. However, we now know that the pancreas allograft 
may show a discrepant rejection profile compared with the kidney allograft, possibly 
requiring a different therapeutic regime. Furthermore, early graft survival rates of the 
pancreas lag behind the kidney allograft in these simultaneously transplanted patients. 
Prospective studies in which both kidney and pancreas biopsies are studied are necessary 
to discover whether pancreas-tailored therapy can improve the overall graft survival in this 
patient group. For PTA or PAK, the relevance of monitoring the pancreas graft through 
biopsies is even more essential, as in these cases, the kidney and pancreas are from different 
donors. We have established that not only TCR can take place in both organs but also that 
AMR is a valid type of rejection in the pancreas as well as in the kidney. 
Islet transplantation will become a feasible ß-cell replacement therapy once it has 
improved sufficiently to overcome its current shortcomings. Theoretically, the islet 
transplantation process is less invasive and could be applied at a much earlier point than the 
current most successful ß-cell replacement therapy, which is whole pancreas transplantation. 
Regardless of the time these improvements may take, at present, there is no therapy available 
to prevent the onset of type 1 diabetes. Consequently, the demand for a cure, preferentially 
one relatively early in the progressive course of microvascular complications, is likely to 
increase further. The chronicity of the disease, the numerous secondary complications 
involved, and the increasing disease incidence will spur research efforts and bring ß-cell 
replacement therapy through islet transplantation closer to broad applicability. 
Cellular immune modulation of the recipient is essential in ß-cell replacement therapy, 
as this transplant setting will remain ineffective if current immunosuppressive protocols are 
retained. In other transplant settings, improved tolerance of the recipient will also improve 
survival rates, and the efforts currently undertaken will not be in vain. Unfortunately, the 
same applies to cellular immune modulation as for islet transplantation; we are not there 
yet. However, the results are promising, and eventually research efforts will catch up 
with theory, making both cellular immune modulation and islet transplantation widely 
applicable and successful therapies.
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AddendA+

nederlAndse sAmenvAtting
Diabetes type 1 is een chronische auto-immuun ziekte, veroorzaakt door de zelfvernietiging 
van insuline producerende ß-cellen in de pancreas (alvleesklier). Ongeveer 15% van alle 
diabetes patiënten heeft diabetes type 1. Diabetes type 2 wordt veroorzaakt door een 
tekort in insuline productie om te compenseren voor de steeds toenemende insuline 
resistentie en obesiteit. In dit proefschrift gaat het alleen over diabetes type 1. Wanneer in 
deze samenvatting ‘diabetes’ is gebruikt, wordt de type 1 variant bedoeld. 
Hoe deze ziekte ontstaat, is nog grotendeels onbekend en daarom zijn er ook nog 
geen therapeutische middelen om het ontstaan van diabetes type 1 tegen te gaan. Op 
dit moment is er maar één manier om patiënten met diabetes type 1 van hun ziekte 
te genezen: herstel van de ß-cel populatie door middel van transplantatie. Er zijn twee 
soorten transplantatie mogelijk om herstel van de ß-cel populatie te bewerkstelligen:
1. pancreastransplantatie, al dan niet gelijktijdig met een niertransplantatie, en 
2. transplantatie van eilandjes van Langerhans. 
In dit proefschrift worden pancreas-, eilandjes van Langerhans en niertransplantatie 
naast elkaar gelegd en wordt onderzocht hoe acute antilichaam gemedieerde afstoting hier 
een rol in speelt. 
pancreastransplantatie
Pancreastransplantatie wordt sinds 1966 uitgevoerd en is een erkende behandeling voor 
patiënten met diabetes. Bij pancreastransplantatie wordt de pancreas van een overleden 
donor uitgenomen en in de patiënt met diabetes overgezet. De patiënt kan op deze manier 
definitief van zijn diabetes genezen zijn. Hij zal geen dagelijkse insuline-injecties meer 
nodig hebben en niet meer blootstaan aan de ontwikkeling van secundaire complicaties 
van diabetes zoals retinopathie, neuropathie, cardiovasculaire schade en nefropathie. Deze 
laatstgenoemde secundaire complicatie heeft nierfalen tot gevolg en zorgt ervoor dat de 
patiënt afhankelijk wordt van dialyse. Wanneer deze patiënt in aanmerking komt voor een 
niertransplantatie kan er eventueel tegelijkertijd een pancreas getransplanteerd worden. 
Dit zorgt ervoor dat de onderliggende ziekte, diabetes, ook behandeld wordt en de nieuwe 
donornier niet zal blootstaan aan bovengenoemde diabetes-gerelateerde complicaties. 
Een transplantatie waarbij zowel de nier als de pancreas worden vervangen heeft een 
positief effect op de overleving van beide getransplanteerde organen en dat komt weer de 
gezondheid van de patiënt ten goede. Een pancreastransplantatie wordt daarom vaak in 
combinatie met een niertransplantatie uitgevoerd. 
Om acute afstoting van het getransplanteerde orgaan tegen te gaan zal de patiënt 
levenslang immunosuppressieve medicijnen moeten nemen om het immuunsysteem te 
onderdrukken. Afstoting vindt plaats doordat het immuunsysteem de donororganen 
herkent als lichaamsvreemd en er zodoende alles aan doet om deze ‘indringers’ te 
verwijderen. Medicatie kan deze afstoting tegengaan, maar helaas zitten er ook nadelen 
aan deze medicijnen. Op lange termijn kunnen zij nierschade induceren. Daarnaast zijn de 
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insuline producerende ß-cellen erg gevoelig voor deze immunosuppressieve medicatie en 
kunnen zij erdoor beschadigd raken. Daarom is het belangrijk een goede balans te vinden 
tussen het tegengaan van afstoting enerzijds, en toxiciteit door geneesmiddelen anderzijds. 
Om dit te monitoren worden er protocollair, of op medische indicatie, biopten van het 
niertransplantaat genomen. Bij gecombineerde nier-pancreastransplantatie wordt vaak 
alleen naar een biopsie uit de nier gekeken en gaat men ervan uit dat dit voorspelt of er al 
dan niet afstoting plaatsvindt in het pancreastransplantaat. Aan de hand van de bevindingen 
in de biopten wordt geëvalueerd welke behandeling het meest geschikt is en wordt er 
gecontroleerd of de toegediende therapie ook het gewenste positieve effect heeft gehad.
Afstoting kan op twee manieren plaatsvinden: T-cel gemedieerde afstoting en 
antilichaam gemedieerde afstoting. T-cel gemedieerde afstoting werd het eerst ontdekt en 
de meeste therapieën die zijn ontwikkeld richten zich op T-cellen die schade induceren. 
Antilichaam gemedieerde afstoting is pas recentelijk ontdekt en na deze ontdekking 
duurde het enige tijd voordat het fenomeen ook klinisch werd geaccepteerd. De rol die 
antilichaam gemedieerde afstoting speelt, is ontdekt in getransplanteerde nieren en veel 
onderzoek hiernaar heeft zich dan ook op niertransplantatie gericht. Of antilichaam 
gemedieerde afstoting ook een rol speelt in de afstoting van andere getransplanteerde 
organen, wordt momenteel (onder andere in dit proefschrift) onderzocht. 
Antilichaam gemedieerde afstoting wordt veroorzaakt door ontsteking van kleine 
vaatjes in het orgaan met infiltratie van neutrofielen – dit zijn witte bloedcellen- 
en door het achterblijven van moleculaire restanten van complementactivatie. 
Het complementsysteem is een onderdeel van het aangeboren afweersysteem. Het 
complementsysteem kan geactiveerd worden wanneer een antilichaam gericht tegen 
het donororgaan zich bindt aan het orgaan. Dit resulteert in een cascade van activatie 
componenten waarbij er een fragment van complementfactor 4, C4d, achter blijft als 
een soort “voetafdruk” van de activatie van het immuunsysteem. C4d kan vervolgens 
gevisualiseerd worden in het biopt door middel van immunohistologische technieken. 
De afstoting wordt systemisch gekenmerkt door antilichamen die zich specifiek tegen 
het donororgaan richten en niet aan het weefsel van de ontvanger kunnen binden. De 
combinatie van 3 componenten -histologische kenmerken, C4d-depositie in het weefsel 
en donorspecifieke antilichamen in het bloed- bepaalt of er sprake is van antilichaam 
gemedieerde afstoting in de getransplanteerde nier.
In hoofdstuk 2 worden de resultaten beschreven aangaande de prognostische waarde 
van 1 van de 3 componenten voor de diagnose antilichaam gemedieerde afstoting, C4d-
depositie, voor niertransplantaat overleving. Deze studie is uitgevoerd in nierbiopten 
met histologische gedefinieerde acute rejectie episodes verkregen uit een populatie van 
transplantatie patiënten met een standaard immunologisch risico profiel. In deze studie 
beschrijven wij dat C4d niet op zichzelf kan voorspellen of er sprake zal zijn van steroid 
resistentie bij behandeling van de rejectie episode. Niertransplantatie patiënten met 
C4d-aankleuring in hun biopt hadden dezelfde patiënt- en niertransplantaatoverleving 
als de niertransplantatiepatiënten zonder C4d aankleuring in hun biopt. Daarnaast is er 
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geen verschil gebleken in de functionaliteit van de getransplanteerde nieren. In de studie 
beschreven in hoofdstuk 2 hebben we aangetoond dat C4d-depositie op zichzelf, in dit 
cohort biopten genomen binnen 6 maanden na niertransplantatie, niet gerelateerd is aan 
het klinische resultaat van transplantatie.
Over de rol van antilichaam gemedieerde afstoting bij pancreastransplantatie is nog 
weinig bekend. In het werk beschreven in hoofdstuk 3 is gekeken naar histopathologische 
laesies, C4d aankleuringspatronen en donorspecifieke antilichamen in relatie tot 
pancreastransplantaatoverleving. In deze studie beschrijven we dat de lange termijnsoverleving 
van het pancreastransplantaat slechter is bij die patiënten die in hun pancreastransplantaatbiopt 
een positieve interacinaire C4d-aankleuring lieten zien en bij wie in het serum donorspecifieke 
antilichamen gevonden werden. Deze resultaten zijn vergeleken met patiënten bij wie geen 
van bovenstaande kenmerken te zien waren in het pancreastransplantaatbiopt en serum. 
Verschillende specifieke histologische parameters bleken geassocieerd te zijn met de diagnose 
antilichaam gemedieerde afstoting, maar omdat er maar 28 biopten bestudeerd konden 
worden, is meer onderzoek nodig om de onderscheidende waarde van deze kenmerken te 
verifiëren. Wij concluderen dat zowel een diffuus positieve C4d-aankleuring als donorspecifieke 
antilichamen aanwezig moeten zijn om de diagnose antilichaam gemedieerde afstoting in het 
pancreastransplantaat te kunnen stellen.
In het onderzoek beschreven in hoofdstuk 4 is de studie uit hoofdstuk 3 uitgebreid door 
de histopathologische analyse van pancreastransplantectomiepreparaten. Biopsiemateriaal 
van de getransplanteerde pancreas is schaars en een biopt bestaat in de regel uit een zeer 
klein stukje weefsel. Materiaal van transplantectomieën is wel in overvloed voorhanden. 
In gecombineerde nier-pancreastransplantaties wordt vaak het niertransplantaat bij 
verdenking op afstoting gebiopteerd. Men neemt aan dat bevindingen in het nierbiopt 
ook voorspellen wat zich in het pancreastransplantaat afspeelt, zoals eerder vermeld. Het is 
echter al aangetoond, door zowel onze groep als anderen, dat deze aanname onjuist is. In 
gecombineerde nier-pancreastransplantaties is de pancreastransplantaatoverleving slechter 
dan de niertransplantaatoverleving. Het is bekend dat veel van de falende pancreata ten 
onder gaan aan technisch falen direct na transplantatie. Technisch falen gaat vaak gepaard 
met de ontwikkeling van trombose en interventiestrategieën zijn schaars. Aan het onstaan 
van trombose kunnen verschillende factoren ten grondslag liggen die mogelijk preventief 
of op indicatie behandeld kunnen worden.
Wanneer trombose binnen een jaar na transplantatie pancreastransplantaatverlies 
tot gevolg heeft, zou dat onder andere veroorzaakt kunnen zijn door antilichaam 
gemedieerde afstoting. Dit is onderzocht en beschreven in hoofdstuk 4. Wij hebben in 
deze studie alle pancreastransplantectomiepreparaten in het LUMC binnen een jaar na 
gecombineerde nier-pancreastransplantatie geïncludeerd (n=33). Deze zijn onderzocht 
en vergeleken met een controlegroep (n=66) waar het pancreastransplantaat minimaal 4 
jaar functioneel was. Donorleeftijd en het geslacht van de ontvanger blijken geassocieerd 
te zijn met het falen van het pancreastransplantaat. In de pancreastransplantectomie 
preparaten is er zowel gekeken naar C4d-depositie in het weefsel, als naar donorspecifieke 
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antilichaamontwikkeling in het serum van de ontvanger. Van de 33 patiënten die binnen 
een jaar na transplantatie een pancreastransplantectomie ondergingen, waren er 7 patiënten 
met antilichaam gemedieerde afstoting. Van deze 7 patiënten met een gecombineerde nier-
pancreastransplantatie, hebben er 6 hun nier binnen een jaar na transplantatie verloren, 
doch op een ander tijdstip dan het pancreastransplantaat verloren ging. Daarnaast was het 
kenmerkend dat het verlies van deze 7 antilichaam gemedieerde pancreastransplantaten 
op één na vóór 1994 plaatsvond. Sinds 1994 zijn er veel ontwikkelingen geweest in de 
samenstelling en het gebruik van immunosuppressieve medicatie. Dat zou mogelijk een 
verklaring kunnen zijn voor deze bevinding. Deze studie laat zien dat pancreastransplantaat 
verlies wel degelijk door antilichaam gemedieerde afstoting veroorzaakt kan worden, en 
dat dit histologisch vaak gepaard gaat met trombotische lesies.
transplantatie van eilandjes van langerhans
Transplantatie van eilandjes van Langerhans (eilandjes) is een recentere behandelmethode 
voor patiënten met diabetes, die nochtans alleen als onderzoekgerelateerde behandeling 
wordt toegepast. De pancreas bestaat voor 1 à 2% uit eilandjes van Langerhans. In die 
eilandjes bevinden zich de insuline producerende ß-cellen die defect zijn gegaan bij een 
patiënt met diabetes. Hoofdstuk 5 is een literatuurstudie die terugblikt op de opgedane 
kennis aangaande eilandjes van Langerhans transplantatie. Het gaat over de potentie die 
eilandjes van Langerhans transplantatie heeft, over de limitaties die uitgebreide succesvolle 
implementatie nog in de weg staan, en over mogelijke handreikingen voor behandelend 
artsen. Eilandjes van Langerhans transplantatie is een minder invasieve behandeling dan 
pancreastransplantatie en kan in theorie eerder na het ontstaan van diabetes toegepast 
worden dan een pancreastransplantatie. De 5-jaarsoverleving van het eilandjes van 
Langerhans transplantaat is momenteel 6.5%. Dit zal eerst verbeterd moeten worden 
voordat deze behandeling wijdverspreid toegepast kan worden.
Hoofdstuk 6 is een literatuurstudie die aangevuld is met eigen bevindingen over de 
histopathologische kenmerken van eilandjes van Langerhans transplantatieonderzoek 
bij ratten. De kenmerken waar we ons op gericht hebben in hoofdstuk 6 bestonden 
uit innervatie, vascularisatie door bloedvaten, en lymfatische vascularisatie van het 
eilandjestransplantaat onder het nierkapsel van de ontvangerrat. Eilandjes van Langerhans 
worden bij ratten onder het nierkapsel getransplanteerd. Dit verschilt van humane 
eilandjestransplantatie waarbij de eilandjes door infusie via de poortader vastlopen in 
de lever. De reden om de eilandjes van Langerhans bij de rat op een andere lokatie te 
transplanteren zijn divers. Eén reden is dat lokalisatie van de eilandjes onder het nierkapsel 
visualisatie vergemakkelijkt. Dit maakt de rat als proefdiermodel uitermate geschikt 
voor onderzoek naar eilandjes van Langerhans transplantatie. In het werk beschreven in 
hoofdstuk 6 wordt duidelijk dat, nadat de eilandjes van Langerhans zijn getransplanteerd, 
vele verschillende connecties tussen transplantaat en ontvanger hersteld moeten worden 
om de transplantatie tot een succes te maken. Het samenspel van alle componenten is 
essentieel en het is daarom onvoldoende slechts één aspect te bestuderen. 
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Zoals eerder beschreven zijn de insuline producerende ß-cellen in de eilandjes 
van Langerhans erg gevoelig voor immunosuppressieve therapie. Bij voorkeur zou er 
een alternatief voorhanden moeten zijn die huidige immunosuppressive medicatie 
overbodig maakt, bijvoorbeeld door de ontvanger van de eilandjes van Langerhans vóór 
transplantatie tolerant te maken voor de donor. De ontvanger zou dan de donoreilandjes 
van Langerhans niet meer als lichaamsvreemd zien, maar de eilandjes accepteren als “eigen” 
en op die manier kan afstoting worden verhinderd. In hoofdstuk 7 hebben wij getracht 
om door middel van celtherapie een tolerante omgeving te creëren bij de ontvanger van 
het transplantaat. Zodoende zou afstoting worden tegengegaan. Hiervoor is gebruik 
gemaakt van een proefdiermodel, waarbij één rattenstam fungeert als de eilandjes van 
Langerhans donor en een andere stam fungeert als diabetische ontvanger van het eilandjes 
transplantaat. Geïsoleerde eilandjes van verschillende donoren werden getransplanteerd 
onder het nierkapsel van één diabetische ontvanger. Wanneer de ontvanger normoglycemie 
heeft bereikt, kan de eilandjes-bevattende-nier verwijderd worden waarna de ontvangerrat 
weer diabeet zou moeten worden. Dit is een interne controle voor het induceren van 
diabetes en dient tevens om te bezien of de getransplanteerde eilandjes functioneel 
waren. De celtherapie om tolerantie te induceren bestaat uit dendritische cellen die uit 
de donorrat zijn geïsoleerd. Deze dendritische cellen zijn 7 dagen voor transplantatie bij 
de ontvanger ingespoten. De dendritische cellen zijn zo behandeld dat zij permanent 
immatuur zijn en een tolerante omgeving in de ontvangerrat zouden moeten kunnen 
creëren. De bevindingen beschreven in hoofdstuk 7 laten echter het tegenovergestelde 
zien. Behandeling van de ontvangerrat vóór transplantatie met permanent immature 
dendritische cellen van de donor, versnelt juist de afstoting van de eilandjes van Langerhans. 
Bij de ontvanger die behandeld is met de dendritische cellen zijn al vóór transplantatie 
donorspecifieke antilichamen te vinden. Deze kunnen, net zoals eerder beschreven, 
voor antilichaam gemedieerde afstoting zorgen. De snelheid waarmee de afstoting in 
dit model plaatsvindt wijst erop dat de afstoting veroorzaakt wordt door antilichaam-
afhankelijke, cel-gemedieerde cytotoxiciteit. Hierbij zorgt de antilichaambinding niet voor 
complementactivatie maar voor directe cellysis door activatie van Natural Killer cellen. 
De celtherapie heeft niet het gewenste resultaat laten zien en meer onderzoek is nodig 
voordat het gebruik van celtherapie overwogen kan worden voor het humane eilandjes 
transplantatie veld. Eilandjes van Langerhans transplantie is dus nog niet zo succesvol 
als gewenst, maar stap voor stap wordt er meer kennis vergaard zodat dit uiteindelijk zal 
leiden tot wijdverbreide implementatie van deze behandeling.
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AbbreviAtion list
ADCC  antibody-dependent cellular cytotoxicity
AMR   antibody-mediated rejection
APC   antigen presenting cells
CDC  complement dependent cytotoxicity
DAF  decay accelerating factor
DC  dendritic cells
dexDC  dexamethasone-pretreated dendritic cells
DSA   donor-specific antibodies
ENDAT  endothelial activation transcripts
ESRF   end stage renal failure
FDA  food and drugs administration
GSTT1  Glutathione S-transferase theta-1
HLA  human leukocyte antigen
HUVEC human umbilical vein endothelial cell
IAC  interacinar capillaries
IAK   islet after kidney transplantation
IBMIR  instant blood-mediated inflammatory reaction
IPTR   International Pancreas Transplant Registry 
ITA   islet transplantation alone
LUMC  Leiden University Medical Center
MAC   membrane attack complex
MCP  membrane cofactor protein
MHC   major histocompatibility complex
MICA  human major histocompatibility complex class I chain-related A protein
MICB  human major histocompatibility complex class I chain-related B protein
MRI  magnetic resonance imaging
NK  natural killer
PAK   pancreas after kidney transplantation
PTA   pancreas transplantation alone
PTC  peritubular capillaries
SPKT   simultaneous pancreas kidney transplantation
TCR  T-cell mediated cellular rejection
TF  tissue factor
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